var title_f39_51_40752="Gentamicin: Patient drug information";
var content_f39_51_40752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gentamicin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/23/28020?source=see_link\">",
"       Gentamicin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/8/18564?source=see_link\">",
"       Gentamicin (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/59/38835?source=see_link\">",
"       Gentamicin (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11375 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40752=[""].join("\n");
var outline_f39_51_40752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/23/28020?source=related_link\">",
"      Gentamicin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/8/18564?source=related_link\">",
"      Gentamicin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/59/38835?source=related_link\">",
"      Gentamicin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40753="Retinal whitening";
var content_f39_51_40753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal whitening",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitening, a change seen in areas of the retina in patients with cerebral malaria. This mosaic-like appearance is the result of capillary non-perfusion. In the image on the lower right, the pathological whitening is in the perimacular area, similar to the upper, left image. The extra-macular changes are a reflections from flash on the fundus camera.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Lewallen and Nicholas Beare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40753=[""].join("\n");
var outline_f39_51_40753=null;
var title_f39_51_40754="Insect sting kit: Drug information";
var content_f39_51_40754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insect sting kit: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ana-Kit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insect stings (Children and Adults): I.M. or SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epinephrine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;2 years: 0.05-0.1 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-6 years: 0.15 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 0.2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;12 years : 0.3 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chlorpheniramine:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;6 years: 1 tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 2 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;12 years: 4 tablets",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F182399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kit: Epinephrine hydrochloride 1:1000 [prefilled syringe, delivers two 0.3 mL doses; contains sodium bisulfite] (1 mL), chlorpheniramine maleate chewable tablet 2 mg (4), sterile alcohol pads [isopropyl alcohol 70%] (2), tourniquet (1)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylaxis emergency treatment of insect bites or stings by the sensitive patient that may occur within minutes of insect sting or exposure to an allergic substance",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F182400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F12808378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Epinephrine monograph.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8985 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40754=[""].join("\n");
var outline_f39_51_40754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182396\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182401\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182397\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182399\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182398\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182390\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182391\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182400\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182385\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12808378\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182393\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40755="HS granuloma inguinale";
var content_f39_51_40755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Indolent ulcers of granuloma inguinale mimicking hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40755=[""].join("\n");
var outline_f39_51_40755=null;
var title_f39_51_40756="Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis";
var content_f39_51_40756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of acute/subacute paracoccidioidomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Marcio Nucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Arnaldo L Colombo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40756/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/51/40756/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungus, Paracoccidioides brasiliensis. The fungus has a geographic distribution limited to Central and South America, where paracoccidioidomycosis is the most frequent systemic endemic mycosis.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    (juvenile) paracoccidioidomycosis will be reviewed here. The clinical manifestations and diagnosis of chronic paracoccidioidomycosis, as well as the mycology, epidemiology, and treatment of paracoccidioidomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=see_link\">",
"     \"Mycology and epidemiology of paracoccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=see_link\">",
"     \"Treatment of paracoccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following inhalation, Paracoccidioides brasiliensis typically causes asymptomatic pulmonary infection that may be detected by a positive paracoccidioidin intradermal test. If the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection and is most common, and the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Acute/subacute",
"    </span>",
"    paracoccidioidomycosis (also known as juvenile paracoccidioidomycosis) is almost always observed in children, adolescents, and adults under 30 years of age, and represents fewer than 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In children, it affects girls and boys in equal numbers; this is in contrast to the chronic form, which is much more frequent in adult men. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=see_link&amp;anchor=H3#H3\">",
"     \"Mycology and epidemiology of paracoccidioidomycosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissemination of infection to the reticuloendothelial system results in lymphadenopathy, hepatosplenomegaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow dysfunction (eg, aplastic anemia) (",
"    <a class=\"graphic graphic_table graphicRef65466 \" href=\"mobipreview.htm?8/6/8300\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/4\">",
"     4",
"    </a>",
"    ]. Constitutional signs such as fever and weight loss occur frequently. Less common features include bone and skin involvement (",
"    <a class=\"graphic graphic_picture graphicRef54429 \" href=\"mobipreview.htm?0/45/725\">",
"     picture 1",
"    </a>",
"    ). In contrast to the chronic form, lung involvement is very unusual with the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    form.",
"   </p>",
"   <p>",
"    Superficial lymph node involvement is most common in the cervical, axillary, and inguinal regions, and draining fistulae may develop (",
"    <a class=\"graphic graphic_picture graphicRef54429 \" href=\"mobipreview.htm?0/45/725\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52733 \" href=\"mobipreview.htm?20/1/20498\">",
"     picture 2",
"    </a>",
"    ). Enlarged abdominal lymph nodes often cause diffuse abdominal pain and occasionally compression of various structures such as the biliary tract (jaundice), and intestines (partial obstruction, malabsorption).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 63 children with paracoccidioidomycosis, the following laboratory abnormalities were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anemia &mdash; 90 percent",
"     </li>",
"     <li>",
"      Hypergammaglobulinemia &mdash; 89 percent",
"     </li>",
"     <li>",
"      Eosinophilia &mdash; 76 percent",
"     </li>",
"     <li>",
"      Hypoalbuminemia &mdash; 73 percent",
"     </li>",
"     <li>",
"      Hyperbilirubinemia &mdash; 44 percent",
"     </li>",
"     <li>",
"      Mildly elevated transaminases &mdash; 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course progresses rapidly, and if left untreated, the patient's condition becomes seriously compromised within weeks to a few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/5\">",
"     5",
"    </a>",
"    ]. The course of",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    paracoccidioidomycosis is generally more severe than the chronic form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of paracoccidioidomycosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sequelae in patients with acute paracoccidioidomycosis are infrequent, and mostly represented by malabsorption related to fibrosis of mesenteric lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    paracoccidioidomycosis includes lymphoma and systemic infections associated with generalized lymphadenopathy, hepatosplenomegaly, fever, weight loss and anemia. Infections that may have a similar clinical presentation include disseminated histoplasmosis, tuberculosis, syphilis, cat scratch disease, and a mononucleosis-like syndrome lasting more than 4 weeks (eg, Epstein-Barr virus, cytomegalovirus, Toxoplasma gondii). Primary HIV infection should also be considered in patients with risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of paracoccidioidomycosis is based upon the microscopic visualization of fungal elements suggestive of P. brasiliensis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by culturing this fungus from clinical specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/3\">",
"     3",
"    </a>",
"    ]. Serologic testing can be useful both for diagnosis and for monitoring the response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/6\">",
"     6",
"    </a>",
"    ]. The tests used to diagnose",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    paracoccidioidomycosis are identical to those used for chronic paracoccidioidomycosis, and are discussed in detail separately. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36935?source=see_link&amp;anchor=H10#H10\">",
"      \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\", section on 'Diagnosis'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute/subacute",
"    paracoccidioidomycosis should be considered in children or young adults (&lt;30 years old) with the following clinical presentation (or a combination of them):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Localized or generalized superficial lymphadenopathy",
"     </li>",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Abdominal masses (lymph nodes) with or without compressive manifestations",
"     </li>",
"     <li>",
"      Signs of bone marrow failure (especially anemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of paracoccidioidomycosis is sought in patients who present with suggestive epidemiological and clinical findings. A typical example would be a child or adolescent from a rural area who presents with fever, weight loss, and diffuse lymphadenopathy. The diagnosis of the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    form of paracoccidioidomycosis is most often established by direct examination and culture of material obtained by aspiration of enlarged superficial lymph nodes, as well as by results of serologic tests.",
"   </p>",
"   <p>",
"    The initial evaluation should include all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging of affected areas to determine the extent of lymph node involvement (including the presence of compressive manifestations). All patients should be evaluated by abdominal ultrasound or abdominal computed tomograph (CT). Chest CT is usually not performed and is important only if signs and symptoms suggest lung involvement (rare) or mediastinal lesion (eg, compression of superior vena cava). Gallium-67 scans may be of help in revealing bone lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Direct examination and culture of specimens obtained by aspiration or biopsy of enlarged lymph nodes are routinely performed.",
"     </li>",
"     <li>",
"      Serologic testing (preferably by quantitative immunodiffusion). Antibody titers in the serum (by immunodiffusion) are usually high (&ge;1:32) in patients with acute paracoccidioidomycosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36935?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\", section on 'Serologic tests'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients should be assessed for the presence and severity of bone marrow failure, and nutritional status. Additional tests may be indicated depending on the presence of clinical findings suggestive of involvement of other organs (eg, central nervous system, gastrointestinal tract, adrenal, bone, joints).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IMMUNOCOMPROMISED HOSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paracoccidioidomycosis in HIV-infected patients has some features in common with the",
"    <span class=\"nowrap\">",
"     acute/subacute",
"    </span>",
"    form of the disease, such as widespread involvement and rapid progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40756/abstract/8\">",
"     8",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36935?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis\", section on 'Immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paracoccidioidomycosis is a systemic endemic mycotic disease caused by the thermally dimorphic fungus Paracoccidioides brasiliensis, which has a geographic distribution limited to Central and South America. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paracoccidioides brasiliensis typically causes asymptomatic pulmonary infection. However, if the infection is not contained by the host, the disease may evolve into one of two patterns: the chronic form, which represents reactivation of the primary infection, and the",
"      <span class=\"nowrap\">",
"       acute/subacute",
"      </span>",
"      form. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Acute/subacute",
"      </span>",
"      paracoccidioidomycosis (also known as juvenile paracoccidioidomycosis) is almost always observed in children, adolescents, and adults under 30 years of age, and represents fewer than 10 percent of all cases of paracoccidioidomycosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In",
"      <span class=\"nowrap\">",
"       acute/subacute",
"      </span>",
"      paracoccidioidomycosis, dissemination of infection to the reticuloendothelial system results in lymphadenopathy, hepatosplenomegaly, and bone marrow dysfunction (eg, aplastic anemia). Constitutional signs such as fever and weight loss are common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of paracoccidioidomycosis is based upon the microscopic visualization of fungal elements suggestive of P. brasiliensis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      by culturing this fungus from clinical specimens. Serologic testing can be useful both for diagnosis and for monitoring the response to therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/1\">",
"      Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/2\">",
"      Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993; 6:89.",
"     </a>",
"    </li>",
"    <li>",
"     Restrepo A, Tobon AM, Agudelo CA. Paracoccidioidomycosis. In: Diagnosis and Treatment of Human Mycoses, 1st edition, Hospenthal, DR, Rinaldi, MG (Eds), Humana Press, Totowa, NJ 2008. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/4\">",
"      Pereira RM, Bucaretchi F, Barison Ede M, et al. Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. Rev Inst Med Trop Sao Paulo 2004; 46:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/5\">",
"      Nogueira MG, Andrade GM, Tonelli E. Clinical evolution of paracoccidioidomycosis in 38 children and teenagers. Mycopathologia 2006; 161:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/6\">",
"      de Camargo ZP. Serology of paracoccidioidomycosis. Mycopathologia 2008; 165:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/7\">",
"      Yamaga LY, Benard G, Hironaka FH, et al. The role of gallium-67 scan in defining the extent of disease in an endemic deep mycosis, paracoccidioidomycosis: a predominantly multifocal disease. Eur J Nucl Med Mol Imaging 2003; 30:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40756/abstract/8\">",
"      Morej&oacute;n KM, Machado AA, Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009; 80:359.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2438 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40756=[""].join("\n");
var outline_f39_51_40756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IMMUNOCOMPROMISED HOSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2438|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/45/725\" title=\"picture 1\">",
"      Acute subacute paracocci",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/1/20498\" title=\"picture 2\">",
"      Acute paracoccoci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/6/8300\" title=\"table 1\">",
"      Acute paracocci findings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/19/41268?source=related_link\">",
"      Mycology and epidemiology of paracoccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/37/30295?source=related_link\">",
"      Treatment of paracoccidioidomycosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40757="Amiloride and hydrochlorothiazide: Drug information";
var content_f39_51_40757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amiloride and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/28/19909?source=see_link\">",
"    see \"Amiloride and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ami-Hydro;",
"     </li>",
"     <li>",
"      Apo-Amilzide&reg;;",
"     </li>",
"     <li>",
"      Gen-Amilazide;",
"     </li>",
"     <li>",
"      Moduret;",
"     </li>",
"     <li>",
"      Novamilor;",
"     </li>",
"     <li>",
"      Nu-Amilzide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension, edema: Oral: Initial: 1 tablet/day; may be increased to 2 tablets/day if needed; usually given in a single dose",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     to 1 tablet/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2606648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manufacturer&rsquo;s recommendations: Use of amiloride in patients with diabetes mellitus or S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.5 mg/dL should be done with caution and is contraindicated in patients with anuria, acute or chronic renal insufficiency, or evidence of diabetic nephropathy.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 5/50: Amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9405973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium-sparing diuretic; antihypertensive",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hypochloremic alkalosis and hyponatremia can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia:",
"     <b>",
"      [U.S. Boxed Warning]: Hyperkalemia can occur; patients at risk include those with renal impairment, diabetes, the elderly, and the severely ill. Serum potassium levels must be monitored at frequent intervals especially when dosages are changed or with any illness that may cause renal dysfunction.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with extreme caution in patients with diabetes mellitus; may see a change in glucose control. Monitor closely; discontinue amiloride 3 days prior to glucose tolerance testing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use hydrochlorothiazide with caution in patients with severe hepatic dysfunction; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use hydrochlorothiazide with caution in patients with moderate or high cholesterol concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabolic/respiratory acidosis: Use with caution in patients who are at risk for metabolic or respiratory acidosis (eg, cardiopulmonary disease, uncontrolled diabetes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Avoid use of hydrochlorothiazide in severe renal disease (ineffective).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: AMILoride may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Hydrochlorothiazide.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F133114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amiloride-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-50 mg (100): $32.86",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adco-Retic (ZA);",
"     </li>",
"     <li>",
"      Add-Acten (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Ameride (ES);",
"     </li>",
"     <li>",
"      Amil-Co (GB);",
"     </li>",
"     <li>",
"      Amilco (DK);",
"     </li>",
"     <li>",
"      Amilco Mite (DK);",
"     </li>",
"     <li>",
"      Amilocomp beta (DE);",
"     </li>",
"     <li>",
"      Amiloretic (ZA);",
"     </li>",
"     <li>",
"      Amizide (AU, TW);",
"     </li>",
"     <li>",
"      Amuretic (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Apo-Amilzide (MY);",
"     </li>",
"     <li>",
"      Biduret (IN);",
"     </li>",
"     <li>",
"      Bildiuretic (TH);",
"     </li>",
"     <li>",
"      Co-Amilozide (AU, GB);",
"     </li>",
"     <li>",
"      Hydrozide (NZ);",
"     </li>",
"     <li>",
"      Hyperetic (TH);",
"     </li>",
"     <li>",
"      Kaluril (IL);",
"     </li>",
"     <li>",
"      Lorinid Mite (ID);",
"     </li>",
"     <li>",
"      Mengdaqing (CL);",
"     </li>",
"     <li>",
"      Moduretic (AU, BE, BF, BJ, BR, CH, CI, CO, CZ, DE, EE, ET, FI, GB, GH, GM, GN, GR, HK, IE, IT, KE, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, PE, PK, PT, PY, SC, SD, SE, SL, SN, TH, TN, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Moure-M (TH);",
"     </li>",
"     <li>",
"      Mourinate (TH);",
"     </li>",
"     <li>",
"      Sefaretic (HK);",
"     </li>",
"     <li>",
"      Sparkal (DK);",
"     </li>",
"     <li>",
"      Tiaden (TW);",
"     </li>",
"     <li>",
"      Uniretic (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Yostiretic (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/51/40757/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/51/40757/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/51/40757/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8604 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40757=[""].join("\n");
var outline_f39_51_40757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708617\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133118\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133133\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133121\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133122\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2606648\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682645\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133106\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133094\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9405973\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133109\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133131\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133097\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298734\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133101\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133102\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133113\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133124\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133114\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524327\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133115\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133111\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8604\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8604|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/28/19909?source=related_link\">",
"      Amiloride and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40758="Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus";
var content_f39_51_40758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Virulence determinants of community acquired methicillin-resistant Staphylococcus aureus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40758/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40758/contributors\">",
"     Franklin D Lowy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40758/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40758/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40758/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/51/40758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997 a report of four fatal pediatric cases of MRSA in children from the community (without traditional risk factors for MRSA infection) heralded the onset of an epidemic of community associated MRSA (CA-MRSA) outbreaks that have occurred in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most prevalent strain, USA300, is now among the most common causes of skin and soft tissue infections in urban emergency departments across the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/2\">",
"     2",
"    </a>",
"    ]. Up to 10 percent of these infections are invasive infections such as sepsis, meningitis, osteomyelitis, and necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The virulence and relatively facile transmission of CA-MRSA have raised interest in understanding the pathogenesis of this organism. Issues related to evolution and virulence determinants of CA-MRSA will be reviewed here. Issues related to the microbiology of MRSA are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVOLUTION OF CA-MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the emergent CA-MRSA strain sequences demonstrate striking similarity to other clonal MRSA strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The genetic persistence of these strains over time suggests they have core genomic determinants that facilitate their survival and virulence. A small number of clones have been implicated for most MRSA infections. The original methicillin-resistant isolate is strikingly similar in nucleotide sequence to the epidemic strain USA300 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the southwest Pacific strain that has caused infections in Australia and other countries in the region is a descendent of the phage",
"    <span class=\"nowrap\">",
"     80/81",
"    </span>",
"    strain that caused outbreaks in newborn nurseries in the 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VIRULENCE DETERMINANTS AND THEIR REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enhanced virulence of the CA-MRSA strains is not fully understood but appears to result from several contributing factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of the antibiotic resistance gene for methicillin",
"     </li>",
"     <li>",
"      Virulence determinants unique to these strains",
"     </li>",
"     <li>",
"      Regulatory genes that modulate expression of virulence determinants",
"     </li>",
"     <li>",
"      The host response to infection by these strains",
"     </li>",
"     <li>",
"      Factors facilitating transmission and survival of these strains in the environment (",
"      <a class=\"graphic graphic_figure graphicRef69391 \" href=\"mobipreview.htm?13/51/14133\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Panton-Valentine leukocidin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panton-Valentine leukocidin (PVL) was among the staphylococcal toxins first described in the 1930s by investigators seeking targets for development of antisera in an era prior to therapeutic antimicrobials or staphylococcal penicillin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These toxins included leukocidins (destructive for phagocytes), hemolysins, necrotoxins (necrotic when injected subcutaneously), and lethal toxin (fatal for rabbits after intravenous injection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PVL is a cytotoxin that causes leukocyte destruction and tissue necrosis; it is encoded by genes lukS-PV and lukF-PV (together, the two components are referred to as lukSF-PV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/11\">",
"     11",
"    </a>",
"    ]. The genes are present in many strains with one of the mobile genetic elements that carry the methicillin resistance gene, staphylococcal cassette chromosome mec (SCCmec) type IV and V (CA-MRSA strains), although they are seldom present among SCCmec types I, II, and III (HA-MRSA strains) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/12-20\">",
"     12-20",
"    </a>",
"    ]. Although uncommon, the PVL is also present in some methicillin-susceptible strains of S. aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. PVL-containing S. aureus has been most frequently associated with soft tissue infection and necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a strong epidemiologic association between skin and soft tissue infections and PVL production by the MRSA strain USA300 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/27\">",
"     27",
"    </a>",
"    ]. USA300 refers to the strain's pulse field gel electrophoresis pattern; this pattern is the most common among US MRSA isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, USA300 contains staphylococcal cassette chromosome (SCCmec) type IV, which is relatively short (about 20 kb), and, as a result, is capable of rapid horizontal spread among strains of staphylococci.",
"   </p>",
"   <p>",
"    Among 320 patients with soft tissue infections presenting to emergency departments in 11 US cities in 2004, MRSA was the predominant pathogen (78 percent of isolates), and 98 percent of these were USA300 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/27\">",
"     27",
"    </a>",
"    ]. Nearly all of the USA300 isolates contained SCCmec type IV and the lukSF-PV genes encoding PVL, whereas genes for common staphylococcal enterotoxins and toxic shock syndrome were seldom present. Subsequently, both MRSA and MSSA USA300 PVL-positive strains were noted among 843 patients admitted to a large public hospital in Los Angeles in 2005, but there were no reliable epidemiologic factors to distinguish those with CA-MRSA from those with CA-MSSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inevitably, MRSA isolates elaborating PVL have also spread to hospitalized patients causing nosocomial infections. Among 37 clinical MRSA isolates at a veterans hospital, for example, 60 percent were USA300 PVL positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/24\">",
"     24",
"    </a>",
"    ]. The strain has also spread to several countries on various continents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/13,30\">",
"     13,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although PVL has a strong epidemiologic association with community-associated MRSA infections, its role in the pathogenesis and spread of infection is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/14,31-35\">",
"     14,31-35",
"    </a>",
"    ]. The most compelling clinical data has been the association of PVL with necrotizing pneumonia, particularly in the setting of post-influenza respiratory infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A rabbit model of necrotizing pneumonia demonstrated that PVL plays a critical role in infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/36\">",
"     36",
"    </a>",
"    ]. The authors hypothesized that, in the presence of a sufficient number of bacteria, PVL is produced, resulting in the activation of PMNS and macrophages with the consequent release of inflammatory cytokines. In addition, the PVL lyses PMNs causing the release of granules and proteolytic enzymes.",
"   </p>",
"   <p>",
"    In other settings, the presence of PVL may not be as important. Among 109 patients with MRSA hospital-acquired pneumonia and ventilator-acquired pneumonia (including PVL+ strains in 27 percent of cases), the severity of disease and clinical outcome was not influenced by the presence of the PVL gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/37\">",
"     37",
"    </a>",
"    ]. Expression of the PVL gene may be variably in different settings. This was illustrated in an analysis of 31 S. aureus strains collected from patients with infections of varying severity; the quantity of PVL produced in vitro did not correlate with severity of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alpha-hemolysin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-hemolysin is a well-characterized toxin capable of forming pores in selected host cells; it appears to play a critical role in the pathogenesis of infection in a mouse model. In mice infected with isogenic strains of USA300, alpha-hemolysin was essential for development of pneumonia, but PVL was not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/35\">",
"     35",
"    </a>",
"    ]. Subsequent studies demonstrated vaccination with the toxin protected mice from infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Phenol Soluble Modulins (PSMs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSMs are small cytolytic peptides that appear to be secreted in greater quantities by CA-MRSA than traditional isolates. These peptides are capable of attracting and lysing polymorphonuclear leukocytes, impairing the host defense against staphylococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Arginine catabolic mobile element (ACME)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACME is a pathogenicity island identified in USA300; it is rarely found in other strains of S. aureus, and its role in virulence is still uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. ACME is usually linked to SCCmec and inserts into the same region, orfX. The gene cluster in ACME consists of arc and opp-3. The arc gene encodes the arginine deaminase system; depletion of arginine may reduce nitric oxide production. The opp-3 gene is a part of the ABC transporter system and may contribute to survival in the environment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colonization of host tissue sites. It is also speculated that these genes may play a role in both innate and adaptive immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Accessory gene regulator",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accessory gene regulator (agr) is a regulatory gene in S. aureus that can control expression of virulent genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/43\">",
"     43",
"    </a>",
"    ]. agr has several polymorphisms (I-IV), and strains can be grouped based on these polymorphisms. In one study of CA-MRSA virulence in a rat pneumonia model using USA300 and USA400 strains, higher levels of regulatory genes including agr were produced by USA300 in vitro, suggesting one potential mechanism for its apparent enhanced virulence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of agr and other regulatory genes in CA-MRSA infections is not fully understood. Study of strains defective for agr in an animal model of endocarditis has demonstrated that it plays a critical role in the ability of S. aureus to cause infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3839286\">",
"    <span class=\"h2\">",
"     sasX gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mobile genetic element-encoded gene, sasX, appears to play an important role in the invasiveness and transmissibility of the Asian epidemic clone of MRSA sequence type 239 (ST239) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H991050596\">",
"    <span class=\"h2\">",
"     Transmission and survival in the environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CA-MRSA epidemic clones may be more efficient than other strains at colonizing multiple body sites and surviving on environmental surfaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. These factors may contribute to an enhanced risk of reinfections in community reservoirs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40758/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      USA300 is the most prevalent strain of methicillin-resistant Staphylococcus aureus (MRSA) and is now among the most common causes of skin and soft tissue infections in the United States and other countries (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The virulence and relatively facile transmission of CA-MRSA have raised interest in understanding the pathogenesis of this organism. The enhanced virulence of the CA-MRSA strains is not fully understood, but appears to result from several contributing factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Virulence determinants and their regulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several of the emergent CA-MRSA strain sequences demonstrate striking similarity to other clonal MRSA strains. The genetic persistence of these strains over time suggests they have core genomic determinants that facilitate their survival and virulence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evolution of CA-MRSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial virulence determinants include Panton-Valentine leukocidin (PVL), alpha-hemolysin, phenol soluble modulins (PSMs), and arginine catabolic mobile element (ACME). The accessory gene regulator (agr) is a regulatory gene in S. aureus that can control expression of virulent genes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Virulence determinants and their regulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus &mdash; Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/2\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/3\">",
"      Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/4\">",
"      Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/5\">",
"      Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006; 367:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/6\">",
"      Robinson DA, Kearns AM, Holmes A, et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005; 365:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/7\">",
"      Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol 2008; 16:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/8\">",
"      Lowy FD. Secrets of a superbug. Nat Med 2007; 13:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/9\">",
"      Panton, PN, Valentine, FCO. Staphylococcal toxin. Lancet 1932; 1:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/10\">",
"      Panton, PN, Valentine, FCO, Dix, VW. Staphylococcal infection and antitoxin treatment. Lancet 1931; 2:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/11\">",
"      John JF Jr, Lindsay JA. Clones and drones: do variants of Panton-Valentine leukocidin extend the reach of community-associated methicillin-resistant Staphylococcus aureus? J Infect Dis 2008; 197:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/12\">",
"      Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/13\">",
"      Larsen AR, B&ouml;cher S, Stegger M, et al. Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004. J Clin Microbiol 2008; 46:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/14\">",
"      Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 2007; 87:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/15\">",
"      Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/16\">",
"      Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/17\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/19\">",
"      Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007; 44:e88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/20\">",
"      Sola C, Saka HA, Vindel A, et al. High frequency of Panton-Valentine leukocidin genes in invasive methicillin-susceptible Staphylococcus aureus strains and the relationship with methicillin-resistant Staphylococcus aureus in C&oacute;rdoba, Argentina. Eur J Clin Microbiol Infect Dis 2007; 26:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/21\">",
"      Aires-de-Sousa M, Concei&ccedil;&atilde;o T, de Lencastre H. Unusually high prevalence of nosocomial Panton-Valentine leukocidin-positive Staphylococcus aureus isolates in Cape Verde Islands. J Clin Microbiol 2006; 44:3790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/22\">",
"      Bocchini CE, Hulten KG, Mason EO Jr, et al. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006; 117:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/23\">",
"      Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007; 45:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/24\">",
"      Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/25\">",
"      Lina G, Pi&eacute;mont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/26\">",
"      Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/27\">",
"      McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003; 41:5113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/28\">",
"      Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/29\">",
"      Gonzalez BE, Rueda AM, Shelburne SA 3rd, et al. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/30\">",
"      Tristan A, Bes M, Meugnier H, et al. Global distribution of Panton-Valentine leukocidin--positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007; 13:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/31\">",
"      Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/32\">",
"      Zhang K, McClure JA, Elsayed S, et al. Coexistence of Panton-Valentine leukocidin-positive and -negative community-associated methicillin-resistant Staphylococcus aureus USA400 sibling strains in a large Canadian health-care region. J Infect Dis 2008; 197:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/33\">",
"      Bubeck Wardenburg J, Bae T, Otto M, et al. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007; 13:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/34\">",
"      Diep BA, Sensabaugh GF, Somboonna N, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004; 42:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/35\">",
"      Hamilton SM, Bryant AE, Carroll KC, et al. In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis 2007; 45:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/36\">",
"      Diep BA, Chan L, Tattevin P, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 2010; 107:5587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/37\">",
"      Peyrani P, Allen M, Wiemken TL, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis 2011; 53:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/38\">",
"      Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/39\">",
"      Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007; 13:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/40\">",
"      Diep BA, Stone GG, Basuino L, et al. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 2008; 197:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/41\">",
"      Montgomery CP, Boyle-Vavra S, Daum RS. The arginine catabolic mobile element is not associated with enhanced virulence in experimental invasive disease caused by the community-associated methicillin-resistant Staphylococcus aureus USA300 genetic background. Infect Immun 2009; 77:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/42\">",
"      Cheung AL, Eberhardt KJ, Chung E, et al. Diminished virulence of a sar-/agr- mutant of Staphylococcus aureus in the rabbit model of endocarditis. J Clin Invest 1994; 94:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/43\">",
"      Montgomery CP, Boyle-Vavra S, Adem PV, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes USA300 and USA400 in a rat model of pneumonia. J Infect Dis 2008; 198:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/44\">",
"      von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/45\">",
"      Li M, Du X, Villaruz AE, et al. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat Med 2012; 18:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/46\">",
"      Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/47\">",
"      Yang ES, Tan J, Eells S, et al. Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect 2010; 16:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/48\">",
"      Desai R, Pannaraj PS, Agopian J, et al. Survival and transmission of community-associated methicillin-resistant Staphylococcus aureus from fomites. Am J Infect Control 2011; 39:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40758/abstract/49\">",
"      Uhlemann AC, Knox J, Miller M, et al. The environment as an unrecognized reservoir for community-associated methicillin resistant Staphylococcus aureus USA300: a case-control study. PLoS One 2011; 6:e22407.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3152 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40758=[""].join("\n");
var outline_f39_51_40758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVOLUTION OF CA-MRSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VIRULENCE DETERMINANTS AND THEIR REGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Panton-Valentine leukocidin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alpha-hemolysin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Phenol Soluble Modulins (PSMs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Arginine catabolic mobile element (ACME)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Accessory gene regulator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3839286\">",
"      sasX gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H991050596\">",
"      Transmission and survival in the environment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3152|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/51/14133\" title=\"figure 1\">",
"      CA-MRSA virulence factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40759="Lyme carditis";
var content_f39_51_40759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lyme carditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40759/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40759/contributors\">",
"     Linden Hu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40759/contributors\">",
"     Allen C Steere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40759/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/51/40759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease is a multisystem disease caused by infection with Borrelia burgdorferi. Cardiac involvement occurs during the early disseminated phase of the disease, usually within weeks to a few months after the onset of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The most common clinical feature of Lyme carditis is atrioventricular (AV) conduction block related to dysfunction of the conduction system, but may also include decreased cardiac contractility due to myopericarditis.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, treatment, and prognosis of Lyme carditis will be reviewed here. Other manifestations of Lyme disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=see_link\">",
"     \"Nervous system Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=see_link\">",
"     \"Musculoskeletal manifestations of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of Lyme carditis has varied in different reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carditis has been reported in approximately 4 to 10 percent in surveillance studies of untreated adults with Lyme disease in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/1,3-5\">",
"       1,3-5",
"      </a>",
"      ]. However, at least some of these studies included palpitations as an indicator of carditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/4\">",
"       4",
"      </a>",
"      ]. In the largest surveillance study of 5016 patients in the United States with Lyme disease, 875 had sufficient data on possible cardiac manifestations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/3\">",
"       3",
"      </a>",
"      ]. Cardiac manifestations were present in 84 patients (10 percent). Palpitations, which could be a nonspecific finding, were the most common manifestation, whereas more objective features of carditis (conduction defects, myocarditis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pericarditis) occurred in 3 percent of patients, or less if some of these patients had more than one manifestation.",
"     </li>",
"     <li>",
"      In Europe, carditis has been reported as a complication of Lyme disease in approximately 0.3 to 4.0 percent of untreated adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/6\">",
"       6",
"      </a>",
"      ]. Some authors have suggested that the incidence of carditis may be lower in Europe compared with the United States. However, given the possible overestimate of clinically significant cardiac manifestations in the United States described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/3\">",
"       3",
"      </a>",
"      ], the incidence of Lyme carditis may be similar in both regions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of carditis in children is not known. In a prospective study that included 14 children with proven Lyme disease in the United States who had electrocardiograms, two patients had first degree atrioventricular block, one had left axis deviation, and one had ventricular ectopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a strong male predominance of approximately 3:1 in cardiac Lyme disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/8\">",
"     8",
"    </a>",
"    ], compared with only a slight predominance of Lyme disease overall among males (53 percent) in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Appropriate antibiotic therapy for erythema migrans or other features of early localized Lyme disease prevents subsequent Lyme disease, including cardiac manifestations of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1784285547\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because biopsies of the heart are rarely performed and because Lyme carditis is not typically fatal, limited information is available regarding the pathophysiology of Lyme carditis in humans. Animal studies in both monkeys and mice have shown that inflammation can be seen transmurally. Inflammation typically has a predominance of macrophages and lymphocytes, which is in distinction to Lyme arthritis, where there is a heavier infiltration of neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/11\">",
"     11",
"    </a>",
"    ]. Although inflammation can affect multiple areas of the heart, in mice the heaviest areas of infiltration include the connective tissue at the base of the heart, the basal interventricular septum, and perivascular regions including the aortic adventitia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans with fatal pancarditis, diffuse infiltrates affecting multiple areas of the heart have been seen. In a case report, infiltrates were particularly prominent in perivascular areas and in the interstitial regions, similar to the findings in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/14\">",
"     14",
"    </a>",
"    ]. It is unknown what type of pathology and localization occurs in less severe cases or during earlier stages of infection in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac features of early disseminated Lyme disease typically occur one to two months (range &lt;1 to 28 weeks) after the onset of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Cardiac disease can be the only feature of infection or can occur together with other features of early Lyme disease, such as erythema migrans or early neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=see_link\">",
"     \"Clinical manifestations of Lyme disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=see_link\">",
"     \"Lyme disease: Clinical manifestations in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cardiac involvement may be asymptomatic or complain of lightheadedness, syncope, shortness of breath, palpitations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest pain.",
"   </p>",
"   <p>",
"    In a surveillance study of Lyme disease cases in the United States, 875 patients had sufficient data on possible cardiac manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/3\">",
"     3",
"    </a>",
"    ]. Cardiac manifestations were present in 84 patients (10 percent), 20 percent of whom were hospitalized. The following manifestations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations &mdash; 58 patients (6.6 percent)",
"     </li>",
"     <li>",
"      Conduction abnormalities &mdash; 16 patients (1.8 percent)",
"     </li>",
"     <li>",
"      Myocarditis &mdash; 8 patients (0.9 percent)",
"     </li>",
"     <li>",
"      Left ventricular failure &mdash; 4 patients (0.5 percent)",
"     </li>",
"     <li>",
"      Pericarditis &mdash; 2 patients (0.2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that palpitations can be a nonspecific finding, and therefore may not represent carditis. Cardiomyopathy has not been observed in patients with Lyme carditis in the United States, but has been reported rarely in patients in Europe. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Chronic cardiomyopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Atrioventricular conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular (AV) conduction block of varying severity is the most common objective manifestation of Lyme carditis. The degree of AV block can fluctuate rapidly, with first degree AV block progressing to second degree or complete AV block and sometimes back to first degree AV block over a matter of minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2\">",
"     2",
"    </a>",
"    ]. In a review of 52 patients with Lyme carditis, 87 percent had AV block; 54 percent had complete or high-grade AV block, which was usually symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/5\">",
"     5",
"    </a>",
"    ]. Another review of 105 patients with Lyme carditis in Europe and North America found similar numbers, with complete AV block in 49 percent, second degree AV block in 16 percent, and first degree AV block in 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The highest risk for progression to complete AV block, which may develop rapidly, occurs in patients with a PR interval greater than 300 milliseconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2\">",
"     2",
"    </a>",
"    ]. As would be anticipated, patients with higher degrees of AV block are more likely to be symptomatic. In one report, all 10 patients with high-grade AV block were symptomatic with syncope, dizziness, dyspnea, chest pain, or palpitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, only two of eight patients with first degree AV block had cardiac symptoms, which consisted only of palpitations.",
"   </p>",
"   <p>",
"    Electrophysiological studies have usually found conduction delay occurring above the bundle of His, often within the AV node. However, heart block can occur at different levels within the conducting system. Sinoatrial node dysfunction (manifested as SA nodal block), abnormal nodal recovery time, intraatrial block, and fascicular and bundle branch block have all been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/5,8,16-19\">",
"     5,8,16-19",
"    </a>",
"    ]. Some patients have variable bundle branch blocks, suggesting multifocal damage in the His-Purkinje system or AV node, whereas others have brief episodes of asystole due to transient failure of an escape rhythm.",
"   </p>",
"   <p>",
"    AV block caused by Lyme disease has been reported to persist for 3 to 42 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2,16,19,20\">",
"     2,16,19,20",
"    </a>",
"    ]. Complete AV block typically improves to lesser degrees of AV block within one week, and more minor conduction disturbances usually resolve within six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different types of AV block are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41574?source=see_link\">",
"     \"First degree atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type II\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=see_link\">",
"     \"ECG tutorial: Atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myopericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme myopericarditis is often self-limited and mild; it rarely leads to cardiomegaly. A mild pericardial effusion may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2\">",
"     2",
"    </a>",
"    ]. In most cases, it is asymptomatic and clinically inapparent. The most frequent manifestation of myocardial involvement in Lyme disease is nonspecific ST and T wave changes on the electrocardiogram. However, occasional patients develop symptomatic myocarditis with cardiac muscle dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated pericarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial biopsy and autopsy specimens have shown a band-like lymphoid and plasmacytic interstitial infiltrate, variable amounts of myocyte necrosis, fibrosis, and edema, and occasional endarteritis obliterans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/16,23-26\">",
"     16,23-26",
"    </a>",
"    ]. In some cases, spirochetal forms have been found in or near the cellular infiltrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], or were grown from biopsy material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. There are no documented patients with valvular damage or aortitis caused by B. burgdorferi.",
"   </p>",
"   <p>",
"    Gallium and anti-myosin indium scans have been abnormal in individual cases, but no systematic or prospective studies of the usefulness of these nonspecific tests have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Europe, scattered case reports and small case series have suggested that B. burgdorferi may be a cause of chronic cardiomyopathy in patients with no history of symptomatic Lyme disease. In contrast, cardiomyopathy has not been observed in patients with Lyme carditis in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/31\">",
"     31",
"    </a>",
"    ]. The following reports from Europe describe the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case report described a patient with chronic congestive cardiomyopathy who was strongly seropositive for anti-Borrelia burgdorferi antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/25\">",
"       25",
"      </a>",
"      ]. Myocardial biopsy revealed spirochetal forms and B. burgdorferi was grown from these specimens.",
"     </li>",
"     <li>",
"      In two patients with idiopathic dilated cardiomyopathy, B. burgdorferi was grown from their myocardial biopsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/27\">",
"       27",
"      </a>",
"      ]. Cardiac function returned to normal in both patients following treatment with IV penicillin in addition to standard medications used for heart failure.",
"     </li>",
"     <li>",
"      In a series of 42 patients with dilated cardiomyopathy, nine were seropositive for anti-B. burgdorferi antibodies and were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      : six recovered fully, two had a partial response, and one showed no improvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Lyme carditis is established by the presence of consistent epidemiologic and clinical features in conjunction with positive results of Lyme serologic testing. It is important to establish the diagnosis of Lyme disease not only so that antibiotics can be administered, but also to avoid placement of a permanent pacemaker in those with severe conduction disturbances; the atrioventricular block associated with Lyme carditis is usually short-lived and can be managed with a temporary pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Telemetry and pacemakers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Associated features",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history should address risk factors or possible evidence of B. burgdorferi infection. These include prior exposure (residence in or travel through an endemic area), previous tick bites, prior or current erythema migrans lesion(s), and coexistence of neurologic dysfunction compatible with neurologic Lyme disease. The first reported series describing 20 patients with Lyme carditis found the following associated features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema migrans in 15 (75 percent)",
"     </li>",
"     <li>",
"      Joint involvement in 13 (65 percent)",
"     </li>",
"     <li>",
"      Meningoencephalitis (some with concurrent facial nerve palsy or radiculoneuritis) in seven (35 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnosis of Lyme carditis is more difficult in patients whose only observed manifestation of Lyme disease is carditis and in those who had only a preceding non-specific febrile illness. In cases of isolated carditis, diagnosis relies on serologic testing in patients with a moderate to high pretest probability of Lyme disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An enzyme-linked immunosorbent assay (ELISA) and confirmatory Western blot analysis should reveal seropositivity for Lyme disease in patients with Lyme carditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/33\">",
"     33",
"    </a>",
"    ]. As with the use of serologic testing for other manifestations of Lyme disease, serologic test results alter the likelihood that a patient has Lyme disease, but do not establish the diagnosis alone. Test results need to be interpreted in light of the pre-test probability that the patient has Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following factors should be kept in mind when obtaining these tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If IgM positivity is found, it is likely that the infection is recent and that B. burgdorferi is the etiologic agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/34\">",
"       34",
"      </a>",
"      ]. However, IgM reactivity, both by ELISA and Western blot, is subject to higher rates of false positivity than IgG tests. In addition, the IgM response may persist for years in patients with prior Lyme disease.",
"     </li>",
"     <li>",
"      Because Lyme carditis is a manifestation of the disseminated stage and typically occurs one to two months after the initial infection, the vast majority of patients have positive serologic responses (either IgM or IgG) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/33\">",
"       33",
"      </a>",
"      ]. Thus, patients with a negative serologic test are very unlikely to have Lyme carditis.",
"     </li>",
"     <li>",
"      Up to 5 percent of the population in Lyme disease-endemic areas is seropositive by ELISA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/33,35\">",
"       33,35",
"      </a>",
"      ]. As a result, a positive ELISA result does",
"      <strong>",
"       not",
"      </strong>",
"      confirm the diagnosis of Lyme carditis; all positive or equivocal ELISA results should be corroborated by a Western blot. &nbsp;",
"     </li>",
"     <li>",
"      Serum antibody levels may persist long after cure of Lyme disease. Thus, even IgM seropositivity may be related to a prior episode of Lyme disease, rather than recent infection, and the current cardiac disease may not be causally related to B. burgdorferi infection. Likewise, persistence of serologic reactivity after an episode of cardiomyopathy does not represent ongoing infection, nor does it suggest a need for prolonged therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Lyme carditis are treated to prevent later complications of Lyme disease and to shorten the duration of the cardiac manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/36\">",
"     36",
"    </a>",
"    ]. Because of the potential for life-threatening complications, patients who are symptomatic (eg, syncope, dyspnea, or chest pain), have second or third degree atrioventricular (AV) block, or have first degree AV block with a markedly prolonged PR interval (&ge;300 milliseconds) should be hospitalized, monitored with cardiac telemetry, and treated with intravenous antibiotics (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;No comparative trials have been performed to identify the optimal antibiotic regimen for Lyme carditis or to confirm that outcomes are improved with initial treatment with intravenous antibiotics compared with oral antibiotics. Supportive data come from case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/27\">",
"     27",
"    </a>",
"    ]. Studies of antibiotics for other manifestations of Lyme disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89979848\">",
"    <span class=\"h3\">",
"     IV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, patients who are symptomatic (eg, syncope, dyspnea, or chest pain), have second or third degree atrioventricular (AV) block, or have first degree AV block with a markedly prolonged PR interval (&ge;300 milliseconds) should be hospitalized, monitored with cardiac telemetry, and treated with intravenous antibiotics (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/36\">",
"     36",
"    </a>",
"    ]. When IV therapy is required, the drug of choice is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily in adults; 50 to 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily in children), but appropriate alternatives include IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ). Desensitization to ceftriaxone, cefotaxime, or penicillin should be considered in patients who require IV therapy but have a history of an IgE-mediated (anaphylactic) reaction to these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"     \"Allergy to penicillins\", section on 'Desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IV antibiotics should be continued until high-grade AV block has resolved and the PR internal has become less than 300 milliseconds. The patient may then be switched to oral therapy to complete of a 21 to 28 day course. Appropriate oral antibiotics include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil, although doxycycline should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children &lt;8 years of age or in pregnant women (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89979907\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with early disseminated disease and first-degree AV block with a PR interval &lt;300 milliseconds who are not admitted to the hospital can be treated initially with oral therapy (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients who are admitted to the hospital for cardiac monitoring should be treated initially with IV antibiotics, but should be switched to an oral regimen prior to or at the time of hospital discharge. The total duration of therapy is 21 days. (See",
"    <a class=\"local\" href=\"#H89979848\">",
"     'IV therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The drugs of choice for oral therapy are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil, although doxycycline should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children &lt;8 years of age or in pregnant women (",
"    <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Telemetry and pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are symptomatic (eg, syncope, dyspnea, or chest pain), have second or third degree atrioventricular (AV) block, or have first degree AV block with a markedly prolonged PR interval (&ge;300 milliseconds) require hospitalization for close monitoring with cardiac telemetry and intravenous antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/36\">",
"     36",
"    </a>",
"    ]. Once the PR interval is &lt;300 milliseconds, monitoring with telemetry is usually continued for an additional 24 to 48 hours.",
"   </p>",
"   <p>",
"    Patients with severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic AV block may require a temporary pacemaker; the indications for pacing are the same as in other causes of heart block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/37\">",
"     37",
"    </a>",
"    ]. Since AV block caused by Lyme disease is usually short-lived, temporary pacing is often required only for several days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link&amp;anchor=H16#H16\">",
"     \"Temporary cardiac pacing\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4\">",
"     'Atrioventricular conduction abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of Lyme carditis is good. In most reports, atrioventricular (AV) block caused by Lyme disease has persisted for 3 to 42 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2,16,19,20\">",
"     2,16,19,20",
"    </a>",
"    ]. Complete AV block typically resolves within one week, and more minor conduction disturbances within six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. There have been a few reports of permanent AV block or persistence of first degree AV block after more severe heart block has resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/6,18,38\">",
"     6,18,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cases of fatal Lyme carditis have been reported in at least three cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/14,24,39\">",
"     14,24,39",
"    </a>",
"    ], infection with B. burgdorferi was not documented according to current standards in one of these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, in one case, the patient had coinfection with babesiosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40759/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/40/30338?source=see_link\">",
"       \"Patient information: Lyme disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/17/32022?source=see_link\">",
"       \"Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=see_link\">",
"       \"Patient information: Lyme disease treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=see_link\">",
"       \"Patient information: Lyme disease prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92092455\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lyme disease is a multisystem disease caused by infection with Borrelia burgdorferi. Cardiac involvement occurs during the early disseminated phase of the disease, usually within weeks to a few months after infection. The most common clinical feature of Lyme carditis is atrioventricular (AV) conduction block related to dysfunction of the conduction system, but may also include decreased cardiac contractility due to myopericarditis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardiac features of Lyme disease typically occur one to two months (range &lt;1 to 28 weeks) after the onset of infection. Cardiac disease can be the only feature of infection or can occur together with other features of early Lyme disease, such as erythema migrans or early neurologic symptoms. Patients with cardiac involvement may be asymptomatic or complain of lightheadedness, syncope, shortness of breath, palpitations,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chest pain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Varying degrees of AV block are the most common manifestation of Lyme carditis. The degree of AV block can fluctuate rapidly, with first degree AV block progressing to second degree or complete AV block and sometimes back to first degree AV block over a matter of minutes. The highest risk for progression to complete AV block occurs in patients with a PR interval greater than 300 milliseconds. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Atrioventricular conduction abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Lyme carditis is established by the presence of clinical features in conjunction with positive results of Lyme serologic testing. An ELISA and Western blot analysis should reveal seropositivity for Lyme disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with early disseminated disease and carditis who are symptomatic, have second or third degree AV block, or have first degree AV block with a prolonged PR interval (&ge;300 msec) should be admitted to the hospital for monitoring with cardiac telemetry and consideration of a temporary pacemaker. We recommend that all patients who require hospital admission be treated with IV antibiotics such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      rather than oral antibiotics (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). IV antibiotics should be continued until high-degree heart block has resolved and the PR interval has become less than 300 milliseconds; the patient may then be switched to oral therapy to complete a 21 to 28 day course (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that asymptomatic patients with early disseminated disease and first-degree AV block with a PR interval &lt;300 milliseconds who are not admitted to the hospital be treated initially with oral therapy (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The total duration of therapy for such patients is 21 days. We suggest that patients who are admitted to the hospital for cardiac monitoring be treated initially with IV antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients should be switched to an oral regimen prior to or at the time of hospital discharge. (See",
"      <a class=\"local\" href=\"#H89979907\">",
"       'Oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate oral antibiotics include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      axetil, although doxycycline should",
"      <strong>",
"       not",
"      </strong>",
"      be used in children &lt;8 years of age or in pregnant women (",
"      <a class=\"graphic graphic_table graphicRef59949 \" href=\"mobipreview.htm?21/35/22078\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of Lyme carditis is good. In most reports, AV block caused by Lyme disease has persisted for 3 to 42 days. Complete AV block typically resolves within one week, and more minor conduction disturbances within six weeks (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/1\">",
"      Fish AE, Pride YB, Pinto DS. Lyme carditis. Infect Dis Clin North Am 2008; 22:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/2\">",
"      Steere AC, Batsford WP, Weinberg M, et al. Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980; 93:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/3\">",
"      Ciesielski CA, Markowitz LE, Horsley R, et al. Lyme disease surveillance in the United States, 1983-1986. Rev Infect Dis 1989; 11 Suppl 6:S1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/4\">",
"      Schmid GP, Horsley R, Steere AC, et al. Surveillance of Lyme disease in the United States, 1982. J Infect Dis 1985; 151:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/5\">",
"      McAlister HF, Klementowicz PT, Andrews C, et al. Lyme carditis: an important cause of reversible heart block. Ann Intern Med 1989; 110:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/6\">",
"      Mayer W, Kleber FX, Wilske B, et al. Persistent atrioventricular block in Lyme borreliosis. Klin Wochenschr 1990; 68:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/7\">",
"      Woolf PK, Lorsung EM, Edwards KS, et al. Electrocardiographic findings in children with Lyme disease. Pediatr Emerg Care 1991; 7:334.",
"     </a>",
"    </li>",
"    <li>",
"     Vlay, SC. Cardiac manifestations in Lyme disease, Coyle, P (Ed), Mosby-Yearbook, St Louis 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/9\">",
"      Bacon RM, Kugeler KJ, Mead PS, Centers for Disease Control and Prevention (CDC). Surveillance for Lyme disease--United States, 1992-2006. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/10\">",
"      Sangha O, Phillips CB, Fleischmann KE, et al. Lack of cardiac manifestations among patients with previously treated Lyme disease. Ann Intern Med 1998; 128:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/11\">",
"      Cadavid D, Bai Y, Hodzic E, et al. Cardiac involvement in non-human primates infected with the Lyme disease spirochete Borrelia burgdorferi. Lab Invest 2004; 84:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/12\">",
"      Armstrong AL, Barthold SW, Persing DH, Beck DS. Carditis in Lyme disease susceptible and resistant strains of laboratory mice infected with Borrelia burgdorferi. Am J Trop Med Hyg 1992; 47:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/13\">",
"      Saba S, VanderBrink BA, Perides G, et al. Cardiac conduction abnormalities in a mouse model of Lyme borreliosis. J Interv Card Electrophysiol 2001; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/14\">",
"      Tavora F, Burke A, Li L, et al. Postmortem confirmation of Lyme carditis with polymerase chain reaction. Cardiovasc Pathol 2008; 17:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/15\">",
"      van der Linde MR. Lyme carditis: clinical characteristics of 105 cases. Scand J Infect Dis Suppl 1991; 77:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/16\">",
"      Cox J, Krajden M. Cardiovascular manifestations of Lyme disease. Am Heart J 1991; 122:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/17\">",
"      Reznick JW, Braunstein DB, Walsh RL, et al. Lyme carditis. Electrophysiologic and histopathologic study. Am J Med 1986; 81:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/18\">",
"      van der Linde MR, Crijns HJ, de Koning J, et al. Range of atrioventricular conduction disturbances in Lyme borreliosis: a report of four cases and review of other published reports. Br Heart J 1990; 63:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/19\">",
"      van der Linde MR, Crijns HJ, Lie KI. Transient complete AV block in Lyme disease. Electrophysiologic observations. Chest 1989; 96:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/20\">",
"      Costello JM, Alexander ME, Greco KM, et al. Lyme carditis in children: presentation, predictive factors, and clinical course. Pediatrics 2009; 123:e835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/21\">",
"      Vlay SC, Dervan JP, Elias J, et al. Ventricular tachycardia associated with Lyme carditis. Am Heart J 1991; 121:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/22\">",
"      Lorcerie B, Boutron MC, Portier H, et al. [Pericardial manifestations of Lyme disease]. Ann Med Interne (Paris) 1987; 138:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/23\">",
"      de Koning J, Hoogkamp-Korstanje JA, van der Linde MR, Crijns HJ. Demonstration of spirochetes in cardiac biopsies of patients with Lyme disease. J Infect Dis 1989; 160:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/24\">",
"      Marcus LC, Steere AC, Duray PH, et al. Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. Ann Intern Med 1985; 103:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/25\">",
"      Stanek G, Klein J, Bittner R, Glogar D. Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy. N Engl J Med 1990; 322:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/26\">",
"      Duray PH. Histopathology of clinical phases of human Lyme disease. Rheum Dis Clin North Am 1989; 15:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/27\">",
"      Lardieri G, Salvi A, Camerini F, et al. Isolation of Borrelia burgdorferi from myocardium. Lancet 1993; 342:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/28\">",
"      Alpert LI, Welch P, Fisher N. Gallium-positive Lyme disease myocarditis. Clin Nucl Med 1985; 10:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/29\">",
"      Jacobs JC, Rosen JM, Szer IS. Lyme myocarditis diagnosed by gallium scan. J Pediatr 1984; 105:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/30\">",
"      Cas&aacute;ns I, Villar A, Almenar V, Blanes A. Lyme myocarditis diagnosed by indium-111-antimyosin antibody scintigraphy. Eur J Nucl Med 1989; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/31\">",
"      Sonnesyn SW, Diehl SC, Johnson RC, et al. A prospective study of the seroprevalence of Borrelia burgdorferi infection in patients with severe heart failure. Am J Cardiol 1995; 76:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/32\">",
"      Gasser R, Dusleag J, Reisinger E, et al. Reversal by ceftriaxone of dilated cardiomyopathy Borrelia burgdorferi infection. Lancet 1992; 339:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/33\">",
"      Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for lyme disease. Clin Infect Dis 2008; 47:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/34\">",
"      Steere AC. Lyme disease. N Engl J Med 2001; 345:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/35\">",
"      Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med 1998; 339:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/36\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/37\">",
"      L&oacute;rincz I, Lakos A, Kov&aacute;cs P, et al. Temporary pacing in complete heart block due to Lyme disease: a case report. Pacing Clin Electrophysiol 1989; 12:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/38\">",
"      Artigao R, Torres G, Guerrero A, et al. Irreversible complete heart block in Lyme disease. Am J Med 1991; 90:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40759/abstract/39\">",
"      Cary NR, Fox B, Wright DJ, et al. Fatal Lyme carditis and endodermal heterotopia of the atrioventricular node. Postgrad Med J 1990; 66:134.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7915 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40759=[""].join("\n");
var outline_f39_51_40759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H92092455\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1784285547\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Atrioventricular conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Associated features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89979848\">",
"      - IV therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H89979907\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Telemetry and pacemakers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92092455\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7915|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/35/22078\" title=\"table 1\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41574?source=related_link\">",
"      First degree atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14681?source=related_link\">",
"      Nervous system Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/40/30338?source=related_link\">",
"      Patient information: Lyme disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/0/27649?source=related_link\">",
"      Patient information: Lyme disease prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/17/32022?source=related_link\">",
"      Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/41/5778?source=related_link\">",
"      Patient information: Lyme disease treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/998?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40760="Treatment of Candida infection in neonates";
var content_f39_51_40760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Candida infection in neonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40760/contributors\">",
"     Mohan Pammi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40760/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40760/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40760/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/51/40760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida has emerged as an important cause of neonatal infections with significant morbidity and mortality, especially in extremely low and very low birth weight infants, defined as birth weights below 1000 g and 1500 g, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Successful management of neonatal candidiasis requires effective treatment of candidal infection with appropriate antifungal therapy and supportive care, and preventive measures to reduce the risk of systemic candidal infections.",
"   </p>",
"   <p>",
"    The treatment of Candida infections in neonates will be reviewed here. The clinical manifestations, diagnosis, etiology, risk factors and prevention of neonatal candidal infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=see_link\">",
"     \"Epidemiology and risk factors for Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9991?source=see_link\">",
"     \"Prevention of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the treatment of breastfeeding mothers with candidal infections skin infections is also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=see_link&amp;anchor=H14#H14\">",
"     \"Common problems of breastfeeding and weaning\", section on 'Candidal infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of Candida infections is dependent upon the clinical presentation of candidal infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candidemia and invasive focal infection &ndash; Treatment consists of systemic antifungal agents and the removal of any potentially contaminated medical hardware, such as a central venous catheter or bladder catheter.",
"     </li>",
"     <li>",
"      Mucocutaneous candidiasis &ndash; Topical antifungal agents alone are effective treatment in most patients with oropharyngeal candidiasis (thrush), diaper dermatitis, and uncomplicated congenital candidiasis in term infants. In more severe mucocutaneous disease that is likely to result in disseminated disease, systemic antifungal agents are required.",
"     </li>",
"     <li>",
"      Prevention of candidiasis &ndash; Preventive measures to reduce the risk of developing candidal infections include efforts to reduce Candida cross-transmission and risk factors associated with fungal infections, and the use of prophylactic antifungal agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CANDIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates with systemic candidiasis, treatment consists of removing any source of infection, such as a venous or bladder catheter, and the administration of systemic antifungal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Removal of medical hardware or fungal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of medical hardware that is a focus for Candida decreases the mortality rate and increases the clearance rate of systemic infection. In one retrospective study of 104 neonates with a positive Candida blood culture cared for in a neonatal intensive care unit (NICU), the failure to remove a central venous catheter as soon as candidemia was detected was associated with an increased mortality rate (0 versus 39 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/8\">",
"     8",
"    </a>",
"    ]. Infants who had their central venous catheter removed as soon as candidemia was detected compared to those with late-removal of catheter had a shorter median duration of candidemia (three versus six days).",
"   </p>",
"   <p>",
"    Surgical resection of infected tissue may be needed, if systemic antifungal therapy is not successful in eradicating the infection or if the infected tissue causes functional impairment. Functional impairment may be seen in patients a fungal mass causing urinary obstruction or hemodynamic compromise of the right atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Overview systemic antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four different classes of antifungal agents are currently available to treat neonatal candidemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyenes &ndash; Polyenes include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , which is the most commonly used antifungal treatment for neonatal candidemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Triazoles &ndash; The most commonly used triazole in neonates is",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Nucleoside analogues &ndash; The most commonly used nucleoside analogue in neonates is",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"       flucytosine",
"      </a>",
"      . It is commonly used in combination with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in neonates with central nervous system candidal infections.",
"     </li>",
"     <li>",
"      Echinocandins &ndash; In neonates with candidemia, case reports demonstrate echinocandins successfully treated neonates with candidemia that was refractory or resistant to conventional therapy with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is the most commonly used antifungal agent used to treat neonatal candidemia, there are reports of systemic infections with Candida species that are refractory (eg, C. glabrata and C. krusei) or resistant to amphotericin B (eg, C. lusitaniae). Thus, in each case of candidemia, the species of Candida should be isolated and its antifungal susceptibility should be determined so that the most effective agent can be administered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    (also referred to as amphotericin B deoxycholate), a polyene, binds to ergosterol in the fungal cell membrane leading to cell leakage and death. Most Candida species are sensitive to amphotericin B and this drug is efficacious and well-tolerated in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. As a result, amphotericin B is the recommended and most commonly used drug in the treatment of systemic neonatal candidal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amphotericin is only available in parenteral form. Pharmacokinetic data demonstrate achievement of therapeutic plasma levels with administered dosing regimens between 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, although there is patient variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Successful treatment of systemic candidal infections has been reported using this dosing regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In patients with pre-existing renal insufficiency, the dosing of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    does not need be adjusted as serum concentrations are not significantly increased. However, if there is renal toxicity thought to be drug-related, alternate-day dosing should be used in preference to a decrease in daily dose.",
"   </p>",
"   <p>",
"    In our practice, we start with an initial dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which is followed in 12 hours by a dose of 1.0",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which is then give daily throughout the course of therapy.",
"   </p>",
"   <p>",
"    In patients with CNS (or suspected CNS involvement), we consider adding",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    at 50 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into four doses if the CSF does not become sterile within a few days or if the patient is becoming more ill on",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    monotherapy at a dose between 1.0 and 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of amphotericin appear to be less common and severe in neonates than in older children and adults. Although there is a potential for nephrotoxicity and hypokalemia due to renal losses, it appears that most infants display no or transient nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/19\">",
"     19",
"    </a>",
"    ]. This was illustrated in a retrospective review of 92 infants less than 90 days of age (median gestational age 26 weeks, range 23 to 41 weeks) who received at least three doses of amphotericin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/20\">",
"     20",
"    </a>",
"    ]. Nephrotoxicity (defined as an increase in serum creatinine [SCr] of 0.4",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    developed in 15 (16 percent) patients, and the maximum creatinine values did not exceed 2",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    In addition, 16 patients (17 percent) developed hypokalemia (defined as serum potassium &lt;3",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    which was more likely in patients with nephrotoxicity. By the end of amphotericin therapy, SCr levels returned to baseline in eight patients, were decreasing in three patients, and remained elevated in four patients. Amphotericin therapy was not discontinued, and there was no dose reduction in any of the patients. There was no difference between infants who did or did not develop nephrotoxicity in terms of gestational age, birth weight, gender, underlying medical conditions, use of other potentially nephrotoxic medications or amphotericin exposure, and duration of therapy.",
"   </p>",
"   <p>",
"    Other reported adverse effects include hypomagnesemia caused by excessive renal losses, bone marrow suppression with anemia and thrombocytopenia, and an increase in hepatic enzymes. These abnormalities are infrequent, dose dependent, and resolve with cessation of the drug.",
"   </p>",
"   <p>",
"    Because of the potential adverse effects, infants should have serial monitoring of serum potassium, magnesium, and creatinine, liver enzymes, and complete blood count while receiving",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In infants, the initial test dose commonly administered in older children and adults is not generally given because of the lower rate of infusion-related side effects, and the desire to as quickly as possible reach therapeutic levels of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    due to the high risk of dissemination and poor outcome of neonatal candidemia. As noted above, we begin with an initial dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    followed in 12 hours by a dose of 1.0",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which is then administered daily throughout the course of therapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of therapy is unclear. Most neonatologists and pediatric infectious disease specialists treat for a minimum of 14 days after sterilization of the infected body fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/13\">",
"     13",
"    </a>",
"    ]. Others suggest that a cumulative dose of 25 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    be administered, especially in very low or extremely low birth infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of therapy for focal complicated infections, such as endocarditis or renal fungal masses, which are often persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    difficult to eradicate, is also unclear. Because of the difficulty of eradication, therapy is generally prolonged in these infants. Imaging studies can be used to identify fungal abscesses in the kidney, heart, or brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/21\">",
"     21",
"    </a>",
"    ]. Renal ultrasonography has been used to assess clearance of renal fungal masses but these studies appear to poorly correlate with the course of the infection and patient outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Nevertheless, treatment should be continued until there is complete resolution of fungal abscesses or masses by imaging studies.",
"   </p>",
"   <p>",
"    Based upon the limited data, we treat neonates with candidemia without a complicated focal infection for a minimum of 14 days after the first sterile blood culture is obtained. In patients with a focal infection due to systemic dissemination that is likely to be difficult to eradicate, the duration of therapy may have to be prolonged to 4 to 12 weeks along with surgical removal of the foci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/6\">",
"     6",
"    </a>",
"    ]. Decisions are based upon sterilization of blood cultures as well as eradication of any sign of infection by imaging studies.",
"   </p>",
"   <p>",
"    In patients with catheter-associated infection who do not have multi-organ involvement or disseminated disease, a shorter course of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (cumulative dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in conjunction with catheter removal provides a favorable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Amphotericin B lipid formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-based",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulations have the ability to deliver a higher dose of medication with lower levels of toxicity but are significantly more expensive than standard amphotericin B. They are typically reserved for patients who develop intolerant infusion-related reactions or renal dysfunction during standard amphotericin B administration.",
"   </p>",
"   <p>",
"    Data on the use of these agents in neonates are limited to case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Most reports show that lipid-based",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    preparations successfully treated neonates with candidemia and were not associated with any major adverse effects. However, in a multicenter retrospective review of 730 infants with positive blood, urine or cerebrospinal fluid cultures for Candida species, multivariate analysis showed higher mortality for infants receiving amphotericin B lipid products compared with infants receiving amphotericin B deoxycholate (odds ratio [OR] 1.96, 95% CI 1.16-3.33) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    (OR 2.39, 95% CI 1.18-4.83) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, we prefer conventional",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (ie, amphotericin B deoxycholate) to the lipid formulation, as the lipid agents do not appear to be superior and may be less beneficial to the less expensive amphotericin B. The lipid formulations should be avoided if Candida infection involves the urinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     Fluconazole",
"    </a>",
"    , a first generation triazole, is the most commonly used triazole in the treatment of neonatal candidal infections. It inhibits the fungal enzyme 14-alpha-sterol demethylase, which is necessary for the production of ergosterol, a major component of the fungal cell membrane.",
"   </p>",
"   <p>",
"    In infants with systemic candidal infections,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    is the most commonly used alternate medication to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . Fluconazole has several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excellent bioavailability when taken orally, potentially reducing the need for intravenous administration",
"     </li>",
"     <li>",
"      Excellent therapeutic levels throughout the body including the CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excellent agent for the treatment of Candida urinary tract infection because it is excreted unchanged in high concentrations into the urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have shown",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    to be effective in treating neonatal systemic candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In one small trial of 23 infants with proven fungal septicemia, patients were randomly assigned fluconazole (intravenously or enterally) or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no difference in patient outcome with deaths occurring in 3 of 12 patients who received fluconazole and 5 of 11 patients who received amphotericin B. Patients who received fluconazole appeared to have less hepatotoxicity with lower serum bilirubin and alkaline phosphatase concentrations.",
"   </p>",
"   <p>",
"    The major disadvantage of this agent is the emergence of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant Candida species, such as C. krusei, C. glabrata, and C. parapsilosis. The use of fluconazole prophylaxis to reduce candidal infections may also be a contributing factor for fluconazole resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9991?source=see_link\">",
"     \"Prevention of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    should not be used as the initial sole therapy in an infant with candidemia or suspected candidemia. It should be given only after identifying the Candida species and determining that the organism is sensitive to fluconazole. This is especially important if prior fluconazole prophylaxis has been given to the infant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9991?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of Candida infection in neonates\", section on 'Antifungal prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon plasma samples of 55 infants (range of gestational age between 23 and 40 weeks gestation), a dose of 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day during the first 90 days of life is needed to achieve optimal serum",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    concentration to treat candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/34\">",
"     34",
"    </a>",
"    ]. The dosing interval may be extended to 48 hours in extremely premature infants with impaired renal clearance. One small study suggests that administrating fluconazole as an initial loading dose, which is routinely used in older patients, was safe and achieved therapeutic levels more rapidly than current regimens without an initial loading dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/35\">",
"     35",
"    </a>",
"    ]. In this study, an initial loading dose of 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    was given, followed by maintenance dosing of 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Further studies are needed to confirm that this is a safe and more effective dosing regimen.",
"   </p>",
"   <p>",
"    Lower doses of 3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice weekly may be adequate to prevent candidal infections in preterm infants (gestational age less than 30 weeks). Centers should consider the minimum inhibitory concentration (MIC) range of the isolates of colonizing Candida species found in their unit when deciding upon dosing regimen.",
"   </p>",
"   <p>",
"    Second generation triazoles, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/60/12234?source=see_link\">",
"     voriconazole",
"    </a>",
"    , have been developed with a broader spectrum of activity and increased potency. In adult trials, they are effective in",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    -resistant species, but there are not comparable data in neonates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Azoles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, the most commonly used nucleoside analogue is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    , a fluorine analogue of cytosine. It inhibits thymidylate synthetase, which disrupts DNA synthesis. Because this mechanism of action is not specific to Candida, there are significant side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link&amp;anchor=H13#H13\">",
"     \"Pharmacology of flucytosine (5-FC)\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"     flucytosine",
"    </a>",
"    as a sole agent is limited because of the rapid development of resistance when used as monotherapy. It is mainly used in combination with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in neonates with CNS candidiasis because flucytosine has excellent penetration into the CSF and is synergistic with amphotericin B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"     Flucytosine",
"    </a>",
"    is only available in enteral form, thus limiting its use in critically ill neonates. The oral dose is 50 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into four doses at six-hour intervals. It is critical to monitor blood levels of flucytosine to avoid bone marrow toxicity. Peak plasma concentrations obtained 60 to 120 minutes after administration should be maintained between 40 and 60",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    and trough levels obtained prior to the next dose should be less than 25",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Bone marrow suppression is increased with sustained levels greater than 100",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins prevent the formation of glucan polymers, a major component of the fungal cell wall, by inhibiting the 1,3-beta-D-glucan synthase enzyme complex. These agents appear to be well-tolerated with a minimum of adverse effects, because this enzymatic complex is not found in mammals. Resistance to this class of antifungal agents is uncommon.",
"   </p>",
"   <p>",
"    Echinocandins include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/47/21237?source=see_link\">",
"     caspofungin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/29/9686?source=see_link\">",
"     micafungin",
"    </a>",
"    , which have all been shown to be effective and safe in adult patients. In neonates, data are limited. Case reports, small case series, and open-label studies of micafungin suggest that echinocandins are well-tolerated in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One open-label phase 1 trial demonstrated no serious adverse effects of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/29/9686?source=see_link\">",
"       micafungin",
"      </a>",
"      in 23 premature infants. In addition, it demonstrated that there is a more rapid micafungin clearance rate in neonates compared to published data in older children and adults, suggesting that dosing will need to be modified in neonatal patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second open-label study of 12 preterm infants also reported no adverse events related to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/29/9686?source=see_link\">",
"       micafungin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/40\">",
"       40",
"      </a>",
"      ]. Pharmokinetic data suggest that 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      dosing in preterm infants corresponds to a 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      dosing in adults. No adverse events related to micafungin were observed.",
"     </li>",
"     <li>",
"      In a study of 47 infants with a proven or presumptive diagnosis of disseminated candidiasis, the administration of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/29/9686?source=see_link\">",
"       micafungin",
"      </a>",
"      in escalating doses to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      was safe. A dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day resulted almost all patients (83 percent) having concentrations in an area under the concentration-time curve that was associated with near-maximal decline in fungal burden within the central nervous system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 18 infants that were receiving amphotericin for suspected or proven candidiasis and less than 3 months of age, an infusion of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/47/21237?source=see_link\">",
"       caspofungin",
"      </a>",
"      at 25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once a day over an hour was well tolerated with comparable plasma levels to adults receiving 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although echinocandins appear to be a promising class of antifungal agents in the treatment of neonatal candidemia, further data on their efficacy, safety, and dosing regimen in neonates are needed before they can be recommended for general use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Our approach to treating candidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is our approach in managing systemic candidal infection in the neonate, which is in agreement with the 2009 Infectious Diseases Society of America guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For disseminated disease, we suggest that",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      be given as a daily dose of 0.5 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily until a total cumulative dose of 25 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      has been administered. Alternate therapy includes",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      as monotherapy. In addition, all potentially contaminated medical hardware should be removed.",
"     </li>",
"     <li>",
"      In infants with a positive culture for any sterile body fluid or urine, further testing is required to evaluate for disseminated invasive focal infection. This includes cultures of the blood, urine, and cerebral spinal fluid, dilated eye examination, cardiac echocardiogram, and diagnostic imaging of the liver, spleen, and kidney. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Invasive focal infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For catheter-associated candidemia without evidence of dissemination, we suggest a shorter course of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      total cumulative dose) be given in conjunction with catheter removal.",
"     </li>",
"     <li>",
"      In patients with CNS (or suspected CNS involvement), we consider adding",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"       flucytosine",
"      </a>",
"      at 50 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into four doses if the CSF does not become sterile within a few days or if the patient is becoming more ill on",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      monotherapy at a dose between 1.0 and 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day.",
"     </li>",
"     <li>",
"      In all patients with positive cultures, the Candida species and its susceptibility to antifungal agents are determined. Based upon the results, the choice of antifungal agent is modified. If the species is sensitive to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , monotherapy is the preferred choice of therapy.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"       Fluconazole",
"      </a>",
"      is an alternative agent for susceptible isolates.",
"     </li>",
"     <li>",
"      Echinocandins are not routinely used. They may be considered in infants for whom the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      and amphotericin is precluded because of drug toxicity or candidal resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In instances where clearance of candidemia is not observed after primary treatment with amphotericin, a second agent (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      or an echinocandin) is added. There is paucity of evidence to guide the best combination therapy in such neonatal cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surveillance cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic screening for Candida colonization has been proposed as a useful tool in determining when antifungal therapy should be initiated.",
"   </p>",
"   <p>",
"    In one retrospective study that obtained Candida surveillance cultures in 51 preterm infants born at &le;28 weeks gestation, all 16 infants who had positive culture results (ie, stool and bronchoalveolar lavage fluid) were treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    when colonization was detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/45\">",
"     45",
"    </a>",
"    ]. All patients subsequently developed Candida infection; 12 with candidemia, 2 with mucocutaneous candidiasis, and 2 with candidal pneumonia. Although six infants with candidal infections died, only one death was attributed to Candida infection. The remaining 35 infants with negative cultures did not develop Candida infection and did not receive antifungal therapy.",
"   </p>",
"   <p>",
"    However, further studies are needed to see whether antifungal therapy should be initiated when colonization is detected by a positive surveillance culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MUCOCUTANEOUS CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with noninvasive mucocutaneous candidiasis (ie, thrush, diaper dermatitis, and uncomplicated congenital candidiasis in term infants) with a low risk for disseminated systemic infection can be treated with topical antifungal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/46\">",
"     46",
"    </a>",
"    ]. Topical antifungal agents include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/23/34160?source=see_link\">",
"     nystatin",
"    </a>",
"    and azole topical preparations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral candidiasis &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/23/34160?source=see_link\">",
"       Nystatin",
"      </a>",
"      , a polyene topical agent antibiotic, is usually the initial agent to treat oral candidiasis (thrush), as it is not absorbed systemically from the gastrointestinal tract. It is administered as an oral suspension (100,000",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      as a dose of 0.5 mL to each side of the mouth, given four times a day. Reported cure rates vary from 29 to 85 percent with the use of nystatin suspension given four to six times a day between feeds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Oral miconazole gel has a better cure rate of more than 90 percent, but systemic absorption may occur, and gastrointestinal side effects are reported in 6 percent of premature neonates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/46\">",
"       46",
"      </a>",
"      ]. In recalcitrant cases of thrush, oral fluconazole (3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      once a day for seven days) may be used and has a cure rate of 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diaper dermatitis &ndash; Diaper dermatitis is treated with topical",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      , miconazole cream, or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/58/34720?source=see_link\">",
"       clotrimazole",
"      </a>",
"      cream [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/46\">",
"       46",
"      </a>",
"      ]. Uncomplicated congenital cutaneous candidiasis in term infants is treated with topical nystatin or azole creams, but in complicated infants (clinical signs of sepsis or respiratory distress) or premature infants (where there is a risk of systemic dissemination) systemic antifungal therapy with amphotericin is warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of diaper dermatitis in infants and children\", section on 'Antifungal agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systemic antifungal agents are used when the candidal infection is refractory to topical therapy. In most cases, the agent of choice is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"     fluconazole",
"    </a>",
"    because it is well-tolerated and effective in neonates. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Fluconazole'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\", section on 'Fluconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with mucocutaneous candidiasis with a high likelihood of systemic infection (eg, invasive fungal dermatitis or premature infants with congenital candidiasis),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"     amphotericin B",
"    </a>",
"    should be the initial therapy while awaiting the results of blood cultures and in some cases, skin biopsy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Amphotericin B'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Mucocutaneous candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of infants with invasive candidal infections remains poor with reported mortality rates of 40 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In the survivors of candidemia, there is a significant risk of neurodevelopmental impairment, especially in those with CNS invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40760/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of neonatal candidal infection is based upon the clinical presentation and is separated into treatment of neonates with candidemia or mucocutaneous candidiasis, and prevention of candidal infections.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with known or suspected candidemia or candidal central nervous system (CNS) infection require immediate systemic antifungal therapy. If candidemia is confirmed, all catheters must be",
"      <span class=\"nowrap\">",
"       removed/replaced.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      as the preferred initial therapy in neonates with candidemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternate therapy includes",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/43/26297?source=see_link\">",
"       fluconazole",
"      </a>",
"      as monotherapy or in combination with amphotericin B. Once culture results are received, therapy should be modified if the organism is resistant to amphotericin B. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Candidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with or suspected to have candidal CNS infections, we suggest treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      . (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/46/27365?source=see_link\">",
"       Flucytosine",
"      </a>",
"      may be added if cultures of cerebral spinal fluid remain positive or the patient&rsquo;s clinical condition deteriorates with monotherapy of amphotericin B. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Amphotericin B'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating low-risk mucocutaneous candidiasis with topical therapy rather than systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical antifungal agents include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/23/34160?source=see_link\">",
"       nystatin",
"      </a>",
"      and azole topical preparations. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mucocutaneous candidiasis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=see_link&amp;anchor=H27#H27\">",
"       \"Overview of diaper dermatitis in infants and children\", section on 'Antifungal agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of oropharyngeal and esophageal candidiasis\", section on 'Topical therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest initially treating mucocutaneous candidiasis that has a high likelihood of systemic infection (eg, invasive fungal dermatitis or premature infants with congenital candidiasis) with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      while awaiting blood culture results (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Mucocutaneous candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite treatment measures, the prognosis remains poor for infants with invasive candidal infections with reported mortality rates of 40 to 50 percent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/1\">",
"      Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/2\">",
"      Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/3\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/4\">",
"      Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/5\">",
"      Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/6\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/7\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/8\">",
"      Karlowicz MG, Hashimoto LN, Kelly RE Jr, Buescher ES. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics 2000; 106:E63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/9\">",
"      Eckstein CW, Kass EJ. Anuria in a newborn secondary to bilateral ureteropelvic fungus balls. J Urol 1982; 127:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/10\">",
"      Khan MY. Anuria from candida pyelonephritis and obstructing fungal balls. Urology 1983; 21:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/11\">",
"      Johnson DE, Base JL, Thompson TR, et al. Candida septicemia and right atrial mass secondary to umbilical vein catheterization. Am J Dis Child 1981; 135:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/12\">",
"      Faix RG, Feick HJ, Frommelt P, Snider AR. Successful medical treatment of Candida parapsilosis endocarditis in a premature infant. Am J Perinatol 1990; 7:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/13\">",
"      Rowen JL, Tate JM. Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr Infect Dis J 1998; 17:1007.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Candidiasis. In: Pickering LK, 29th, Red Book: 2012 Report of the Committee on Infectious Diseases (Ed), American Academy of Pediatrics, Elk Grove Village 2012. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/15\">",
"      Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/16\">",
"      Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/17\">",
"      Starke JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987; 155:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/18\">",
"      Hall JE, Cox F, Karlson K, Robertson A. Amphotericin B dosage for disseminated candidiasis in premature infants. J Perinatol 1987; 7:194.",
"     </a>",
"    </li>",
"    <li>",
"     Bendel CM. Candidiasis. In: Infectious diseases of the fetus and newborn infant, 6th, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.1107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/20\">",
"      Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009; 28:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/21\">",
"      Foker JE, Bass JL, Thompson T, et al. Management of intracardiac fungal masses in premature infants. J Thorac Cardiovasc Surg 1984; 87:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/22\">",
"      Benjamin DK Jr, Fisher RG, McKinney RE Jr, Benjamin DK. Candidal mycetoma in the neonatal kidney. Pediatrics 1999; 104:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/23\">",
"      Berman LH, Stringer DA, St Onge O, et al. An assessment of sonography in the diagnosis and management of neonatal renal candidiasis. Clin Radiol 1989; 40:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/24\">",
"      Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999; 18:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/25\">",
"      Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998; 17:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/26\">",
"      Juster-Reicher A, Flidel-Rimon O, Amitay M, et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003; 22:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/27\">",
"      Juster-Reicher A, Leibovitz E, Linder N, et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/28\">",
"      Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998; 26:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/29\">",
"      Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J 2012; 31:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/30\">",
"      Sax&eacute;n H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993; 54:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/31\">",
"      Wainer S, Cooper PA, Gouws H, Akierman A. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997; 16:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/32\">",
"      Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996; 15:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/33\">",
"      Wenzl TG, Schefels J, H&ouml;rnchen H, Skopnik H. Pharmacokinetics of oral fluconazole in premature infants. Eur J Pediatr 1998; 157:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/34\">",
"      Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009; 28:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/35\">",
"      Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011; 30:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/36\">",
"      Smith PB, Steinbach WJ, Cotten CM, et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/37\">",
"      Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/38\">",
"      Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/39\">",
"      Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/40\">",
"      Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009; 28:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/41\">",
"      Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/42\">",
"      S&aacute;ez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/43\">",
"      Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol 2009; 29:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/44\">",
"      Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010; 26:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/45\">",
"      Vendettuoli V, Tana M, Tirone C, et al. The role of Candida surveillance cultures for identification of a preterm subpopulation at highest risk for invasive fungal infection. Pediatr Infect Dis J 2008; 27:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/46\">",
"      Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. Pediatr Infect Dis J 1997; 16:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/47\">",
"      Goins RA, Ascher D, Waecker N, et al. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J 2002; 21:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/48\">",
"      Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. Pediatrics 2000; 105:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/49\">",
"      Lee BE, Cheung PY, Robinson JL, et al. Comparative study of mortality and morbidity in premature infants (birth weight, &lt; 1,250 g) with candidemia or candidal meningitis. Clin Infect Dis 1998; 27:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/50\">",
"      Faix RG, Kovarik SM, Shaw TR, Johnson RV. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989; 83:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40760/abstract/51\">",
"      Friedman S, Richardson SE, Jacobs SE, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000; 19:499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5029 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-AE2128909E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40760=[""].join("\n");
var outline_f39_51_40760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CANDIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Removal of medical hardware or fungal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Overview systemic antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Amphotericin B lipid formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Flucytosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Our approach to treating candidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surveillance cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MUCOCUTANEOUS CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24039?source=related_link\">",
"      Epidemiology and risk factors for Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9991?source=related_link\">",
"      Prevention of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40761="Intraosseous infusion";
var content_f39_51_40761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraosseous infusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     Pamela Bailey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40761/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/51/40761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishment of access to the circulation is a critical component of resuscitation. The preferred venous access site during cardiopulmonary resuscitation (CPR) is the largest, most accessible vein that does not require the interruption of resuscitation. Peripheral venous access is attempted before attempting other forms of vascular access if peripheral veins can be readily seen or palpated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=see_link\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6361?source=see_link\">",
"     \"Peripheral venous access in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraosseous infusion, a technique for vascular access, was described first in 1922 and was widely used for drug administration in children in the 1940s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. It fell out of favor during the 1950s and 1960s, when disposable intravenous catheters were developed and techniques for insertion improved. In the 1980s, after the publication of numerous clinical reports of its effective use in children and animal models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], the practice of intraosseous infusion increased. Use in adults has also grown, especially in the prehospital setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Today, the procedure is reserved for acute, life-threatening or medically necessary situations when standard venous access methods cannot be rapidly achieved and as the first attempt at vascular access in cardiopulmonary arrest or severe shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6338267\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraosseous (IO) infusion is possible because of the presence of veins that drain the medullary sinuses in the bone marrow of long bones (",
"    <a class=\"graphic graphic_figure graphicRef77643 \" href=\"mobipreview.htm?25/0/25600\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/13\">",
"     13",
"    </a>",
"    ]. These veins, supported by the bony matrix, do not collapse in patients with shock or hypovolemia. The major vessels into which the intramedullary veins drain depend upon the insertion site. The following list provides the site and draining vessels for the most commonly used sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proximal tibia &ndash; Popliteal vein",
"     </li>",
"     <li>",
"      Femur &ndash; Branches of the femoral vein",
"     </li>",
"     <li>",
"      Distal tibia (medial malleolus) &ndash; Great saphenous vein",
"     </li>",
"     <li>",
"      Proximal humerus &ndash; Axillary vein",
"     </li>",
"     <li>",
"      Manubrium (upper sternum) &ndash; Internal mammary and azygos veins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anterior inferior iliac spine, clavicle, and distal radius have also been used successfully for IO vascular access as have bones without medullary cavities, including the calcaneous and radial styloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that infants and children in full cardiopulmonary arrest or severe shock who do not have readily available intravenous access undergo IO cannulation for medication administration, fluid therapy, and diagnostic studies rather than central venous line placement or surgical venous cutdown. We suggest that adults in full cardiopulmonary arrest or severe shock who do not have readily available intravenous access also undergo IO cannulation rather than central venous line placement or surgical venous cutdown.",
"   </p>",
"   <p>",
"    Intraosseous cannulation may also be appropriate in emergent or urgent situations where reliable venous access cannot be achieved quickly (eg, patients with shock, sepsis, status epilepticus, extensive burns, multiple trauma) or in patients for whom intravascular access is medically necessary and cannot be achieved by other means despite multiple attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraosseous cannulation allows for intravascular access through which diagnostic studies may be obtained and a wide variety of medications can be rapidly delivered. (See",
"    <a class=\"local\" href=\"#H17935753\">",
"     'Diagnostic studies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17935746\">",
"     'Fluid and drug administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The American Heart Association and the International Committee on Resuscitation endorse the use of IO access as a safe and effective means of vascular access in critically ill children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. IO cannulation permits rapid intravascular access in critically ill children and adults as demonstrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial comparing success rates and time to insertion between IO and peripheral IV access among children requiring fluid resuscitation for severe dehydration in a hospital setting, the IO route was successful within five minutes for 100 percent of patients, as compared with 67 percent success within five minutes for peripheral IV placement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective series describing attempts by paramedics to establish peripheral IV access for 300 children (0 to 18 years) in the prehospital setting, IV access was successful in two-thirds of all children and in only 49 percent of a subset of children younger than six years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational series describing the use of IO cannulation in patients of all ages in the prehospital setting, the overall success rate was 76 percent, with 85 percent success in children between one and two years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intraosseous vascular access was achieved in less than one minute for 85 percent of cases in a prospective report evaluating the time to insertion and success rate of intraosseous cannulation in a variety of prehospital settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial of 182 adults receiving vascular access for cardiac arrest in the prehospital setting, tibial IO placement was associated with a significantly higher frequency of initial vascular access success than peripheral IV placement (91 versus 43 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/24\">",
"       24",
"      </a>",
"      ]. Although initial success with humeral IO access was higher than for peripheral IV access (71 versus 49 percent), overall success was not significantly different because of a high rate of displacement for patients with humeral IO cannulas. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sites of placement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A trial of IO needle placement using a battery-powered driver or spring-loaded device in 40 adults receiving prehospital care found that vascular access was successfully achieved on the first attempt in 80 to 90 percent of patients within two minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective observational study compared IO cannulation using a battery-operated driver device (EZIO&reg;) with internal jugular or subclavian central venous access in 10 adult patients, all of whom received both procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/26\">",
"       26",
"      </a>",
"      ]. IO access was achieved on the first attempt more frequently (90 versus 60 percent) and took significantly less time (2 versus 10 minutes) than central venous access.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that establishing peripheral IV access often is delayed or unsuccessful during resuscitation of critically ill patients, particularly small children. Furthermore, alternative methods of vascular access such as central venous access by percutaneous or surgical venous cutdown takes much longer and is less likely to be successful than IO placement. Finally, all drugs and fluids that might be delivered through peripheral or central venous lines can be administered through an IO cannula. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=see_link&amp;anchor=H13#H13\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'Central access'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=see_link&amp;anchor=H22#H22\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'Venous cutdown'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17935746\">",
"     'Fluid and drug administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In adults, difficult or failed peripheral vascular access is also problematic, especially in the prehospital setting. Alternative approaches to IO cannulation such as ultrasound-guided peripheral IV access and central venous access also achieve high success rates but take longer to perform than IO access. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H18#H18\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Dynamic ultrasound to guide vein cannulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H1232393406#H1232393406\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Peripheral intravenous access'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IO cannulation by manual insertion becomes progressively more difficult as children age because the cortex of bone becomes thicker and the tibial bone marrow cavity becomes smaller [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/6,27\">",
"     6,27",
"    </a>",
"    ]. The development of devices such as impact-driven devices and battery-operated handheld drivers has made IO cannulation feasible for patients of all ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/18,28,29\">",
"     18,28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17936377\">",
"     'Techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17935746\">",
"    <span class=\"h2\">",
"     Fluid and drug administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any intravenous drug or routine resuscitation fluid can be administered safely by the intraosseous (IO) route including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    , dopamine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    , adenosine, antibiotics, digitalis,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , neuromuscular blocking agents, crystalloids, colloids, and blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/8,10,27,30-33\">",
"     8,10,27,30-33",
"    </a>",
"    ]. Drug and fluid dosing is the same as for intravenous administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/17,32\">",
"     17,32",
"    </a>",
"    ]. However, the IO route may not be as effective as upper extremity peripheral intravenous access for the treatment of supraventricular tachycardia with adenosine in some young infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When medications are given, the IO cannula should be flushed before and after each medication that is administered. Only compatible drugs may be administered simultaneously through an IO needle or catheter.",
"   </p>",
"   <p>",
"    Crystalloid fluids (eg, normal saline) for rapid volume expansion and viscous drugs and solutions should be administered under pressure using an infusion pump, pressure bag, or manual injection through a syringe and stopcock. These approaches overcome the resistance of emissary veins that lead from the intramedullary cavity to the general circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/35\">",
"     35",
"    </a>",
"    ]. Infusion rates equivalent to a 21 gauge peripheral intravenous catheter are typically achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/36\">",
"     36",
"    </a>",
"    ]. The IO site and extremity should be monitored frequently for infiltration during rapid fluid administration. &nbsp;",
"   </p>",
"   <p>",
"    The onsets of action and drug concentrations after intraosseous infusion during cardiopulmonary resuscitation (CPR) are comparable to those achieved after intravenous administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/9,37\">",
"     9,37",
"    </a>",
"    ]. Studies in animals suggest that the intraosseous route is as effective as is the central intravenous route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/9,38,39\">",
"     9,38,39",
"    </a>",
"    ] and may be superior to the peripheral intravenous route during cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In awake patients, analgesia should be provided by slowly administering 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    preservative-free",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    2 percent (20",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    maximum dose: 40 mg) over one minute through the IO catheter prior to flushing and drug administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17935753\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon comparisons of venous blood and bone marrow samples in children with cancer, bone marrow samples initially obtained from an intraosseous line during placement may be used for a variety of diagnostic studies including glucose, hemoglobin, pH, pCO2, serum bicarbonate, sodium, chloride blood urea nitrogen, creatinine, serum drug levels, and cultures (eg, bacterial, viral, or fungal cultures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In contrast, bone marrow values for blood oxygenation, white blood cell count, potassium, aspartate aminotransferase, alanine aminotransferase or ionized calcium may not be accurate.",
"   </p>",
"   <p>",
"    In a study of 28 adult patients, bone marrow aspirates accurately identified blood ABO and Rh type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, bone marrow samples may also be used for type and screen if a standard blood sample is not available.",
"   </p>",
"   <p>",
"    A canine model suggests that IO drug administration may alter subsequent laboratory measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, most experts do not advise using IO access for diagnostic studies once drugs have been administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively few absolute contraindications to intraosseous (IO) infusions exist because the technique is primarily indicated in life-threatening emergencies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A fractured bone or previously penetrated bone cannot be used because fluids will exit through the fracture or puncture site.",
"     </li>",
"     <li>",
"      An extremity with vascular interruption, either from trauma or cutdown attempt, is not suitable for IO infusion because the fluid or drugs administered into the bone marrow will leak through the open blood vessel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If possible, IO cannulation should be avoided in the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cellulitis, burns, or osteomyelitis involving the cannulation site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/35,38\">",
"       35,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with osteogenesis imperfecta or osteopetrosis due to bone fragility. However, successful IO cannulation in a child with osteogenesis imperfecta has been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with right-to-left intracardiac shunts (eg, tetralogy of Fallot, pulmonary atresia) who may be at greater risk for cerebral fat or bone-marrow emboli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/38,44,45\">",
"       38,44,45",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, intraosseous (IO) cannulation occurs as part of care for a life-threatening emergency. Thus, informed consent is typically implied. In awake patients for whom IO needle placement is necessary, the patient and, in children, the caretaker should receive a detailed explanation of the procedure and provide informed consent. Awake patients should also receive local anesthesia prior to IO cannulation attempts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936252\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be assembled prior to the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"       Povidone iodine",
"      </a>",
"      solution or similar antiseptic",
"     </li>",
"     <li>",
"      Surgical mask and eye covering for the clinician performing the procedure",
"     </li>",
"     <li>",
"      Sterile latex-free gloves",
"     </li>",
"     <li>",
"      10 mL syringe",
"     </li>",
"     <li>",
"      Syringe with saline flush",
"     </li>",
"     <li>",
"      Intraosseous needle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      device",
"     </li>",
"     <li>",
"      In awake patients, small-volume syringe (eg, 3 mL) containing",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      1 percent for infiltration via a small bore needle (eg, 25 gauge needle)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936215\">",
"    <span class=\"h3\">",
"     Intraosseous (IO) needles and devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different commercially available intraosseous cannulation devices are available. These are preferred for IO cannulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Manual IO needles",
"      </strong>",
"      &ndash; Examples include the Jamshidi (Cardinal Health, McGraw Park, IL) and the modified Dieckmann (Cook Critical Care, Bloomington, IN). Important features include a trocar, a short needle length with a handle that provides a resting place for the palm and an adjustable flange or depth marking to guide placement. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual insertion technique'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Battery-powered driver (EZIO&reg;)",
"      </strong>",
"      &ndash; The EZIO&reg; comes with a",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/38/1639?source=see_link\">",
"       lithium",
"      </a>",
"      powered battery driver and needle sets in three lengths for placement in children and adults. (See",
"      <a class=\"local\" href=\"#H17936325\">",
"       'Battery-powered driver'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Impact-driven devices (Bone injection gun [BIG&reg;], FAST1&reg;)",
"      </strong>",
"      &ndash; The bone injection gun comes in two sizes that allow IO placement in children and adults. The FAST1&reg; is designed for sternal IO catheter placement in patients &ge;12 years of age. (See",
"      <a class=\"local\" href=\"#H6338311\">",
"       'Impact-driven devices'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other types of needles may be used if an IO needle or device is not available including bone marrow needles, styletted needles, or spinal needles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/38,46\">",
"     38,46",
"    </a>",
"    ]. Of these, bone marrow needles are best because they are least likely to bend. Standard hypodermic needles should",
"    <strong>",
"     not",
"    </strong>",
"    be used for intraosseous infusion because they often become clogged with bone and bone marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sites of placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that all patients who undergo intraosseous (IO) placement for life-threatening illness (eg, cardiac arrest) have the first attempt occur at the proximal tibial site, unless otherwise contraindicated. Alternative sites vary based upon the age and skeletal maturity of the patient (",
"    <a class=\"graphic graphic_table graphicRef53119 \" href=\"mobipreview.htm?4/52/4940\">",
"     table 1",
"    </a>",
"    ). A battery-powered or impact driven device is typically required to accomplish IO placement in the proximal tibia of patients over six years of age. If such a device is not available, then the clinician should attempt manual placement at the medial or lateral malleolus in older patients. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a trial of 183 adults undergoing prehospital vascular access for cardiac arrest, tibial IO placement was significantly more likely to result in overall successful vascular access when compared to humeral IO or peripheral intravenous (IV) access (91 versus 53 and 41 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/24\">",
"     24",
"    </a>",
"    ]. Loss of vascular access during transport was more likely with humeral IO access than either tibial IO or peripheral IV placement. The time to achieve vascular access ranged from five to seven minutes and was similar among the three techniques.",
"   </p>",
"   <p>",
"    The primary anatomic locations for intraosseous (IO) cannulation are as follows (",
"    <a class=\"graphic graphic_table graphicRef53119 \" href=\"mobipreview.htm?4/52/4940\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/32,38\">",
"     32,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Proximal tibia",
"      </strong>",
"      &ndash; In children, the proximal tibial site is approximately 2 cm below the tibial tuberosity and up to 1 cm medially on the tibial plateau (",
"      <a class=\"graphic graphic_figure graphicRef67266 \" href=\"mobipreview.htm?14/61/15316\">",
"       figure 2",
"      </a>",
"      ). In skeletally mature adolescents and adults, the recommended site is 2 cm medial and 1 cm above the tibial tuberosity. The proximal tibial site is rapidly identified and most familiar to emergency clinicians. Furthermore, in patients with cardiac arrest, proximal tibial IO placement also avoids interfering with ongoing cardiac compressions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual insertion technique'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H6337564\">",
"       'Bone injection gun'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Distal femur",
"      </strong>",
"      &ndash; The distal femur site is in the midline approximately 1 to 2 cm above the superior border of the patella with the leg in extension. This site is an alternative site for manual placement in infants and young children in whom the IO needle can traverse the tissues of the distal thigh and still reach the marrow cavity (",
"      <a class=\"graphic graphic_figure graphicRef56412 \" href=\"mobipreview.htm?4/49/4883\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual insertion technique'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Distal tibia or fibula",
"      </strong>",
"      &ndash; The malleoli sites are approximately 1 to 2 cm superior to the malleoli in the midline. The medial malleolus (distal tibia) is preferred to the lateral malleolus (",
"      <a class=\"graphic graphic_figure graphicRef51195 \" href=\"mobipreview.htm?1/62/2019\">",
"       figure 4",
"      </a>",
"      ). These sites are available for manual or device-assisted IO placement in children, adolescents, and adults. (See",
"      <a class=\"local\" href=\"#H17936377\">",
"       'Techniques'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Proximal humerus",
"      </strong>",
"      &ndash; The greater tubercle of the proximal humerus is appropriate for IO placement in skeletally mature adolescents and adults. To identify this site, the clinician should adduct and internally rotate the upper arm (hand on abdomen) to make damage to the medial structures of the axillary plexus unlikely. The greater tubercle of the proximal humerus is located approximately 2 cm below the acromion process. Alternatively, it can be directly palpated from below. (",
"      <a class=\"graphic graphic_figure graphicRef57495 \" href=\"mobipreview.htm?29/16/29957\">",
"       figure 5",
"      </a>",
"      ). This site typically requires a battery-powered driver or spring-loaded impact device for successful IO cannulation. (See",
"      <a class=\"local\" href=\"#H17936325\">",
"       'Battery-powered driver'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H6337564\">",
"       'Bone injection gun'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Manubrium",
"      </strong>",
"      &ndash; The superior one-third of the sternum may be accessed in adults using a specially designed IO device (FAST1&reg; Intraosseous infusion system, PYNG medical, Richmond, British Columbia, Canada) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/47\">",
"       47",
"      </a>",
"      ]. The device comes with a target patch that is applied along the sternal notch to assist with site identification and placement. (See",
"      <a class=\"local\" href=\"#H6337732\">",
"       'FAST1'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4931995\">",
"    <span class=\"h2\">",
"     Choice of device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence to guide the choice of intraosseous (IO) insertion device is limited to observational studies and small trials that vary according to the setting (eg, prehospital, hospital), clinical provider (eg, paramedic, medic, physician), site of insertion, and patient population (pediatric or adult) and do not allow direct comparisons among all devices available. In order to maximize the chance of successful IO cannulation, proper training is essential prior to use, regardless of which intraosseous insertion technique is chosen. (See",
"    <a class=\"local\" href=\"#H4932231\">",
"     'Training'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Available evidence indicates the following overall success rates and time to IO insertion in children and adults undergoing resuscitation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manual needles: 76 to 100 percent (50 to 67 percent in patients over one year of age) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/22,48-50\">",
"       22,48-50",
"      </a>",
"      ], median time to insertion 38 seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Battery-powered driver: 87 to 97 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/29,51,52\">",
"       29,51,52",
"      </a>",
"      ], median time to insertion &lt;10 seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bone injection gun: 45 to 91 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/49,53-55\">",
"       49,53-55",
"      </a>",
"      ], median time to insertion 49 seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      FAST1&reg;: 72 to 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/49,52,56\">",
"       49,52,56",
"      </a>",
"      ], median time to insertion 62 seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, we suggest that, in infants under one year of age, clinicians use manual needles or battery-powered devices for IO insertion rather than an impact-driven device. Observational studies suggest that the success rate for manual placement and battery-powered devices in infants is similar to each other and both techniques have been shown to be easy to learn by a variety of health care providers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/29,51,57,58\">",
"     29,51,57,58",
"    </a>",
"    ]. Manual IO needles are less expensive and are more widely available than other devices. Time to manual IO placement is longer than for a battery-powered device but shorter than for an impact-driven device.",
"   </p>",
"   <p>",
"    We suggest that, in children &ge;1 year of age, adolescents, and adults, clinicians use a battery-powered device for IO placement, if available, rather than a manual needle or impact-driven device. Success rates for patients in these age categories appear to be higher with battery-powered IO placement and time to insertion is shorter.",
"   </p>",
"   <p>",
"    Suggested sites of IO placement are discussed separately. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Sites of placement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4932231\">",
"    <span class=\"h2\">",
"     Training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraosseous (IO) cannulation is likely to be used by the emergency care provider during resuscitation when tensions are high. The patient&rsquo;s life may well depend upon the clinician&rsquo;s ability to secure vascular access, and the clinician will be under considerable stress. Thus, emergency physicians and others who might need to perform intraosseous cannulation should learn to do so well in advance of need.",
"   </p>",
"   <p>",
"    Training can be accomplished on simulation models, animal bones (eg, chicken or turkey legs), or a cadaver. IO placement is taught as part of the Pediatric Advanced Life Support, Advanced Pediatric Advanced Life Support, and Advanced Trauma Life Support Courses. After proper training, typically consisting of a one hour lecture followed by a one hour hands-on experience, novice users have achieved success rates of 93 to 97 percent for manual and battery-powered IO placement in a variety of simulated settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/57-61\">",
"     57-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Battery-powered IO placement during field and hospital care has also shown high success rates after training:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paramedics achieved an 87 percent success rate for field IO placement in infants under two years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Military medics achieved a 97 percent success rate for IO cannulation in children and adults during combat situations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physicians achieved a 94 percent success rate for IO placement in 95 children treated in an emergency department [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936377\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraosseous needles may be placed manually or with the assistance of specifically designed devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Manual insertion technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual insertion in the proximal tibia is generally difficult to perform in patients over six years of age. The distal tibial site is preferred in older patients. A high quality video is available in the reference to assist with learning the manual placement technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following step-by-step technique for manual intraosseous cannulation assumes the use of the proximal tibial location (",
"    <a class=\"graphic graphic_figure graphicRef81759 \" href=\"mobipreview.htm?38/17/39190\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef67266 \" href=\"mobipreview.htm?14/61/15316\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/38,63\">",
"     38,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Don a surgical mask, eye protection, and latex-free sterile gloves.",
"     </li>",
"     <li>",
"      Prepare the injection site with an antiseptic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      solution).",
"     </li>",
"     <li>",
"      If the child is awake, infiltrate the skin, subcutaneous tissue, and periosteum with 1 percent",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Place the leg with knee extended in neutral position and then slightly externally rotate at the hip to expose the flat part of the tibial surface, and externally rotate the foot.",
"     </li>",
"     <li>",
"      Check the needle to ensure that the bevels of the outer needle and the internal stylet are properly aligned.",
"     </li>",
"     <li>",
"      Grasp the leg distally and lateral to the insertion site with the palm and fingers of the nondominant hand to brace the leg against the force of IO placement and to prevent distal leg movement during the procedure (",
"      <a class=\"graphic graphic_figure graphicRef68441 \" href=\"mobipreview.htm?36/57/37781\">",
"       figure 7",
"      </a>",
"      ). In infants and young children, the nondominant hand may be placed above the site and wrap around the knee and thigh (",
"      <a class=\"graphic graphic_figure graphicRef81759 \" href=\"mobipreview.htm?38/17/39190\">",
"       figure 6",
"      </a>",
"      ). No portion of the stabilizing hand should rest behind the insertion site. .",
"     </li>",
"     <li>",
"      Palpate the landmarks to identify the flat surface of the tibia approximately 1 to 2 cm below and slightly medial (up to 1 cm) to the tibial tuberosity and insert the IO needle through the skin (",
"      <a class=\"graphic graphic_figure graphicRef81759 \" href=\"mobipreview.htm?38/17/39190\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Direct the IO needle perpendicular to the entry site (",
"      <a class=\"graphic graphic_figure graphicRef68441 \" href=\"mobipreview.htm?36/57/37781\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef81759 \" href=\"mobipreview.htm?38/17/39190\">",
"       figure 6",
"      </a>",
"      ) or, in skeletally immature children, at a slight angle (10 to 15 degrees) from vertical (caudad for the proximal tibia (",
"      <a class=\"graphic graphic_figure graphicRef67266 \" href=\"mobipreview.htm?14/61/15316\">",
"       figure 2",
"      </a>",
"      ); cephalad for the distal tibia or femur (",
"      <a class=\"graphic graphic_figure graphicRef51195 \" href=\"mobipreview.htm?1/62/2019\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56412 \" href=\"mobipreview.htm?4/49/4883\">",
"       figure 3",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Apply pressure with a twisting motion (",
"      <a class=\"graphic graphic_figure graphicRef68441 \" href=\"mobipreview.htm?36/57/37781\">",
"       figure 7",
"      </a>",
"      ). Avoid rocking the needle side to side which may bend it or enlarge the access hole and lead to extravasation of fluid. As the needle passes through the cortex and into the marrow cavity, a \"give\" or release of resistance is felt. Clinicians not experienced in bone marrow needle insertion should understand that considerable force is needed to introduce the needle into the bone marrow when traditional methods are used (rather than a spring-loaded device or battery-powered driver). A back-and-forth-twisting motion works best to pierce the bony cortex.",
"     </li>",
"     <li>",
"      Unscrew the needle cap and remove the stylet. If the needle has an adjustable flange, carefully screw the flange down to the skin surface while stabilizing the needle.",
"     </li>",
"     <li>",
"      Confirm correct needle placement. (See",
"      <a class=\"local\" href=\"#H2685868\">",
"       'Confirmation of placement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the patient is awake, slowly administer 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      (2 percent [20",
"      <span class=\"nowrap\">",
"       mg/mL]",
"      </span>",
"      preservative-free formulation, maximum dose: 40 mg) through the IO catheter prior to flushing.",
"     </li>",
"     <li>",
"      Once proper placement is confirmed, flush the needle with 10 mL of normal saline and connect it to conventional IV tubing. Some clinicians prefer to flush once with heparinized saline. Secure the bone marrow needle with tape and a dressing that does not obscure the needle placement site so that infiltration can be rapidly detected. Intraosseous needles that are properly placed are secure and not easily dislodged.",
"     </li>",
"     <li>",
"      <strong>",
"       Removal",
"      </strong>",
"      &ndash; Remove the needle by grasping the shaft and pulling up with a slight rotary motion. Apply pressure to the IO site. Dress the site using aseptic technique.",
"      <br/>",
"      <br/>",
"      Technical difficulties with manual intraosseous needle placement usually decrease with experience and familiarity with the procedure. Strategies to improve the success rate of intraosseous needle placement include emphasizing rotary motion, stabilizing the tubing and limb, monitoring continuously for extravasation, and using strong, sharp needles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936325\">",
"    <span class=\"h2\">",
"     Battery-powered driver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Battery-powered intraosseous driver and needle sets are available for use in children and adults (EZ-IO&reg;, VidaCare Corporation, Shavano Park, Texas, USA). The 15 gauge needles come in three lengths as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      15 mm (pink) for placement in patients 3 to 39 kg",
"     </li>",
"     <li>",
"      25 mm (blue) for placement in patients &ge;40 kg with normal subcutaneous tissue",
"     </li>",
"     <li>",
"      45 mm (yellow) for placement in patients &ge;40 kg with excessive subcutaneous tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A high quality video is available in the reference to assist with learning the battery-powered driver technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/62\">",
"     62",
"    </a>",
"    ]. The needles may be inserted in the proximal or distal tibia or, in skeletally mature adolescents and adults, the proximal humerus as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/14,47,65\">",
"     14,47,65",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Sites of placement'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify the placement site based upon anatomic landmarks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sites of placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Don appropriate personal protective equipment and prepare the insertion site as for the manual insertion technique. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual insertion technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ensure that the appropriate needle is selected based upon the patient&rsquo;s weight and amount of subcutaneous tissue over the selected insertion site.",
"     </li>",
"     <li>",
"      Securely seat the needle on the battery-powered driver.",
"     </li>",
"     <li>",
"      Remove the needle safety cap.",
"     </li>",
"     <li>",
"      Position the driver with the needle at a 90 degree angle to the bone.",
"     </li>",
"     <li>",
"      Gently drive or manually press the needle until the tip touches the bone. Ensure that at least 5 mm of the catheter is visible above the skin at this point.",
"     </li>",
"     <li>",
"      Squeeze the driver trigger and apply light but steady downward pressure to penetrate the bone. Excessive pressure may result in the needle not penetrating the bone.",
"     </li>",
"     <li>",
"      Release the trigger to stop insertion when a sudden decrease in resistance is felt (&ldquo;give&rdquo; or &ldquo;pop&rdquo;) or when the appropriate depth, as indicated on the needle, is reached.",
"     </li>",
"     <li>",
"      Wait for the driver to stop spinning. Then, while holding the catheter in place, remove the driver by pulling straight up from the catheter and unscrew the needle stylet by rotating it counter-clockwise.",
"     </li>",
"     <li>",
"      Aspirate bone marrow to identify correct placement of the IO catheter and, if desired, to obtain a sample for laboratory analysis using a syringe attached directly to the hub or the manufacturer provided extension set. (See",
"      <a class=\"local\" href=\"#H2685868\">",
"       'Confirmation of placement'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17935753\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient is awake, slowly administer 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      (2 percent [20",
"      <span class=\"nowrap\">",
"       mg/mL]",
"      </span>",
"      preservative-free formulation, maximum dose: 40 mg) through the IO catheter prior to flushing.",
"     </li>",
"     <li>",
"      Once proper placement is confirmed, flush the needle with 10 mL of normal saline using the manufacturer supplied IV connector tubing. Some clinicians prefer to flush once with heparinized saline.",
"     </li>",
"     <li>",
"      <strong>",
"       Removal",
"      </strong>",
"      &ndash; Attach a Luer lock syringe to the catheter hub. While stabilizing the extremity, rotate the catheter and syringe clockwise while pulling straight back. Apply pressure to the IO site. Dress the site using aseptic technique.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6338311\">",
"    <span class=\"h2\">",
"     Impact-driven devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact-driven devices consist of the bone injection gun (BIG&reg;, WaisMed Ltd, Houston, Texas, USA) and the FAST1&reg; (Pyng Medical Corporation, Vancouver, Canada).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6337564\">",
"    <span class=\"h3\">",
"     Bone injection gun",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spring-loaded bone injection gun is available in sizes and automated insertion depth suitable for patients over 12 years of age (blue casing, 15 gauge needle, insertion depth 2.5 cm) and children from term newborn to 12 years of age (red casing, 18 gauge needle, adjustable insertion depth 0.5 to 1.5 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/14,47,66\">",
"     14,47,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A training video is available in the reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intraosseous (IO) cannulation of the proximal tibia (all patients) or proximal humerus (skeletally mature adolescents and adults) is accomplished as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identify the placement site based upon anatomic landmarks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sites of placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Don appropriate personal protective equipment and prepare the insertion site as for the manual insertion technique. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual insertion technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choose the appropriate size bone injection gun (over 12 years of age: adult, term infant to 12 years of age: pediatric). In children, set the insertion depth using the marker located on the device as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      0 to 3 years: 0.5 to 1 cm",
"     </li>",
"     <li>",
"      3 to 6 years: 1 to 1.5 cm",
"     </li>",
"     <li>",
"      6 to 12 years: 1.5 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place the device over the insertion site by holding the barrel at a 90 degree angle using the nondominant hand.",
"     </li>",
"     <li>",
"      Squeeze the sides of the orange safety latch and remove it from the device using the dominant hand. Save the safety latch for later use.",
"     </li>",
"     <li>",
"      While firmly holding the device in place with the nondominant hand, use the dominant hand to deploy the needle by grasping under the wings of the device with two fingers and steadily and gently pressing the palm against the top of the device. A &ldquo;pop&rdquo; will be heard when the needle is successfully deployed.",
"     </li>",
"     <li>",
"      Remove the housing of the bone injection gun by pulling upward while rocking it gently from side to side.",
"     </li>",
"     <li>",
"      Remove the stylet from the cannula.",
"     </li>",
"     <li>",
"      Place the safety latch around the cannula and tape it down to provide support.",
"     </li>",
"     <li>",
"      Aspirate bone marrow to identify correct placement of the IO catheter and, if desired, to obtain a sample for laboratory analysis using a syringe attached directly to the hub or the manufacturer provided extension set. (See",
"      <a class=\"local\" href=\"#H2685868\">",
"       'Confirmation of placement'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17935753\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient is awake, slowly administer 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      (2 percent [20",
"      <span class=\"nowrap\">",
"       mg/mL]",
"      </span>",
"      preservative-free formulation, maximum dose: 40 mg) over one minute through the IO catheter prior to flushing.",
"     </li>",
"     <li>",
"      Once placement is confirmed, flush the IO catheter with 10 to 20 mL of normal saline through an intravenous catheter connection set. Some clinicians prefer to flush once with heparinized saline.",
"     </li>",
"     <li>",
"      <strong>",
"       Removal",
"      </strong>",
"      &ndash; Place the safety latch so that the IO catheter hub is seated in the square notch. If the safety latch is not available, attach a Luer lock syringe. Pull upward with a slight rotary motion. Apply pressure to the IO site. Dress the site using aseptic technique.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6337732\">",
"    <span class=\"h3\">",
"     FAST1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FAST1&reg; is an impact-driven device designed for placement of an intraosseous (IO) catheter at a depth of 6 mm into the manubrium of patients &ge;12 years of age through the use of manual pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/47,67\">",
"     47,67",
"    </a>",
"    ]. A training video is available in the reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IO catheter placement in the sternum is performed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expose the upper sternum and ensure that there is no evidence of trauma to it.",
"     </li>",
"     <li>",
"      Don appropriate personal protective equipment and prepare the insertion site as for the manual insertion technique using iodine and isopropyl alcohol provided in the device package. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Manual insertion technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remove the target patch from the package and remove the first backing (labeled &ldquo;1&rdquo;).",
"     </li>",
"     <li>",
"      Identify the sternal notch and place a finger perpendicular to the notch. Apply the patch notches against the finger while maintaining alignment of the patch with the sternal notch.",
"     </li>",
"     <li>",
"      Remove the bottom half of the backing (labeled &ldquo;2&rdquo;) and secure the patch to the patient&rsquo;s sternum and chest.",
"     </li>",
"     <li>",
"      Ensure that the clear &ldquo;target zone&rdquo; is centered over the manubrium (upper sternum).",
"     </li>",
"     <li>",
"      Remove the sharps plug and introducer from the package.",
"     </li>",
"     <li>",
"      Remove the clear sharps cap from the introducer.",
"     </li>",
"     <li>",
"      Confirm alignment of the target patch and then, while firmly holding the introducer perpendicular to the manubrium, place the bone probe needles into the circular target zone.",
"     </li>",
"     <li>",
"      Push down on the introducer steadily while maintaining perpendicular force to the manubrium until the handle separates from the assembly with a &ldquo;pop&rdquo;.",
"     </li>",
"     <li>",
"      Remove the introducer assembly with bone probe needles and use the sharps plug and clear sharps cap to secure the sharps safely.",
"     </li>",
"     <li>",
"      Remove the blue cap from the IO catheter and connect the infusion tube to the friction connector on the tubing attached to the target patch.",
"     </li>",
"     <li>",
"      Remove the white cap from the Luer fitting of the target patch infusion tubing.",
"     </li>",
"     <li>",
"      Aspirate bone marrow to identify correct placement of the IO catheter and, if desired, obtain a sample for laboratory analysis. (See",
"      <a class=\"local\" href=\"#H2685868\">",
"       'Confirmation of placement'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17935753\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flush the IO catheter with 10 to 20 mL of normal saline through an intravenous catheter connection set.",
"     </li>",
"     <li>",
"      Secure the protector dome directly over the target patch.",
"     </li>",
"     <li>",
"      <strong>",
"       Removal",
"      </strong>",
"      &ndash; While holding the target patch against the skin, peel away the protector dome. Disconnect the infusion tube. Grasp the infusion tube close to the skin with fingers or a hemostat and pull upwards perpendicular to the manubrium until the infusion tube, including the metal tip is removed from the chest. Remove the target patch and apply pressure to the infusion site. Dress the site using aseptic technique.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2685868\">",
"    <span class=\"h2\">",
"     Confirmation of placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings indicate correct placement of the intraosseous (IO) cannula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The needle or catheter stands firmly on its own within the bone.",
"     </li>",
"     <li>",
"      Bone marrow is obtained with aspiration of the needle or catheter although this may not always occur even with a properly placed intraosseous needle or catheter.",
"     </li>",
"     <li>",
"      Flushing of the needle or catheter occurs without evidence of extravasation. Resistance to flushing is expected because, unlike a vein, the bone marrow cavity is not distensible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Correct placement in the bone marrow cavity can also be confirmed radiologically using a mini C-arm fluoroscopic imaging device or bedside Doppler ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Doppler ultrasound can also identify incorrect positioning indicated by extravasation of fluid around the IO needle or catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936282\">",
"    <span class=\"h1\">",
"     DURATION OF USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraosseous (IO) cannulation provides rapid temporary vascular access. An IO needle should be replaced with a venous line as soon as possible. In one retrospective series describing 58 intraosseous placements in children requiring critical care transport, IO needles were left in place for a mean of 5.2 hours (range 10 minutes to 36 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/48\">",
"     48",
"    </a>",
"    ]. The only reported complications were local edema and infiltration, occurring in 12 percent of patients. Prolonged intraosseous infusions beyond 24 hours are associated with an increased risk of osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraosseous (IO) cannulation is considered to be relatively safe, with a rate of serious complications of less than 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/5,72\">",
"     5,72",
"    </a>",
"    ]. Several types of complications have been reported. Potential problems include tibial fracture, compartment syndrome, skin necrosis, osteomyelitis, and subcutaneous abscess. Theoretical long-term complications include damage to the bone marrow and disturbance in growth of the bone, as well as fat embolism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral tibial fractures have been described in a single case of a three-month-old infant for whom attempts at intraosseous cannulation using a large bore needle were unsuccessful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infusion of fluids into the subcutaneous tissue has caused compartment syndrome and resulted in amputation of an extremity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/73\">",
"       73",
"      </a>",
"      ]. Osteomyelitis is a rare complication. A review of the publications describing 4270 intraosseous infusions found only 27 cases (0.6 percent) of osteomyelitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/71\">",
"       71",
"      </a>",
"      ]. Most reported infections occurred when the needle remained in place for a prolonged period (more than 24 hours). One observational study from 1940 suggested an increased risk of osteomyelitis with infusion of hypertonic fluids, but this association has not been subsequently validated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No long-term effects on tibial growth were found in a prospective study of 23 children with mean follow-up of 29 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/74\">",
"       74",
"      </a>",
"      ]. A smaller study had similar results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/75\">",
"       75",
"      </a>",
"      ]. Follow-up studies of bone and bone marrow after intraosseous infusions in experimental models also have shown only short-term periostitis and no or minimal long-term sequelae on bone marrow or bone growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]. The metaphyseal changes after insertion of a bone marrow needle resolve by three weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Microscopic fat and bone marrow emboli were found in the pulmonary autopsy specimens of two children who received intraosseous infusion during resuscitation attempts and in 100 percent of study subjects in several animal studies of intraosseous infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. However, the clinical relevance of these emboli is not clear. No significant alterations in arterial oxygenation or intrapulmonary shunting occurred during a four-hour study period, despite the universal finding of fat and bone marrow emboli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The only reported deaths resulting from intraosseous infusions were associated with the sternal approach using a manual technique. These deaths were from mediastinitis, hydrothorax, and cardiac or great vessel injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936385\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Videos are available in the references to assist with learning techniques for intraosseous cannulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manual placement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Battery-powered driver technique [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bone injection gun [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fast1&reg; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40761/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17936405\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraosseous (IO) cannulation provides intravascular access via the medullary sinuses in the bone marrow of long bones (",
"      <a class=\"graphic graphic_figure graphicRef77643 \" href=\"mobipreview.htm?25/0/25600\">",
"       figure 1",
"      </a>",
"      ). These veins, supported by the bony matrix, do not collapse in patients with shock or hypovolemia. (See",
"      <a class=\"local\" href=\"#H6338267\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that infants and children in full cardiopulmonary arrest or severe shock who do not have readily available intravenous access undergo IO cannulation for medication administration, fluid therapy, and diagnostic studies rather than percutaneous central venous line placement or surgical venous cutdown (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that adults in full cardiopulmonary arrest or severe shock who do not have readily available intravenous access undergo IO cannulation for medication administration, fluid therapy, and diagnostic studies rather than percutaneous central venous line placement or surgical venous cutdown (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IO cannulation may also be appropriate in patients with emergent or urgent conditions where reliable venous access cannot be achieved quickly (eg, shock, sepsis, status epilepticus, extensive burns, multiple trauma) or in patients for whom intravascular access is medically necessary and cannot be achieved by other means. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IO cannulation should not be performed in fractured bones, bones with a prior failed IO placement attempt, or in extremities with vascular disruption. IO access also should be avoided in patients with osteogenesis imperfecta, osteopetrosis, right to left congenital cardiac shunts, or those with burns or infection near the access site. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all patients who undergo intraosseous (IO) placement for life-threatening illnesses (eg, cardiac arrest) have the first attempt occur at the proximal tibial site, unless otherwise contraindicated (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Alternative sites vary based upon the age and skeletal maturity of the patient (",
"      <a class=\"graphic graphic_table graphicRef53119 \" href=\"mobipreview.htm?4/52/4940\">",
"       table 1",
"      </a>",
"      ). A battery-powered or impact driven device is typically required to accomplish IO placement in the proximal tibia of patients over six years of age. If such a device is not available, then the clinician should attempt manual placement at the medial or lateral malleolus in older patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sites of placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that, in infants under one year of age, clinicians use manual needles or battery-powered devices for IO insertion rather than an impact-driven device (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4931995\">",
"       'Choice of device'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17936377\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that, in children &ge;1 year of age, adolescents, and adults, clinicians use a battery-powered device for IO placement, if available, rather than a manual needle or impact-driven device (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4931995\">",
"       'Choice of device'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17936377\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Videos are available in the references to assist with learning techniques for intraosseous cannulation. (See",
"      <a class=\"local\" href=\"#H17936385\">",
"       'Additional resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/1\">",
"      Drinker, CK, Drinker, KR, Lund, CC. The circulation in the mammalian bone marrow. Am J Physiol 1922; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/2\">",
"      Fo&euml;x BA. Discovery of the intraosseous route for fluid administration. J Accid Emerg Med 2000; 17:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/3\">",
"      Josefson, A. A new method of treatment - intraossal injections. Acta Med Scand 1934; 81:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/4\">",
"      Tocantins, LM. Rapid absorption of substances injected into the bone marrow. Proc Soc Exp Biol Med 1940; 45:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/5\">",
"      Tocantins, LM, O'Neill, JF, Jones, HW. Infusions of blood and other fluids via the bone marrow: Application in pediatrics. JAMA 1941; 117:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/6\">",
"      HEINILD S, SONDERGAARD T, TUDVAD F. Bone marrow infusion in childhood; experiences from a thousand infusions. J Pediatr 1947; 30:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/7\">",
"      Valdes MM. Intraosseous fluid administration in emergencies. Lancet 1977; 1:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/8\">",
"      Berg RA. Emergency infusion of catecholamines into bone marrow. Am J Dis Child 1984; 138:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/9\">",
"      Spivey WH, Lathers CM, Malone DR, et al. Comparison of intraosseous, central, and peripheral routes of sodium bicarbonate administration during CPR in pigs. Ann Emerg Med 1985; 14:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/10\">",
"      Fiser DH. Intraosseous infusion. N Engl J Med 1990; 322:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/11\">",
"      Reades R, Studnek JR, Garrett JS, et al. Comparison of first-attempt success between tibial and humeral intraosseous insertions during out-of-hospital cardiac arrest. Prehosp Emerg Care 2011; 15:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/12\">",
"      Ngo AS, Oh JJ, Chen Y, et al. Intraosseous vascular access in adults using the EZ-IO in an emergency department. Int J Emerg Med 2009; 2:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/13\">",
"      Tobias JD, Ross AK. Intraosseous infusions: a review for the anesthesiologist with a focus on pediatric use. Anesth Analg 2010; 110:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/14\">",
"      Blumberg SM, Gorn M, Crain EF. Intraosseous infusion: a review of methods and novel devices. Pediatr Emerg Care 2008; 24:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/15\">",
"      McCarthy G, O'Donnell C, O'Brien M. Successful intraosseous infusion in the critically ill patient does not require a medullary cavity. Resuscitation 2003; 56:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/16\">",
"      Clem M, Tierney P. Intraosseous infusions via the calcaneus. Resuscitation 2004; 62:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/17\">",
"      Luck RP, Haines C, Mull CC. Intraosseous access. J Emerg Med 2010; 39:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/18\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/19\">",
"      Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/20\">",
"      Banerjee S, Singhi SC, Singh S, Singh M. The intraosseous route is a suitable alternative to intravenous route for fluid resuscitation in severely dehydrated children. Indian Pediatr 1994; 31:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/21\">",
"      Lillis KA, Jaffe DM. Prehospital intravenous access in children. Ann Emerg Med 1992; 21:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/22\">",
"      Glaeser PW, Hellmich TR, Szewczuga D, et al. Five-year experience in prehospital intraosseous infusions in children and adults. Ann Emerg Med 1993; 22:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/23\">",
"      Fuchs S, LaCovey D, Paris P. A prehospital model of intraosseous infusion. Ann Emerg Med 1991; 20:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/24\">",
"      Reades R, Studnek JR, Vandeventer S, Garrett J. Intraosseous versus intravenous vascular access during out-of-hospital cardiac arrest: a randomized controlled trial. Ann Emerg Med 2011; 58:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/25\">",
"      Leidel BA, Kirchhoff C, Braunstein V, et al. Comparison of two intraosseous access devices in adult patients under resuscitation in the emergency department: A prospective, randomized study. Resuscitation 2010; 81:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/26\">",
"      Leidel BA, Kirchhoff C, Bogner V, et al. Is the intraosseous access route fast and efficacious compared to conventional central venous catheterization in adult patients under resuscitation in the emergency department? A prospective observational pilot study. Patient Saf Surg 2009; 3:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/27\">",
"      McNamara RM, Spivey WH, Unger HD, Malone DR. Emergency applications of intraosseous infusion. J Emerg Med 1987; 5:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/28\">",
"      de Caen A. Venous access in the critically ill child: when the peripheral intravenous fails! Pediatr Emerg Care 2007; 23:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/29\">",
"      Horton MA, Beamer C. Powered intraosseous insertion provides safe and effective vascular access for pediatric emergency patients. Pediatr Emerg Care 2008; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/30\">",
"      Glaeser PW, Losek JD. Emergency intraosseous infusions in children. Am J Emerg Med 1986; 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/31\">",
"      Katan BS, Olshaker JS, Dickerson SE. Intraosseous infusion of muscle relaxants. Am J Emerg Med 1988; 6:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/32\">",
"      Buck ML, Wiggins BS, Sesler JM. Intraosseous drug administration in children and adults during cardiopulmonary resuscitation. Ann Pharmacother 2007; 41:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/33\">",
"      Friedman FD. Intraosseous adenosine for the termination of supraventricular tachycardia in an infant. Ann Emerg Med 1996; 28:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/34\">",
"      Goodman IS, Lu CJ. Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia. Pediatr Emerg Care 2012; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/35\">",
"      Hodge D 3rd. Intraosseous infusions: a review. Pediatr Emerg Care 1985; 1:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/36\">",
"      Miller L, Kramer GC, Bolleter S. Rescue access made easy. JEMS 2005; 30:suppl 8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/37\">",
"      Orlowski JP, Porembka DT, Gallagher JM, et al. Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. Am J Dis Child 1990; 144:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/38\">",
"      Orlowski JP. Emergency alternatives to intravenous access. Intraosseous, intratracheal, sublingual, and other-site drug administration. Pediatr Clin North Am 1994; 41:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/39\">",
"      Neufeld JD, Marx JA, Moore EE, Light AI. Comparison of intraosseous, central, and peripheral routes of crystalloid infusion for resuscitation of hemorrhagic shock in a swine model. J Trauma 1993; 34:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/40\">",
"      Grisham J, Hastings C. Bone marrow aspirate as an accessible and reliable source for critical laboratory studies. Ann Emerg Med 1991; 20:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/41\">",
"      Ummenhofer W, Frei FJ, Urwyler A, Drewe J. Are laboratory values in bone marrow aspirate predictable for venous blood in paediatric patients? Resuscitation 1994; 27:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/42\">",
"      Brickman KR, Krupp K, Rega P, et al. Typing and screening of blood from intraosseous access. Ann Emerg Med 1992; 21:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/43\">",
"      Johnson L, Kissoon N, Fiallos M, et al. Use of intraosseous blood to assess blood chemistries and hemoglobin during cardiopulmonary resuscitation with drug infusions. Crit Care Med 1999; 27:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/44\">",
"      Orlowski JP, Julius CJ, Petras RE, et al. The safety of intraosseous infusions: risks of fat and bone marrow emboli to the lungs. Ann Emerg Med 1989; 18:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/45\">",
"      Fiallos M, Kissoon N, Abdelmoneim T, et al. Fat embolism with the use of intraosseous infusion during cardiopulmonary resuscitation. Am J Med Sci 1997; 314:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/46\">",
"      Ellemunter H, Simma B, Traw&ouml;ger R, Maurer H. Intraosseous lines in preterm and full term neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80:F74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/47\">",
"      Day MW. Intraosseous devices for intravascular access in adult trauma patients. Crit Care Nurse 2011; 31:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/48\">",
"      Fiorito BA, Mirza F, Doran TM, et al. Intraosseous access in the setting of pediatric critical care transport. Pediatr Crit Care Med 2005; 6:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/49\">",
"      Hartholt KA, van Lieshout EM, Thies WC, et al. Intraosseous devices: a randomized controlled trial comparing three intraosseous devices. Prehosp Emerg Care 2010; 14:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/50\">",
"      Seigler RS, Tecklenburg FW, Shealy R. Prehospital intraosseous infusion by emergency medical services personnel: a prospective study. Pediatrics 1989; 84:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/51\">",
"      Cooper BR, Mahoney PF, Hodgetts TJ, Mellor A. Intra-osseous access (EZ-IO) for resuscitation: UK military combat experience. J R Army Med Corps 2007; 153:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/52\">",
"      Frascone RJ, Jensen JP, Kaye K, Salzman JG. Consecutive field trials using two different intraosseous devices. Prehosp Emerg Care 2007; 11:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/53\">",
"      David JS, Dubien PY, Capel O, et al. Intraosseous infusion using the bone injection gun in the prehospital setting. Resuscitation 2009; 80:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/54\">",
"      Schwartz D, Amir L, Dichter R, Figenberg Z. The use of a powered device for intraosseous drug and fluid administration in a national EMS: a 4-year experience. J Trauma 2008; 64:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/55\">",
"      Gerritse BM, Scheffer GJ, Draaisma JM. Prehospital intraosseus access with the bone injection gun by a helicopter-transported emergency medical team. J Trauma 2009; 66:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/56\">",
"      Macnab A, Christenson J, Findlay J, et al. A new system for sternal intraosseous infusion in adults. Prehosp Emerg Care 2000; 4:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/57\">",
"      Abe KK, Blum GT, Yamamoto LG. Intraosseous is faster and easier than umbilical venous catheterization in newborn emergency vascular access models. Am J Emerg Med 2000; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/58\">",
"      Anderson TE, Arthur K, Kleinman M, et al. Intraosseous infusion: success of a standardized regional training program for prehospital advanced life support providers. Ann Emerg Med 1994; 23:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/59\">",
"      Levitan RM, Bortle CD, Snyder TA, et al. Use of a battery-operated needle driver for intraosseous access by novice users: skill acquisition with cadavers. Ann Emerg Med 2009; 54:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/60\">",
"      Jun H, Haruyama AZ, Chang KS, Yamamoto LG. Comparison of a new screw-tipped intraosseous needle versus a standard bone marrow aspiration needle for infusion. Am J Emerg Med 2000; 18:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/61\">",
"      Dubick MA, Holcomb JB. A review of intraosseous vascular access: current status and military application. Mil Med 2000; 165:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/62\">",
"      Nagler J, Krauss B. Videos in clinical medicine. Intraosseous catheter placement in children. N Engl J Med 2011; 364:e14.",
"     </a>",
"    </li>",
"    <li>",
"     Ruddy RM. Illustrated techniques of pedatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2006. p.1880.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/64\">",
"      Simmons CM, Johnson NE, Perkin RM, van Stralen D. Intraosseous extravasation complication reports. Ann Emerg Med 1994; 23:363.",
"     </a>",
"    </li>",
"    <li>",
"     Needle set directions for use. Vidacare, Shavano Park, Texas, USA. Available at file://www.vidacare.com/admin/files/VIDO5-8016-REVH_02-26_HIRES.pdf",
"    </li>",
"    <li>",
"     Bone injection gun training movie. file://www.waismed.com/BIGmovie.html accessed April 12, 2011.",
"    </li>",
"    <li>",
"     Trainer's manual. FAST1 Intraosseous infusion system. www.pyng.com, June 2010 available at file://www.pyng.com/wp/wp-content/uploads/FAST1%20Manual%20Jun2010%281%29.pdf (accessed April 12, 2011).",
"    </li>",
"    <li>",
"     FAST! training 1. file://www.pyng.com/education/demonstrations/?pi=138 (Accessed on April 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/69\">",
"      Garcia CT, Cohen DM. Intraosseous needle: use of the miniature C-arm imaging device to confirm placement. Pediatr Emerg Care 1996; 12:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/70\">",
"      Tsung JW, Blaivas M, Stone MB. Feasibility of point-of-care colour Doppler ultrasound confirmation of intraosseous needle placement during resuscitation. Resuscitation 2009; 80:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/71\">",
"      Rosetti VA, Thompson BM, Miller J, et al. Intraosseous infusion: an alternative route of pediatric intravascular access. Ann Emerg Med 1985; 14:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/72\">",
"      La Fleche FR, Slepin MJ, Vargas J, Milzman DP. Iatrogenic bilateral tibial fractures after intraosseous infusion attempts in a 3-month-old infant. Ann Emerg Med 1989; 18:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/73\">",
"      Taylor CC, Clarke NM. Amputation and intraosseous access in infants. BMJ 2011; 342:d2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/74\">",
"      Claudet I, Baunin C, Laporte-Turpin E, et al. Long-term effects on tibial growth after intraosseous infusion: a prospective, radiographic analysis. Pediatr Emerg Care 2003; 19:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/75\">",
"      Fiser RT, Walker WM, Seibert JJ, et al. Tibial length following intraosseous infusion: a prospective, radiographic analysis. Pediatr Emerg Care 1997; 13:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/76\">",
"      Pollack CV Jr, Pender ES, Woodall BN, et al. Long-term local effects of intraosseous infusion on tibial bone marrow in the weanling pig model. Am J Emerg Med 1992; 10:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/77\">",
"      Woodall BN, Pender ES, Pollack CV Jr, et al. Intraosseous infusion of resuscitative fluids and drugs: long-term effect on linear bone growth in pigs. South Med J 1992; 85:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/78\">",
"      Brickman KR, Rega P, Schoolfield L, et al. Investigation of bone developmental and histopathologic changes from intraosseous infusion. Ann Emerg Med 1996; 28:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40761/abstract/79\">",
"      Tocantins LM, O'neill JF. Complications of Intra-Osseous Therapy. Ann Surg 1945; 122:266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6321 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40761=[""].join("\n");
var outline_f39_51_40761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17936405\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6338267\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17935746\">",
"      Fluid and drug administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17935753\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17936252\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17936215\">",
"      - Intraosseous (IO) needles and devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sites of placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4931995\">",
"      Choice of device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4932231\">",
"      Training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17936377\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Manual insertion technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17936325\">",
"      Battery-powered driver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6338311\">",
"      Impact-driven devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6337564\">",
"      - Bone injection gun",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6337732\">",
"      - FAST1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2685868\">",
"      Confirmation of placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17936282\">",
"      DURATION OF USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17936385\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17936405\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6321|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/0/25600\" title=\"figure 1\">",
"      Long bone venous drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/61/15316\" title=\"figure 2\">",
"      Proximal tibia intraosseous site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/49/4883\" title=\"figure 3\">",
"      Femoral intraosseous site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/62/2019\" title=\"figure 4\">",
"      Distal tibia intraosseous site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/16/29957\" title=\"figure 5\">",
"      Proximal humerus intraosseous site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/17/39190\" title=\"figure 6\">",
"      Intraosseous cannulation technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/57/37781\" title=\"figure 7\">",
"      Manual intraosseous needle placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6321|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/52/4940\" title=\"table 1\">",
"      Intraosseous cannula placement site by patient age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6361?source=related_link\">",
"      Peripheral venous access in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40762="Treatment of adrenocortical carcinoma";
var content_f39_51_40762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of adrenocortical carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Gary D Hammer, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/51/40762/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/51/40762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenocortical carcinomas are rare and frequently aggressive tumors that may be functional (hormone-secreting) and cause Cushing's syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    virilization, or nonfunctional and present as an abdominal mass or as an incidental finding.",
"   </p>",
"   <p>",
"    The management of adrenocortical carcinoma (ACC) will be discussed here. The clinical presentation and diagnostic evaluation of patients with adrenal masses, the staging workup for adrenocortical carcinoma, and the management of benign adrenal adenomas are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=see_link\">",
"     \"Treatment of adrenocortical adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956994\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best staging system for ACC is evolving. Although there is a TNM staging system available from the American Joint Commission on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) (",
"    <a class=\"graphic graphic_table graphicRef71328 \" href=\"mobipreview.htm?40/7/41084\">",
"     table 1",
"    </a>",
"    ), most contemporary treatment studies use the modification for stage groupings proposed by the European Network for the Study of Adrenal Tumors (ENSAT), given its superior prognostic stratification with the restriction of stage IV tumors to those having distant metastases (",
"    <a class=\"graphic graphic_table graphicRef83901 \" href=\"mobipreview.htm?2/54/2924\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A modification has been proposed for the ENSAT staging system that incorporates histologic grade of differentiation (",
"    <a class=\"graphic graphic_table graphicRef86178 \" href=\"mobipreview.htm?24/6/24683\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete surgical resection is the only potentially curative treatment for ACC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/2\">",
"     2",
"    </a>",
"    ]. For patients with potentially resectable stage I to III disease (according to the ENSAT stage groupings (",
"    <a class=\"graphic graphic_table graphicRef83901 \" href=\"mobipreview.htm?2/54/2924\">",
"     table 2",
"    </a>",
"    )) who are surgical candidates, we recommend complete surgical resection as initial therapy.",
"   </p>",
"   <p>",
"    The surgery should be performed in a specialized referral center by teams of surgeons with specific expertise to avoid tumor spillage and incomplete resection, which is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6355355\">",
"     'Stage and margin status'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The preoperative preparation for and techniques of surgical adrenalectomy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/38/20073?source=see_link\">",
"     \"Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For potentially resectable tumors invading adjacent organs, surgery often needs to be extensive with en bloc resection of involved organs such as kidney, liver, spleen, pancreas, stomach, and colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/5\">",
"     5",
"    </a>",
"    ]. Intracaval extension or tumor thrombus is not a contraindication to surgery; resection may be facilitated by cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACCs often spread via lymphatic drainage. A benefit for routine lymphadenectomy during adrenalectomy was suggested in a report from the German ACC Study Group of 283 patients with completely resected ACC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/7\">",
"     7",
"    </a>",
"    ]. There was a significantly reduced risk for tumor recurrence and disease-related death (hazard ratio 0.54, 95% CI 0.29-0.99) in patients who underwent lymphadenectomy versus those who did not.",
"   </p>",
"   <p>",
"    Although resection is technically possible for most patients with stage I to III disease (",
"    <a class=\"graphic graphic_table graphicRef71328 \" href=\"mobipreview.htm?40/7/41084\">",
"     table 1",
"    </a>",
"    ), it is not curative for many, presumably because occult micrometastases are present at the time of initial presentation, even with stage I disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. As an example, in a single center report of 202 consecutive cases of ACC, 40 percent of patients with stage I to III disease (according to the Sullivan modification of the McFarlane staging criteria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/13\">",
"     13",
"    </a>",
"    ], which roughly correspond to the 2010",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    stage groupings (",
"    <a class=\"graphic graphic_table graphicRef71328 \" href=\"mobipreview.htm?40/7/41084\">",
"     table 1",
"    </a>",
"    ), had developed distant metastasis two years after diagnosis (27, 46, and 63 percent of patients with stage I, II, and III disease, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is some evidence that outcomes are improving over time. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prognosis and prognostic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Even if the tumor cannot be removed entirely, some clinicians advocate maximal debulking as a means of improving survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/8,15-18\">",
"     8,15-18",
"    </a>",
"    ], although others disagree as to the survival benefit of this strategy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Data to support routine debulking of nonresectable tumors are lacking and decision making must be individualized, taking into account the underlying tumor biology, rate of progression, and the histologic grade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3\">",
"     3",
"    </a>",
"    ]. For patients with advanced functioning tumors, debulking may help to control hormone hypersecretion and increase the efficacy of further therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/2,4,21\">",
"     2,4,21",
"    </a>",
"    ]. Overall, however, patients with unresectable disease have a poor prognosis, particularly with high-grade disease, often surviving only three to nine months, and they are often better palliated with medical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Recurrent or advanced adrenocortical cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of neoadjuvant systemic therapy prior to surgery for patients with locally advanced disease is not defined, and this is not considered a standard approach. The value of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is being addressed in a clinical trial from the Children&rsquo;s Oncology Group that is enrolling individuals up to age 21 with ACC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164554\">",
"    <span class=\"h3\">",
"     Laparoscopic versus open resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic surgery has largely replaced the open technique for management of benign adrenal pathology, and laparoscopic removal of even large adrenal tumors can be performed safely by experienced surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/38/20073?source=see_link\">",
"     \"Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the role of laparoscopic resection for ACCs is controversial, and open surgery remains the standard approach. Several retrospective studies have shown more frequent or earlier recurrences and a shorter disease-free survival when this technique is used for management of ACC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,27-29\">",
"     3,27-29",
"    </a>",
"    ]. This is not a universal finding, however, and others have shown comparable outcomes from laparoscopic and open adrenalectomy, particularly for tumors up to 10 cm in size in specialized centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Nonetheless, this is not a widely accepted approach and we and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/30\">",
"     30",
"    </a>",
"    ] suggest not using laparoscopic resection for known or highly suspected ACC, regardless of size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,27,34\">",
"     3,27,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adjuvant mitotane",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    (Lysodren, o,p'-DDD, a congener of the pesticide dichlorodiphenyltrichloroethane [DDT]) is an adrenocorticolytic drug that has efficacy in patients with adrenocortical carcinoma (ACC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/8,35-37\">",
"     8,35-37",
"    </a>",
"    ]. It has been used in the adjuvant setting, for primary therapy of unresectable disease, and for the treatment of disease recurrence, either alone or in combination with other cytotoxic agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Mitotane monotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6353019\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data demonstrating the benefit of routine postoperative (adjuvant) administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    have been mixed, in large part due to the rarity of ACC and the lack of prospective randomized clinical trials. While a number of uncontrolled reports suggest that adjuvant mitotane may delay or prevent recurrence in patients undergoing complete primary resection for nonmetastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,11,38-46\">",
"     3,11,38-46",
"    </a>",
"    ], others have failed to show any benefit in terms of disease-free or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/4,15,20,47-55\">",
"     4,15,20,47-55",
"    </a>",
"    ]. Among the potential reasons for these disparate results are insufficient dosing in some studies, and variability in an individual tumor's ability to metabolize mitotane (which is required for therapeutic action).",
"   </p>",
"   <p>",
"    The best available evidence that adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    improves outcomes for patients with resected stage I to III ACC comes from a retrospective analysis of 177 patients who had undergone macroscopically complete radical surgery at one of eight Italian and 47 German centers between 1985 and 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/40\">",
"     40",
"    </a>",
"    ]. In the Italian cohort, 47 received adjuvant mitotane while 55 patients did not (Italian control group). None of the 75 patients in the German cohort had received adjuvant mitotane (German control group).",
"   </p>",
"   <p>",
"    The groups were well matched with the exception that the German control patients were more likely to have stage I or II disease (84 versus 67 percent of both Italian groups). With a median follow-up that ranged from 43 to 68 months in the three groups, the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      group, 27 patients received 1 to 3 grams daily, and the remainder received 3 to 5 grams daily. Serum levels were not routinely measured. The median duration of treatment was 29 months for both doses.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      treatment was associated with a significantly longer recurrence-free survival as compared with either control group (median recurrence-free survival 42 versus 10 and 25 months in the Italian and German control groups, respectively).",
"     </li>",
"     <li>",
"      There were also fewer deaths from ACC in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      group than in either control group (25 versus 55 and 41 percent, respectively). Median overall survival durations in the three groups were 110 months in the mitotane group compared with 52 months in the Italian controls and 67 months in the German control group.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      was reasonably well-tolerated. Grade 3 gastrointestinal (nausea or vomiting or elevated serum GGT) or neurologic events (confusion, ataxia, vertigo) were observed in 15 and 20 percent of the patients who received the higher dose mitotane regimen; neither of these problems occurred with lower doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the view that adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    therapy, even at relatively low doses, improves recurrence-free and overall survival after macroscopically complete radical resection for stage I, II, or III ACC. The strengths of this retrospective series include its large size, involvement of multiple institutions, well-matched control cohort, long duration, and systematic nature of follow-up, and carefully conducted statistical analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit was also supported by another report of 149 German ACC registry patients with stage II ACC, in which the subgroup of 35 patients who received adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    displayed a significantly better five-year survival than did the 114 patients not receiving adjuvant mitotane (87 versus 53 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6353026\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, adjuvant therapy has been recommended for most patients with ACC because, even after radical resection, recurrence rates up to 60 to 80 percent were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9,51\">",
"     9,51",
"    </a>",
"    ]. However, newer reports have suggested that the survival rate in localized ACC is probably much better than that of most published retrospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/46\">",
"     46",
"    </a>",
"    ], and this has led to an ongoing debate as to which patients are in need of adjuvant therapy.",
"   </p>",
"   <p>",
"    Increasingly, decisions about adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    are being made on the basis of tumor stage, completeness of resection, and proliferation rate, the three major prognostic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Studies, including data on prognostic factors from the original Weiss criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/59\">",
"     59",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H6355056\">",
"     'Histology'",
"    </a>",
"    below) and unpublished data from the German ACC registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/57\">",
"     57",
"    </a>",
"    ], have shown that a high proliferation rate (as determined by the mitotic rate, MIB1 staining, or Ki67 expression) is associated with a poor prognosis. (See",
"    <a class=\"local\" href=\"#H6355348\">",
"     'Prognostic factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We consider that patients who have the highest risk for recurrence are those who have histologically high-grade disease (Ki67 staining of &gt;10 percent of tumor cells, &gt;20 mitotic figures per 50 high-power fields (HPF) regardless of tumor size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/1,60\">",
"     1,60",
"    </a>",
"    ]), intraoperative tumor spillage or fracture, and some large tumors that are low grade but have vascular or capsular invasion. We suggest adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    use for all patients who meet these criteria.",
"   </p>",
"   <p>",
"    These recommendations differ from those of an international Consensus Panel on the treatment of ACC, which concluded that adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    was indicated for patients with a potentially incomplete resection and for all patients with a high proliferative rate (as assessed by Ki67 staining of &gt;10 percent of cells) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/57\">",
"     57",
"    </a>",
"    ]. However, they also concluded that adjuvant mitotane was not mandatory for stage I or II disease, histologically proven complete (R0) resection, and Ki67 staining of &le;10 percent of cells.",
"   </p>",
"   <p>",
"    It remains unclear whether patients with low-grade ACC who have an open resection and no tumor fracture or spillage at the time of surgery benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    following complete resection. Based upon data from the German ACC registry, some suggest that observation alone is only appropriate if, in addition to the above criteria (stage I or II disease, histologically proven complete (R0) resection, and Ki67 staining of &le;10 percent of cells), patients also have tumor size &lt;8 cm and no microscopic evidence of invasion of blood vessels or the tumor capsule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/61\">",
"     61",
"    </a>",
"    ].",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    guidelines suggest that mitotane be &ldquo;considered&rdquo; (category 3 recommendation, with major disagreement that the intervention is appropriate) for all patients with resected low-grade or high-grade localized ACC regardless of stage or tumor size.",
"   </p>",
"   <p>",
"    We treat some of these patients (eg, those with stage III low-grade disease, or a large [&gt;20 cm] stage II tumor with a borderline mitotic rate or Ki67 score), but in this setting, are more likely to discontinue the drug for side effects, and often treat for shorter periods of time.",
"   </p>",
"   <p>",
"    A large international randomized trial (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    versus observation) in patients with presumably low to intermediate risk resected disease (stage I to III, microscopically complete (R0) resection, Ki67 &lt;10 percent) is currently ongoing (the ADIUVO trial) and, if available, eligible patients should be referred for enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the future, molecular markers might help to better define individual risk for recurrence to tailor decisions about therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/63\">",
"     63",
"    </a>",
"    ], but no test is ready for clinical use yet. (See",
"    <a class=\"local\" href=\"#H6355636\">",
"     'Other factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H957045\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is not known, and there is no consensus on this point, particularly for patients with low-risk disease. In the adjuvant study reported above, the median duration of treatment was 29 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6353019\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most guidelines suggest a minimum of two years of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/58\">",
"     58",
"    </a>",
"    ] and this is the duration being tested in the adjuvant ADIUVO trial described above for intermediate to low risk disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/62\">",
"     62",
"    </a>",
"    ]. International guidelines suggest to aim for two years but treat longer if the patient is doing well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We aim to continue adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    treatment for five years in patients with high-risk ACC independent of stage on the assumption that it is very atypical for a patient with ACC to recur after four to five years. While there is no consensus on the duration of adjuvant mitotane therapy for patients with low-risk ACC, we aim for a minimum of two to three years, and will at times continue for five years if the drug is well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dosing regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dosing regimens of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    for primary therapy or in the adjuvant setting are not known. While benefit in the adjuvant setting has been reported using relatively low doses (1 to 3 grams daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/40\">",
"     40",
"    </a>",
"    ], modern treatment protocols are generally based upon achieving therapeutic serum levels. The measurement of serum mitotane levels, targeting a range of 14 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    has been validated in several studies as correlating with therapeutic response while minimizing toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/5,49,53,64-67\">",
"     5,49,53,64-67",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective series included 91 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      for unresectable or metastatic ACC who underwent assay of serum mitotane levels within three months of attaining the best response to mitotane with or without chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/66\">",
"       66",
"      </a>",
"      ]. A significantly higher number of responders (11 of 17 responders) had serum mitotane levels &gt;14",
"      <span class=\"nowrap\">",
"       mcg/mL,",
"      </span>",
"      and of the six responders who had lower levels, all were receiving concurrent chemotherapy. Survival was also significantly longer among patients with levels &gt;14",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (median survival 24 versus 18 months, hazard ratio for death 0.52, 95% CI 0.28-0.97).",
"     </li>",
"     <li>",
"      In a prospective study, therapeutic monitoring achieved better tolerance of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy with fewer side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Furthermore, in the adjuvant setting, improved outcomes for patients with therapeutic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      levels were shown in a report of 43 consecutive patients undergoing surgical treatment for ACC followed by monitored mitotane; 29 (67 percent) had stage III or IV tumors, and 33 underwent potentially curative surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/5\">",
"       5",
"      </a>",
"      ]. Four patients treated prior to 1990 (when mitotane monitoring was not available) received a low dose of the drug (1 g twice daily), while 13 others did not tolerate the drug and were kept at lower levels; 24 patients (75 percent of whom had stage III or IV tumors) were maintained at mitotane levels exceeding 14",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      Despite the preponderance of stage III and IV tumors, the disease-specific five-year survival rate was high (64 percent). When the hazard ratio for death from ACC was compared over time between the patients with high mitotane levels versus the patients with lower doses or without mitotane treatment, there was a positive survival effect that persisted up to four years after surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Every patient metabolizes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    to different degrees and hence requires unique dosing to achieve therapeutic blood levels. Therapeutic serum levels can at times be achieved with low doses of mitotane. As an example, in one series of eight patients receiving 3 g daily (of the nonmicronized formulation), therapeutic concentrations (14 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    were reached in three to five months (after a cumulative dose of about 360 g), and five patients maintained clinical benefit (stable disease or disease-free) with minimal toxicity for 8 to 40 months with as little as 1 to 2 g daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these observations, we suggest that all patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    (including those being treated for advanced disease) undergo therapeutic monitoring with plasma mitotane levels. The following represents our approach to managing therapy with mitotane:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      is initiated at 0.5 g twice per day and increased to 6",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      over 4 to 12 weeks as tolerated with monitoring of mitotane level every two to three weeks.",
"     </li>",
"     <li>",
"      Because of the long serum half-life and accumulation in adipose tissue, several weeks may be necessary to raise serum",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      concentrations to the target level of 14 to 20",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/53,65\">",
"       53,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When serum",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      monitoring is not available, we suggest trying to push dosing to toxicity (up to 6 to 8 g per day) for patients with high-risk disease, and adjust according to tolerability. Some patients may not tolerate more than 2 g per day.",
"     </li>",
"     <li>",
"      At some centers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      is administered to all patients using rapid escalation of high doses (4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      rapidly escalating to therapeutic doses within two weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/69\">",
"       69",
"      </a>",
"      ]. This regimen may shorten the time needed to reach therapeutic levels of mitotane, but it requires closer follow-up and combined clinical and mitotane level monitoring, and may be more frequently associated with side effects.",
"     </li>",
"     <li>",
"      Nausea should be treated using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      or a 5-HT3 receptor antagonist such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States and Canada, plasma levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    can be measured in commercial laboratories and some academic centers; in Europe, they are available through HRA Pharma, which distributes mitotane as an orphan drug. We recommend monitoring plasma mitotane levels in all patients if possible, as outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192296005\">",
"    <span class=\"h3\">",
"     Monitoring response",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68910287\">",
"    <span class=\"h4\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    can be assessed periodically during therapy by the following techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance for recurrence of disease should include contrast-enhanced CT scans (or MRI) of the chest, abdomen, and pelvis every three months for two to three years, then every four to six months for five years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"       \"Radiation-related risks of imaging studies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the role of fluorodeoxyglucose-PET (FDG-PET) in posttreatment monitoring is not yet established, some centers add integrated",
"      <span class=\"nowrap\">",
"       FDG-PET/CT",
"      </span>",
"      at six month intervals in the posttreatment follow-up strategy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/30\">",
"       30",
"      </a>",
"      ]. Limited studies comparing the usefulness of integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scans (which are typically done without IV contrast) versus diagnostic (ie, contrast-enhanced) CT performed at the same time have shown that integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      detects more lesions than does PET or CT alone, and that PET should be considered a complementary examination to contrast-enhanced CT or MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/70-72\">",
"       70-72",
"      </a>",
"      ]. In one study, PET was more sensitive than CT in detecting local recurrence, while CT was more sensitive in detecting small lung or peritoneal metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/72\">",
"       72",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Nevertheless, the utility of PET in the setting of primary treatment remains controversial. At the University of Michigan, PET is not performed routinely, either prior to primary surgery for a suspected ACC or as a component of the posttreatment surveillance strategy. However, other centers, including that of one of the authors (AL), routinely perform PET prior to surgery for a suspected ACC, and add integrated",
"      <span class=\"nowrap\">",
"       FDG-PET/CT",
"      </span>",
"      at six month intervals in the posttreatment follow-up strategy for patients with high-risk disease who have been shown to have FDG-avid disease preoperatively (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Local therapy'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68910294\">",
"    <span class=\"h4\">",
"     Biochemical",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a completely resected steroid-producing ACC, some groups monitor patients every three months for two years with steroid tumor markers such as cortisol (measured in the morning before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    dose), DHEAS, androstenedione, testosterone, estradiol, or mineralocorticoid based on steroid profile in initial tumor. Other groups do not routinely screen for recurrent hormone excess unless or until there is evidence of recurrent disease.",
"    <br/>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    , which increases serum concentrations of corticosteroid-binding globulin (CBG), may result in serum cortisol values that are artifactually elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/73\">",
"     73",
"    </a>",
"    ] without significant changes in ACTH. Despite alterations in cortisol metabolism induced by mitotane, 24-hour urinary free cortisol excretion remains the best index of cortisol production currently available (",
"    <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of liquid chromatography-mass spectroscopy assays for urine cortisol and its metabolites should eventually offer better tools to assess steroid hormone production and requirements in ACC patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Toxicities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762852265\">",
"    <span class=\"h4\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    routinely induces atrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    steroidogenic inhibition of the normal adrenal glands, thereby causing cortisol deficiency. The zona glomerulosa is more resistant to the adrenolytic effect of mitotane and aldosterone deficiency may not occur until after several months of therapy.",
"   </p>",
"   <p>",
"    Glucocorticoid replacement therapy is routinely given to patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    (unless the ACC is an advanced, glucocorticoid-producing tumor presenting as Cushing&rsquo;s syndrome). Patients undergoing mitotane treatment should wear a medical alert bracelet and be instructed to increase their doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    during stress. Independent of the pharmacologic effects of mitotane, for patients with cortisol-secreting ACC, suppression of the ACTH-adrenal axis will require replacement with glucocorticoids following complete tumor resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Close monitoring of blood sodium, potassium, creatinine, and 24-hour urine free urinary cortisol levels is necessary to avoid adrenal insufficiency and acute hyperkalemia in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    , whether in the adjuvant setting or for advanced disease (",
"    <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=see_link\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The induction of hepatic cytochrome P450 enzymes by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    increases the rate of metabolism of cortisol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    . Several times the usual maintenance doses of glucocorticoids may be needed to relieve the symptoms of adrenal insufficiency and maintain normal concentrations of serum electrolytes and blood pressure. Furthermore, inadequately treated adrenal insufficiency enhances mitotane-induced side effects and reduces drug tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/12,44,64\">",
"     12,44,64",
"    </a>",
"    ]. A brief trial of a higher glucocorticoid dose may mitigate some side effects that could be attributable to inadequate cortisol replacement and allow continuation of mitotane at the same dose.",
"   </p>",
"   <p>",
"    One cannot predict when a patient will become hypocortisolemic after beginning treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    . Therefore, replacement glucocorticoid therapy should be started when mitotane treatment is initiated. For all patients who are receiving mitotane, we initiate replacement with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (30 to 40 mg daily in divided doses, two to three times per day). Of note, most patients eventually require a two- to threefold increase in hydrocortisone. In patients with residual ACC and persistent hypercortisolemia, replacement should",
"    <strong>",
"     not",
"    </strong>",
"    be",
"    <strong>",
"    </strong>",
"    initiated until hypercortisolism is controlled with mitotane and steroid enzyme inhibitors.",
"   </p>",
"   <p>",
"    Unlike glucocorticoid replacement, we do not start mineralocorticoid replacement right away. Instead, we suggest monitoring blood pressure (supine and standing), and serum sodium and potassium at three to four-month intervals, and plasma renin levels every six months (",
"    <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"     table 4",
"    </a>",
"    ). Mineralocorticoid deficiency should be suspected if the patient develops postural hypotension, hyponatremia, or hyperkalemia and has an elevation in plasma renin activity. It can be due to deficient aldosterone secretion or, in a patient already taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    replacement therapy, to increased metabolism of fludrocortisone by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    When clinical and biochemical signs of aldosterone deficiency become present,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (0.1 to 0.3 mg daily) is initiated and adjusted to restore normal clinical and biochemical parameters (",
"    <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Measurement of serum",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    levels together with 24-hour urine free cortisol with an assessment of side effects should guide mitotane and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    dosing. If side effects do not abate with glucocorticoid therapy, temporary discontinuation of mitotane is indicated, followed by reinstitution at a lower dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718899\">",
"    <span class=\"h4\">",
"     Hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women of reproductive age who are scheduled to receive adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    therapy after ACC resection need reliable contraception during and for at least one year post-mitotane therapy, as the drug has a long half-life and is deposited in adipose tissues.",
"   </p>",
"   <p>",
"    The gonadal toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is unknown. For this reason, we suggest contraception in women undergoing adjuvant mitotane therapy. However, as mitotane accelerates steroid metabolism and may decrease the contraceptive efficacy of oral contraceptives, contraceptive methods other than oral contraceptives should be recommended in these patients.",
"   </p>",
"   <p>",
"    In addition to its effect on CBG,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    increases serum concentrations of other binding globulins, including sex-hormone binding globulin (SHBG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/12,64\">",
"     12,64",
"    </a>",
"    ]. Therefore, if serum testosterone levels are measured (for follow-up of an androgen-secreting tumor or when hypogonadism is suspected clinically), results should be interpreted taking into account the changes of SHBG levels induced by mitotane therapy (",
"    <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192296424\">",
"    <span class=\"h4\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its effect on CBG,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    increases serum concentrations of other binding globulins, including thyroid hormone binding globulin (TBG). Therefore, serum concentrations of FT4 may be decreased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/12,64\">",
"     12,64",
"    </a>",
"    ]. In addition, newer studies indicate a direct inhibitory effect of mitotane on TSH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/64\">",
"     64",
"    </a>",
"    ]. As patients on mitotane therapy often present with fatigue, thyroid function tests should be monitored periodically (",
"    <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762852280\">",
"    <span class=\"h4\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    limits tolerability, particularly at doses above 6 grams per day. The most common side effects are fatigue, nausea, vomiting, and anorexia, but skin rash, diarrhea, lethargy, sedation, confusion, dizziness, ataxia, gynecomastia, arthralgias, leukopenia, prolonged bleeding time, hematuria, and reversible growth arrest in children also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/12,77\">",
"     12,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other adverse effects include hypercholesterolemia (elevated LDL cholesterol), hypouricemia, and hepatotoxicity. While increased concentrations of serum gamma-glutamyl transpeptidase (GGT) and alkaline phosphatase are almost invariably observed, a significant rise in transaminases or bilirubin is infrequent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link\">",
"     \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762852034\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     Mitotane",
"    </a>",
"    is a potent inducer of CYP3A4 metabolism. Limited data suggest that this can result in important drug-drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/78\">",
"     78",
"    </a>",
"    ]. In a report of two patients with ACC who were receiving mitotane in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (a drug metabolized by CYP3A4), serum sunitinib concentrations were decreased by approximately 80 percent of expected values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/79\">",
"     79",
"    </a>",
"    ]. Although clinical data are currently unavailable, mitotane administration could reduce the efficacy of other drugs relevant to the management of patients with ACC, such as steroid hormone replacement, benzodiazepines, macrolide antibiotics, some opioids and statins, and dihydropyridine type calcium channel antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific interactions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15861690\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy with or without mitotane",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known if cytotoxic chemotherapy alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is more effective than adjuvant mitotane alone.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    was explored in the adjuvant setting in a small series of five individuals aged 1.2 to 21 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/80\">",
"     80",
"    </a>",
"    ]. All received etoposide 165",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    and cisplatin 90",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    every three to four weeks for at least six cycles, beginning shortly after surgical resection, and all remained in remission 29 to 109 months later. However, ACC in children has a different natural history than that arising in adults. There are no data addressing the benefit of adjuvant chemotherapy in adults with ACC (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Children'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    plus streptozotocin as adjuvant therapy was evaluated in a nonrandomized phase II trial of 17 patients who had undergone complete tumor resection. Disease-free survival was significantly better in patients who then received combination mitotane-streptozotocin adjuvant therapy compared with a separate cohort of 11 patients who received no adjuvant therapy after complete resection (49 versus 12 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/81\">",
"     81",
"    </a>",
"    ]. However, in the absence of a comparator group receiving mitotane alone, it cannot be concluded that combined therapy is superior. This approach should not be considered for adjuvant treatment after a complete resection of ACC outside of the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adjuvant radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, ACC was thought to be a relatively radioresistant tumor. However, this is likely not true with modern RT techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/82\">",
"     82",
"    </a>",
"    ]. While there are no randomized trials testing the efficacy of adjuvant RT in patients with resected ACC, some, but not all, studies support a benefit in certain patients who are at high risk for a local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective report addressing the benefit of adjuvant RT is from the German ACC registry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/83\">",
"       83",
"      </a>",
"      ]. Outcomes of 14 patients (stage I, II, and III (",
"      <a class=\"graphic graphic_table graphicRef71328 \" href=\"mobipreview.htm?40/7/41084\">",
"       table 1",
"      </a>",
"      ) in seven, three, and three patients, respectively) without macroscopic residual disease who received postoperative RT were compared with 14 others who did not receive RT, and who were matched for resection status, use of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      , stage, and tumor size. Local recurrence developed in 2 of 14 irradiated patients compared with 11 of 14 who did not receive RT. However, despite this apparent benefit, neither disease-free nor overall survival were significantly better in irradiated patients.",
"      <br/>",
"      <br/>",
"      A later analysis of patterns of failure in these patients suggested that many of the recurrences developed in the interaortocaval region [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/82\">",
"       82",
"      </a>",
"      ]. This observation emphasizes the importance of covering this area in the radiation portal, as well as the ipsilateral lymphatic drainage bed, if adjuvant RT is planned.",
"     </li>",
"     <li>",
"      A compilation of literature reports since 1960 by the same investigators included 64 patients with adrenal carcinoma who received \"adjuvant\" irradiation after undergoing surgical resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/82\">",
"       82",
"      </a>",
"      ]. Most studies provided no details on the completeness of surgical resection, and technical details such as delivered dose or target volume were not provided. Rates of local control ranged widely from 0 to 86 percent.",
"     </li>",
"     <li>",
"      A study from the University of Michigan reported a 4.7 times increased risk of local recurrence in patients who did not receive adjuvant RT compared with those who did [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a retrospective study of 16 patients with ACC who had undergone either surgery followed by adjuvant RT (n = 16) or surgery only (n = 32), the rate of local recurrence was not significantly reduced by adjuvant RT (7 of 16 [44 percent] and 10 of 32 [31.3 percent] in the RT and control groups, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conflicting observations highlight the need for a collaborative, multicenter, randomized trial to address the benefit of adjuvant RT.",
"   </p>",
"   <p>",
"    Investigators from the German ACC registry currently recommend adjuvant RT for all patients with microscopically incomplete (R1 or R2) or uncertain (Rx) margin status, and for those with stage III disease (according to ENSAT criteria (",
"    <a class=\"graphic graphic_table graphicRef83901 \" href=\"mobipreview.htm?2/54/2924\">",
"     table 2",
"    </a>",
"    )) (see",
"    <a class=\"local\" href=\"#H956994\">",
"     'Staging'",
"    </a>",
"    above) even if resection has been complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/2,82\">",
"     2,82",
"    </a>",
"    ]. They suggest that adjuvant RT be considered for patients who have had a complete (R0) resection of a tumor &gt;8 cm in size with tumor invasion of the blood vessels (but not large tumor thrombus in the vena cava) and a Ki-67 proliferative index of &gt;10 percent, and for patients who have intraoperative violation of the tumor capsule, tumor spillage, or dissemination of &ldquo;necrotic&rdquo; fluid. Because the risk of a local recurrence is highest in the first two years, they recommend starting RT no later than three months after surgery.",
"   </p>",
"   <p>",
"    Larger prospective randomized studies are needed to better define the role of adjuvant RT after resection of ACC, in particular to determine if the decrease in local recurrence rate provides any overall survival benefit. Until more data are available, we recommend adjuvant RT for all patients with incompletely resected ACC, those who have tumor spillage at the time of resection, and for all patients with high-grade ACC (&gt;20 mitotic figures per 50 HPF).",
"   </p>",
"   <p>",
"    There is disagreement as to the role of adjuvant RT in patients who have undergone laparoscopic rather than open resection, and no published data to help in resolving this point. Because there are different opinions regarding the safety and efficacy of laparoscopic resection of primary ACC, it is understandable that there are different&nbsp;opinions regarding the use of adjuvant XRT in the setting of laparoscopic resection, for a resected ACC that does not otherwise meet the criteria described above for adjuvant RT (tumor spillage at the time of resection, incompletely resected, high-grade lesion).",
"   </p>",
"   <p>",
"    The German ACC group does not recommend adjuvant RT in this situation. The Adrenal Cancer Program at the University of Michigan, as reflected in the opinion of one of the authors (GH), does not recommend&nbsp;laparoscopic adrenalectomy for ACC and hence is more aggressive in recommending adjuvant XRT following a laparoscopic resection of ACC if there is any concern that a sufficient oncologic resection was not performed. The other author (AL), does not pursue adjuvant RT after a laparoscopic resection as long as the laparoscopic surgery was performed by an expert surgeon (ie, one who specializes in and is trained in minimally invasive endocrine or oncology surgery, who practices in a large academic referral center, and who does adrenal surgery weekly).",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RECURRENT OR ADVANCED ADRENOCORTICAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no curative therapy for metastatic or recurrent adrenocortical cancer (ACC). However, the symptoms of steroid excess can be controlled by medical therapy. In most cases, metastatic disease is fatal within one year, although there are rare long-term responses ascribed to chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/77,87,88\">",
"     77,87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Local therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive resection of locally recurrent or distant disease may prolong survival in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,4,89-93\">",
"     3,4,89-93",
"    </a>",
"    ], and at least some reports suggest that long-term survival rates are higher among patients who undergo resection of recurrent or metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/51,89,94,95\">",
"     51,89,94,95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 47 patients with ACC undergoing resection for locally recurrent or distant metastatic disease at Memorial Sloan-Kettering Cancer Center (MSKCC), five-year survival rates for patients with completely and incompletely resected locally recurrent disease were 57 and 0 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar outcomes were reported in a series of 57 patients undergoing 116 procedures (23 for liver metastases, 48 for pulmonary metastases, 13 for metastases at other sites, 22 for abdominal disease including local recurrences) for recurrent or metastatic ACC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/95\">",
"       95",
"      </a>",
"      ]. Five-year survival was 41 percent, and median survival was significantly longer for those with a disease-free interval &gt;12 months (6.6 versus 1.7 years). The use of chemotherapy and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      had no effect on survival.",
"     </li>",
"     <li>",
"      In another report of 28 patients undergoing resection for liver metastases from ACC (25 isolated, three with extrahepatic metastases), the five-year survival rate was 39 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Where complete removal is feasible, aggressive surgical resection of locally recurrent disease, with the aim of achieving negative surgical margins, should be undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/39,40,89-91\">",
"     39,40,89-91",
"    </a>",
"    ]. The best candidates are those who have potentially resectable disease with a disease-free interval of at least one year after initial treatment. Resection may also be considered in the rare patient who presents with limited, potentially resectable hepatic or pulmonary metastases. Radiofrequency ablation (RFA) may be an alternative approach for these patients. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Radiofrequency ablation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Resection of locally recurrent disease may also be indicated for patients in whom surgery will be able to remove a majority of tumor burden or decrease severe hypercortisolism that is otherwise difficult to control; however, recovery from surgery may be slow, delaying administration of systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, this approach should be limited to selected patients with uncontrollable symptomatic hormone excess or in imminent danger from organ",
"    <span class=\"nowrap\">",
"     invasion/compression,",
"    </span>",
"    etc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data support the palliative benefit of RT for unresectable local tumor that is causing local symptoms, or for distant symptomatic metastases, such as in bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,39,82,84,96,97\">",
"     3,39,82,84,96,97",
"    </a>",
"    ]. In a survey of published reports totaling 91 patients receiving palliative RT for advanced ACC from the German ACC registry, benefit (ie, pain relief, reduction in paresthesia or paralysis) was observed in 57 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery may be beneficial for patients who have a good performance status and limited metastases to the brain, lung, or liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=see_link\">",
"     \"Stereotactic cranial radiosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous radiofrequency ablation (RFA) may provide short-term local control of an unresectable primary tumor, particularly for those &lt;5 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,98,99\">",
"     3,98,99",
"    </a>",
"    ]. The long-term impact on survival is unknown. RFA has also been used to treat small liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/98,100\">",
"     98,100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    , many other cytotoxic drugs have been studied in patients with advanced ACC, either alone or in combination with mitotane. Mitotane increases the cytotoxic activity of other chemotherapeutic drugs on human adrenal carcinoma cells in vitro, possibly by acting as an antagonist of the multidrug resistance (MDR) protein, which is found in high concentrations in ACC, and functions as a drug efflux pump [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. These data provide a rationale for combination therapy. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Chemotherapy plus mitotane'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unfortunately, because of the rarity of ACC, relatively few large trials of chemotherapy have been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Mitotane monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    may be indicated for patients who have histologically-proven ACC in whom surgery is incomplete, not feasible, or contraindicated.",
"   </p>",
"   <p>",
"    The quality of the available literature on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    monotherapy is poor, and the results are highly variable. Most studies were conducted in early years without monitoring of tumor response with adequate imaging. Moreover, mitotane has been often given in a suboptimal way; much of the variability in outcomes may be attributable to sub-therapeutic serum concentrations (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Dosing regimen'",
"    </a>",
"    above). No data are available on survival or drug tolerance among patients with unresectable disease who are treated with an approach that includes monitoring of plasma mitotane concentrations. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dosing regimen'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Toxicities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment benefits are generally short-lived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and survival is not consistently prolonged. While there are isolated case reports of long-term disease control and rare cases of prolonged complete remission in patients with inoperable or metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/77,103,104\">",
"     77,103,104",
"    </a>",
"    ], these are almost always patients with low-grade disease. In several studies of primary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    therapy, the median survival was only 6.5 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/36,105\">",
"     36,105",
"    </a>",
"    ], not different from that expected in untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/16,50,106\">",
"     16,50,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    for patients with unresectable advanced disease is usually reduction in symptoms of hypercortisolism (weakness, myopathy, diabetes, immunosuppression, insomnia). While a decrease in excess hormone production is reported in up to 75 percent of patients, and tumor size is reduced in as many as one-third of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/36,48,49,105\">",
"     36,48,49,105",
"    </a>",
"    ], mitotane therapy alone is usually not sufficient to significantly decrease cortisol levels or have long lasting effects on tumor growth. In a review of nine prospective series totaling 246 patients with advanced ACC (not restricted to primary therapy), the estimated mean objective regression rate with mitotane was only 26 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, some patients who have an objective response with mitotane are incapacitated by the side effects of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Toxicities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We reserve",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    monotherapy for the few patients who have a minimal burden (low number of tumor-involved organs) of low-grade (ie, low-mitotic rate) disease, and have recurred relatively late (two to three years) after surgery. These are the patients who are likely to have a prolonged survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/108\">",
"     108",
"    </a>",
"    ]. In the setting of extensive (multiple tumor-involved organs) rapidly progressive high-grade disease, mitotane is almost always administered in combination with cytotoxic chemotherapy because of a generally accepted view that response rates are higher. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Chemotherapy plus mitotane'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with active disease and visible lesions,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    is typically continued lifelong or until disease progression. However, several protocols for new targeted agents for ACC specifically require discontinuation of mitotane because of potentially detrimental drug interactions. Specific issues related to dosing, monitoring of serum levels during therapy, side effects, and drug interactions are addressed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dosing regimen'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1762852034\">",
"     'Drug interactions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Toxicities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Dosing, side effects, and monitoring during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    therapy are discussed above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Dosing regimen'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Toxicities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients whose disease progresses while receiving adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    , or whose disease is high grade or rapidly progressing (on or off mitotane), our usual practice is to initiate cytotoxic chemotherapy plus mitotane, given the higher response rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Chemotherapy plus mitotane",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally accepted, though not proven, that chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    produces better outcomes than does mitotane alone. A few prospective trials have explored combination regimens that contain mitotane. Although no chemotherapy regimen has been shown to improve overall survival in patients with advanced ACC, some of the more encouraging results have been with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (EDP) plus mitotane:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early study of EDP plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      in 72 ACC patients described an overall response rate of 49 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest trial of advanced ACC to date, the First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) trial, randomly assigned 304 patients with advanced ACC not amenable to radical surgery to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      plus either EDP or streptozotocin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/110\">",
"       110",
"      </a>",
"      ]. Rates of objective tumor response (23 versus 9 percent) and median progression-free survival (5 versus 2.1 months) were both significantly better in the",
"      <span class=\"nowrap\">",
"       EDP/mitotane",
"      </span>",
"      group, although these benefits did not translate into a significantly prolonged survival (median 14.8 versus 12 months). This lack of significant difference in overall survival, despite better progression-free survival for EDP-M, is possibly due to the cross-over design of the study, since EDP-M was superior as a second-line treatment as well. Rates of serious adverse events did not differ significantly between treatments. The efficacy of both regimens as second-line therapy was similar to their efficacy as first-line therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results with other chemotherapy drugs combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    seem to be less promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/81,111-113\">",
"     81,111-113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9003599\">",
"    <span class=\"h3\">",
"     Chemotherapy without mitotane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    -containing chemotherapy regimens have been tested in ACC, largely due to the rarity of the disease. Progress in therapy of advanced ACC has been limited by the rarity of the disease and the relatively small number of patients in each study.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although they are frequently used, single agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      are associated with response rates that are generally less than 30 percent, and of short duration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/114-116\">",
"       114-116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Results are also disappointing for chemotherapy combinations when not combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/117-121\">",
"       117-121",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4164879\">",
"    <span class=\"h3\">",
"     Newer and investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several novel approaches are under study for treatment of advanced ACC, many of which represent molecularly targeted therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular endothelial growth factor (VEGF) is upregulated in ACC tumor tissue, and some studies have found that circulating VEGF levels are significantly greater in patients with ACC as compared with those with adrenal adenomas. These data have led to interest in targeting of VEGF signaling in ACC. However, while case reports of tumor responses have been published for the antiangiogenic compound",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/122\">",
"       122",
"      </a>",
"      ] or with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/123\">",
"       123",
"      </a>",
"      ], a study of 10 patients with advanced ACC reported no response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , an anti-VEGF humanized monoclonal antibody, in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/124\">",
"       124",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Multikinase inhibitors that target the VEGF receptor, among other tyrosine kinases, are also under study. Single case reports describe sustained responses to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      in patients with ACC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/125,126\">",
"       125,126",
"      </a>",
"      ]. However, a phase II study of sunitinib in 38 patients with refractory ACC (progressing after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      and one to three cytotoxic chemotherapy regimens) reported stable disease as the best response in only five patients, with a progression-free survival duration ranging from 5.6 to 11.2 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/127\">",
"       127",
"      </a>",
"      ]. Moreover, a phase II study of sorafenib plus weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      was prematurely terminated after nine patients were enrolled with no evidence of antitumor activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The finding that over 80 percent of ACCs express the epidermal growth factor receptor (EGFR) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/129,130\">",
"       129,130",
"      </a>",
"      ] provides a rationale for the study of agents that target the EGFR. Unfortunately, salvage chemotherapy with the small molecular EGFR inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was of little benefit in a trial of 10 assessable patients with advanced ACC who had failed at least two other systemic chemotherapy regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/131\">",
"       131",
"      </a>",
"      ]. Only one in nine assessable patients experienced a minor response, while eight patients experienced disease progression.",
"     </li>",
"     <li>",
"      Approximately 80 percent of ACCs also overexpress insulin-like growth factor type 2 (IGF2), which are known to signal predominantly through the IGF receptor-1 (IGFR1). Preclinical studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/132\">",
"       132",
"      </a>",
"      ] and two phase I trials have shown promising results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/133,134\">",
"       133,134",
"      </a>",
"      ] and ongoing phase II and III trials are close to completion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Medical treatment of hypercortisolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal function should be closely monitored in patients with ACC because they can have either adrenal insufficiency (caused by surgery or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    ) or excess cortisol secretion (caused by persistent or recurrent tumor). In patients with hypercortisolism (either those who are not taking mitotane or those whose hypercortisolism is not controlled by mitotane), addition of a more specific adrenal enzyme inhibitor is often required.",
"   </p>",
"   <p>",
"    Control of hypercortisolism is important as patients can die prematurely of infections related to immunosuppression induced by their hypercortisolism and chemotherapy rather than by tumor burden.",
"   </p>",
"   <p>",
"    There have been no published large series to determine which available steroidogenic enzyme inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    result in better control. In addition, the choice of therapy has been influenced by different drug availability in various countries.",
"   </p>",
"   <p>",
"    We consider",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    as the first drug of choice in patients with ACC and hypercortisolism. While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    is effective in benign adrenal disease, it is our experience at the University of Michigan that it is rarely able to control the hypercortisolism in ACC. Metyrapone, which is now more easily available in North America (new distributor HRA Pharma, Paris, France, via its speciality pharmacy Direct Success Inc. with order form available on the web [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/135\">",
"     135",
"    </a>",
"    ] or by phone at 1-855-674-7663), can be very effective in ACC, achieving eucortisolemia within three to seven days. If eucortisolism is not achieved with metyrapone, combination therapy with ketoconazole and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    can be utilized.",
"   </p>",
"   <p>",
"    Medical therapy of hypercortisolism is reviewed in detail separately, but summarized briefly below (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=see_link&amp;anchor=H19#H19\">",
"     \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\", section on 'Oral drugs'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with ACC, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      starting at 250 mg four times daily and increase up to 6 g per day.",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      alone is insufficient or not tolerated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      is started at 200 mg three",
"      <span class=\"nowrap\">",
"       times/day,",
"      </span>",
"      increasing daily as needed to 400 mg three",
"      <span class=\"nowrap\">",
"       times/day.",
"      </span>",
"      Higher doses are seldom more effective.",
"     </li>",
"     <li>",
"      Their effect can be assessed within a few days by measuring 24-hour urine cortisol on a frequent basis initially. Combination of both drugs and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      may be necessary to achieve adequate control.",
"     </li>",
"     <li>",
"      In severe uncontrolled cases, addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      , a glucocorticoid receptor antagonist, can be beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In acute situations with patients who are unable to take drugs orally, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      (which blocks 11-beta-hydroxylase) can be used in a low, nonhypnotic dose of 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour. However, this drug is difficult to use and requires inpatient monitoring. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=see_link\">",
"       \"Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=see_link\">",
"       \"Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adrenal insufficiency is managed as described above using replacement mainly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    . Aldosterone deficiency is replaced with addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (0.1 to 0.3 mg daily) and adjusted to restore normal blood pressure and serum levels of potassium and renin. (See",
"    <a class=\"local\" href=\"#H1762852265\">",
"     'Adrenal insufficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who have increased hypercortisolism and are being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , salt retention and hypertension can occur because of increased production of the mineralocorticoid deoxycorticosterone. We routinely use a mineralocorticoid receptor inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    in this situation, adding diuretics and additional antihypertensive drugs if necessary.",
"   </p>",
"   <p>",
"    When potassium-sparing diuretics are used in association with potassium supplements, frequent serum potassium monitoring is necessary as acute hyperkalemia can occur when hypercortisolism becomes controlled or when renal function is impaired. Adequate control of diabetes and high blood pressure are also important.",
"   </p>",
"   <p>",
"    A small percentage of adult ACC and a high percentage of pediatric ACC often presents with virilization",
"    <span class=\"nowrap\">",
"     with/without",
"    </span>",
"    hypercortisolism. Virilization is best treated with specific androgen blockage with androgen receptor inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    at 50 mg per day) or 5-alpha&ndash;reductase inhibition (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    at 5 mg per day).",
"   </p>",
"   <p>",
"    Rare estrogen producing ACCs are treated with any of the anti-estrogen therapies (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, survival is poor for ACC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/14,15,39-41,47,55,89,137-139\">",
"     14,15,39-41,47,55,89,137-139",
"    </a>",
"    ]. Five-year survival is approximately 45 to 60 percent for early stage disease, and 10 to 25 percent for advanced stage disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6355163\">",
"    <span class=\"h2\">",
"     Modern trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;Past results suggested a poor prognosis even for patients with early stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/8,15,22\">",
"     8,15,22",
"    </a>",
"    ]. However, some contemporary series suggest that outcomes are improving and that patients with these tumors are living longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/41,47,55,89\">",
"     41,47,55,89",
"    </a>",
"    ], as illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 139 patients treated for ACC over a 20-year period at MD Anderson, the five-year survival rate was 60 percent, despite the fact that 47 (34 percent) had distant metastases at diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second series of 113 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC), those who underwent complete resection of primary (not recurrent) disease (n = 68) had a five-year survival of 55 percent (median 74 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients followed closely after surgery for stage II ACC in specialized centers and who received adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      had a much better prognosis than previously reported for this stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The improved prognosis of treated patients in contemporary series can be illustrated by the previously described French Association of Endocrine Surgery series of 253 patients (age range 5 to 81, mean 47) with ACC treated between 1978 and 1997 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/55\">",
"       55",
"      </a>",
"      ]. The distribution by stage was as follows: stage I, 16; stage II, 126; stage III (locoregionally advanced disease), 57; stage IV (distant metastases only), 54. Potentially curative surgery was performed in 182 (72 percent) and postoperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      was administered to 135 (54 percent).",
"      <br/>",
"      <br/>",
"      Five-year survival rates were 38 percent overall and 50 percent in the curatively treated group. Stratified by disease stage, five-year survival rates were 66, 58, 24, and 0 percent for stage I, II, III, and IV (metastatic) disease, respectively. Despite no significant difference in the numbers of patients undergoing potentially curative surgery, outcomes were significantly better among those treated after 1988.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reasons for the improved outcomes from treatment of ACC over time are not clear. Although the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    increased over the 20-year time period, this had a significant impact on prognosis in multivariate analysis only for those patients who did not undergo potentially curative resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6355348\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6355355\">",
"    <span class=\"h3\">",
"     Stage and margin status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important clinical factors that determine prognosis of ACC are disease stage and completeness of resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9,14,15,22,55,140-142\">",
"     9,14,15,22,55,140-142",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Staging'",
"    </a>",
"    .) In the previously cited series of 253 patients from the French Association of Endocrine Surgeons Study Group, five-year overall survival was 66, 58, 24, and 0 percent for stage I, II, III, and IV (metastatic) disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, survival differs widely for any given tumor stage, and many other factors influence outcomes. Regardless of stage, incomplete resection is associated with a poor prognosis (median survival generally less than one year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The influence of margin status on prognosis was shown in a report from the National Cancer Database, in which five-year overall survival rates for patients with ACC and uninvolved, microscopically involved, and macroscopically involved margins were 46, 21, and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6355056\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to stage and completeness of resection, the biologic behavior of ACCs is also influenced by",
"    <span class=\"nowrap\">",
"     pathologic/morphologic",
"    </span>",
"    factors. Histologically, the appearance of ACCs ranges from mild atypia to wildly anaplastic tumors composed of monstrous giant cells. The widely applied multifactorial scoring system of Weiss is based upon nine histopathologic features (nuclear grade, mitotic rate, atypical mitoses, clear cell component, diffuse architecture, tumor necrosis, invasion of venous or sinus structures, or tumor capsule); tumors with less than three features are usually considered as benign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\", section on 'Fine-needle aspiration biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These criteria have been validated as prognostic factors in more contemporary series both in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9,141,142\">",
"     9,141,142",
"    </a>",
"    ]. As an example, in one study of 124 patients with ACC, significant predictors of disease progression included distant metastasis at presentation, tumor invasion of vessels, tumor capsule, or adjacent organs, tumor necrosis, a high mitotic rate, the presence of atypical mitosis, and overexpression of mdm-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9\">",
"     9",
"    </a>",
"    ]. Five-year disease-free survival was significantly different for patients with one or two, three or four, or more than four adverse features (84, 37, and 9 percent, respectively).",
"   </p>",
"   <p>",
"    Several studies confirm the prognostic value of markers of proliferation, including mitotic rate, and Ki-67 expression (as detected by a monoclonal antibody against Ki-67, MIB1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9,47,56,57,108,143\">",
"     9,47,56,57,108,143",
"    </a>",
"    ]. The importance of proliferative rate in prognostication was shown in an analysis of 124 patients with ACC, in whom the five-year disease-specific survival rates for individuals with tumor mitotic rates of &le;5, 6 to 10, 21 to 50, and &gt;50 per 50 high-power fields [HPF] were 63, 50, 25, and 0 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combined utility of tumor stage and mitotic rate to assess prognosis was addressed in a study of 92 patients with malignant ACC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/56\">",
"     56",
"    </a>",
"    ]. Three risk groups were identified (low [stage",
"    <span class=\"nowrap\">",
"     I/II,",
"    </span>",
"    mitoses",
"    <span class=\"nowrap\">",
"     &le;9/HPF],",
"    </span>",
"    intermediate [stage",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    plus &gt;9",
"    <span class=\"nowrap\">",
"     mitoses/HPF",
"    </span>",
"    or stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    plus mitotic rate",
"    <span class=\"nowrap\">",
"     &le;9/HPF],",
"    </span>",
"    and high [stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    and mitotic rate",
"    <span class=\"nowrap\">",
"     &gt;9/HPF])",
"    </span>",
"    that had significantly different rates of mean disease-free survival (62, 17, and 12 months, respectively) and overall survival (not attained, 66, and 26 months, respectively).",
"   </p>",
"   <p>",
"    Molecular predictors of malignant potential and survival are emerging, but none are ready for clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/63,144,145\">",
"     63,144,145",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in children who have ACC appears to be better than that of adults, at least for early stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/140,146-149\">",
"     140,146-149",
"    </a>",
"    ]. In a series of 228 individuals with ACC under the age of 20, the estimated five-year event-free survival (EFS) rate was 54 percent overall; for those with stage I or II disease, it was 91 and 53 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/140\">",
"     140",
"    </a>",
"    ]. Stage I disease (completely excised nonmetastatic tumors &le;200 g), presenting signs of virilization alone, and age less than three years were all associated with significantly better survival, while the prognosis was poor for patients with metastatic or residual disease or larger resected tumors (weighing more than 200 grams).",
"   </p>",
"   <p>",
"    There are other differences between ACCs presenting in childhood and those arising in adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with adrenocortical tumors have associated familial cancer syndromes (mainly Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/150\">",
"       150",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The histopathologic characteristics and molecular mechanisms of ACC in children differ from those in adults. In children, severe histopathologic features (high Weiss score) are not reliable predictors of poor prognosis, unlike adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/151\">",
"       151",
"      </a>",
"      ]. Secondly, about two-thirds of pediatric ACCs in North America are associated with germline mutations in the",
"      <em>",
"       TP53",
"      </em>",
"      gene (which encodes the p53 tumor protein) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/146\">",
"       146",
"      </a>",
"      ]. In adults, loss of heterozygosity for 17p13 (the cytogenetic location of the",
"      <em>",
"       TP53",
"      </em>",
"      gene) occurs in 25 to 70 percent of sporadic ACCs, but germline mutations in",
"      <em>",
"       TP53",
"      </em>",
"      are uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/152-155\">",
"       152-155",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of these distinct pathogenic and prognostic characteristics of pediatric patients, extrapolation of clinical management from studies in adults is unreliable. An International Pediatric Adrenocortical Tumor Registry has been established to facilitate data collection, study, and treatment of these rare pediatric tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/147\">",
"     147",
"    </a>",
"    ]. Furthermore, a group-wide trial from the Children&rsquo;s Oncology Group (COG ARAR 0332) is examining the efficacy of surgery alone for stage I tumors, the role of retroperitoneal lymph node resection in stage II tumors, and the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy for unresectable and metastatic disease (ARAR0332 protocol, NCT00304070).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6355636\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors associated with poor survival included older age at diagnosis and hypersecretion of cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, a few reports suggest the value of immunohistochemical and molecular markers of mutated",
"    <em>",
"     TP53",
"    </em>",
"    , mutated",
"    <em>",
"     b-catenin,",
"    </em>",
"    <em>",
"     ERCC1",
"    </em>",
"    (excision-repair, complementing defective in Chinese Hamster 1 gene),",
"    <em>",
"     IGF-2,",
"    </em>",
"    <em>",
"     SF1",
"    </em>",
"    (splicing factor-1), and the glucose transporter",
"    <em>",
"     GLUT1",
"    </em>",
"    , and as well as low expression of the",
"    <em>",
"     SGK1",
"     <span class=\"nowrap\">",
"     </span>",
"    </em>",
"    (serum/glucocorticoid-regulated",
"    kinase 1) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/156\">",
"     156",
"    </a>",
"    ] as predictors of poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9,151,157-161\">",
"     9,151,157-161",
"    </a>",
"    ]. Global gene expression profiling may also be of value in prognostic stratification of malignant tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/63,144,162\">",
"     63,144,162",
"    </a>",
"    ]. However, none of these molecular assays are in routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/53/851?source=see_link\">",
"       \"Patient information: Adrenal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenocortical cancer (ACC) is a rare but aggressive malignancy that can cause Cushing's syndrome, virilization, hyperaldosteronism, feminization, an abdominal mass, or no symptoms and be discovered incidentally. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"       \"Clinical presentation and evaluation of adrenocortical tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Past results suggest a poor prognosis even for patients with early stage adrenal cancer. However, some contemporary series suggest that patients with ACC are living longer. The reasons for the possible improvement in prognosis are unclear, but adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy appears to be beneficial. (See",
"      <a class=\"local\" href=\"#H6355163\">",
"       'Modern trends'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progress in treating advanced ACC has been severely limited by the rarity of the disease. However, multicenter clinical trials for recurrent and advanced disease, several of which are studying molecularly targeted therapy, are in progress. (See",
"      <a class=\"local\" href=\"#H4164879\">",
"       'Newer and investigational approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only potentially curative treatment for ACC is surgical resection. Although resection is technically possible in most patients with stage I to III disease, it is not curative for many, presumably because occult micrometastases are present at the time of initial presentation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      (Lysodren, o,p'-DDD, a congener of the pesticide dichlorodiphenyltrichloroethane [DDT]) is an adrenocorticolytic drug that has been used for primary therapy, in the adjuvant setting, and for the treatment of disease recurrence, either alone, or in combination with other cytotoxic agents. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adjuvant mitotane'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following represents our general approach to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Initial treatment, potentially resectable disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with potentially resectable stage I to III adrenocortical cancer who are surgical candidates, we recommend complete surgical resection as initial therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest not using laparoscopic resection regardless of size (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In retrospective reports, adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy improves recurrence-free and overall survival after macroscopically complete radical resection for stage I, II, or III ACC. We suggest adjuvant mitotane therapy for all patients who have a high risk of disease recurrence after complete resection, including all those with high-grade disease (Ki67 &gt;10 percent or mitotic rate greater than 20 per 50 HPF), incompletely resected disease, intraoperative tumor spillage or fracture, and some large tumors that are low grade but have vascular or capsular invasion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6353026\">",
"       'Indications'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While some ACC investigators routinely recommend mitotane for all patients with a resected low-grade ACC, it is unclear what degree of benefit an individual with low risk ACC gains from treatment with adjuvant mitotane. This approach is being studied in the ADIUVO trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/51/40762/abstract/62\">",
"       62",
"      </a>",
"      ], and we encourage eligible patients to enroll.",
"     </li>",
"     <li>",
"      The optimal duration of adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy is not established. We treat high-risk patients for five years. For those with a lower risk of recurrence, we prefer five years of therapy, but aim for at least two to three years, as tolerated. (See",
"      <a class=\"local\" href=\"#H957045\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If available, serum monitoring during",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy should be used to achieve therapeutic levels and avoid toxicity. Mitotane levels should be maintained between 14 and 20",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dosing regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoid replacement is necessary following resection of cortisol-secreting ACC. It should also be started in patients with non cortisol-secreting tumors when adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy is initiated because the drug's adrenolytic activity will result in adrenal insufficiency in most patients. We use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      for glucocorticoid coverage. Supraphysiologic doses may be needed because mitotane may accelerate cortisol metabolism by induction of the P450 system. (See",
"      <a class=\"local\" href=\"#H1762852265\">",
"       'Adrenal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      can also eventually cause aldosterone deficiency. We suggest monitoring blood pressure at each visit, serum potassium at every three months, and plasma renin every six months (",
"      <a class=\"graphic graphic_table graphicRef83932 \" href=\"mobipreview.htm?5/33/5661\">",
"       table 4",
"      </a>",
"      ). When clinical and biochemical signs of aldosterone deficiency become present, addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      (0.1 to 0.3 mg daily) is initiated and adjusted to restore normal clinical and biochemical parameters.",
"     </li>",
"     <li>",
"      We suggest the addition of postoperative radiation therapy for all patients with incompletely resected ACC, those who have tumor spillage at the time of resection, and for all patients with high-grade ACC (&gt;20 mitotic figures per 50 HPF) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      There is disagreement as to the role of adjuvant RT in patients who have undergone laparoscopic resection for an ACC that otherwise does not meet criteria for postoperative RT. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surveillance for recurrence of disease involves CT scans of the chest and abdomen every three months for two years, then every six months for five years. At the University of Michigan, PET is not used routinely for either staging or posttreatment surveillance. Other centers, including that of one of the authors (AL), routinely perform PET prior to surgery for a suspected ACC, and add integrated",
"      <span class=\"nowrap\">",
"       FDG-PET/CT",
"      </span>",
"      at six month intervals in the posttreatment follow-up strategy for patients with high-risk disease who have been shown to have FDG-avid disease preoperatively.",
"      <br/>",
"      <br/>",
"      For patients with a completely resected steroid-producing ACC, some groups monitor patients every three months for two years with steroid tumor markers such as cortisol (measured in the morning before",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      dose), DHEAS, androstenedione, testosterone, estradiol, or mineralocorticoid based on the steroid profile in the initial tumor. Other groups do not routinely screen for recurrent hormone excess unless or until there is evidence of recurrent disease. (See",
"      <a class=\"local\" href=\"#H68910294\">",
"       'Biochemical'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Unresectable, recurrent, or advanced disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with isolated locally recurrent ACC that is surgically accessible, we suggest complete surgical resection followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Local therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Resection may also be considered in the rare patient who presents with limited, potentially resectable hepatic or pulmonary metastases. Resection of locally recurrent disease may also be indicated for patients in whom surgery will be able to remove a majority of tumor burden or decrease severe hypercortisolism that is otherwise difficult to control; however, recovery from surgery may be slow, delaying administration of systemic therapy. Thus, we reserve this approach for selected patients with uncontrollable symptomatic hormone excess.",
"     </li>",
"     <li>",
"      For patients with unresectable disease,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      monotherapy is a reasonable option for patients with a limited burden of low-grade, slowly progressive disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Mitotane monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      However, for most patients, we suggest combined",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      plus chemotherapy rather than mitotane or chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients receiving combined therapy, we suggest mitotane in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (EDP) rather than streptozotocin (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). If possible, patients should be referred to centers conducting randomized clinical trials. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Chemotherapy plus mitotane'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Percutaneous radiofrequency ablation (RFA) may provide short-term local control of an unresectable primary tumor, particularly for those &lt;5 cm in diameter. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Radiofrequency ablation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hypercortisolism or other active hormone secretion (who are either not taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/58/16293?source=see_link\">",
"       mitotane",
"      </a>",
"      or whose hypercortisolism is not controlled by mitotane), we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      or, if necessary, its combined use with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      and mitotane to achieve control of hypercortisolism. Appropriate control of glucose, potassium levels, blood pressure, and infections are also important. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Medical treatment of hypercortisolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptoms from locally advanced disease or a symptomatic site of distant metastatic disease (eg, a bone metastasis), we suggest palliative radiation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/1\">",
"      Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 2010; 395:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/2\">",
"      Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2004; 60:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/3\">",
"      Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/4\">",
"      Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996; 119:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/5\">",
"      W&auml;ngberg B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010; 17:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/6\">",
"      Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999; 134:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/7\">",
"      Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/8\">",
"      Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/9\">",
"      Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/10\">",
"      Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 1979; 72:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/11\">",
"      Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982; 117:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/12\">",
"      Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/13\">",
"      Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978; 120:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/14\">",
"      Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006; 91:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/15\">",
"      Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/16\">",
"      MACFARLANE DA. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/17\">",
"      Gr&ouml;ndal S, Cedermark B, Eriksson B, et al. Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/18\">",
"      Thompson NW, Cheung PS. Diagnosis and treatment of functioning and nonfunctioning adrenocortical neoplasms including incidentalomas. Surg Clin North Am 1987; 67:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/19\">",
"      Hogan TF, Gilchrist KW, Westring DW, Citrin DL. A clinical and pathological study of adrenocortical carcinoma: therapeutic implications. Cancer 1980; 45:2880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/20\">",
"      Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/21\">",
"      Zografos GC, Driscoll DL, Karakousis CP, Huben RP. Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 1994; 55:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/22\">",
"      Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003; 169:5.",
"     </a>",
"    </li>",
"    <li>",
"     Information on Children's Oncology Group NCT00304070 protocol  available online at file://clinicaltrials.gov/ct2/show/NCT00304070?term=adrenocortical+cancer&amp;type=Intr&amp;age=0&amp;rank=1 (Accessed on July 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/24\">",
"      Henry JF, Sebag F, Iacobone M, Mirallie E. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World J Surg 2002; 26:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/25\">",
"      Kebebew E, Siperstein AE, Clark OH, Duh QY. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg 2002; 137:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/26\">",
"      Lombardi CP, Raffaelli M, De Crea C, Bellantone R. Role of laparoscopy in the management of adrenal malignancies. J Surg Oncol 2006; 94:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/27\">",
"      Miller BS, Ammori JB, Gauger PG, et al. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg 2010; 34:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/28\">",
"      Prager G, Heinz-Peer G, Passler C, et al. Applicability of laparoscopic adrenalectomy in a prospective study in 150 consecutive patients. Arch Surg 2004; 139:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/29\">",
"      Gonzalez RJ, Shapiro S, Sarlis N, et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005; 138:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/30\">",
"      Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol 2011; 60:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/31\">",
"      Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/32\">",
"      McCauley LR, Nguyen MM. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr Opin Urol 2008; 18:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/33\">",
"      Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol 2010; 57:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/34\">",
"      Porpiglia F, Miller BS, Manfredi M, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/35\">",
"      Henley DJ, van Heerden JA, Grant CS, et al. Adrenal cortical carcinoma--a continuing challenge. Surgery 1983; 94:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/36\">",
"      Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966; 41:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/37\">",
"      Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cortical carcinoma. A study of 77 cases. Cancer 1983; 52:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/38\">",
"      Khorram-Manesh A, Ahlman H, Jansson S, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998; 22:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/39\">",
"      Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001; 127:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/40\">",
"      Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/41\">",
"      Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001; 136:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/42\">",
"      Kasperlik-Za��uska AA, Migdalska BM, Zgliczy��ski S, Makowska AM. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995; 75:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/43\">",
"      Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998; 83:3100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/44\">",
"      Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2000; 33:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/45\">",
"      Schteingart DE. Adjuvant mitotane therapy of adrenal cancer - use and controversy. N Engl J Med 2007; 356:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/46\">",
"      Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95:4925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/47\">",
"      Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001; 92:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/48\">",
"      Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993; 71:3119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/49\">",
"      Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/50\">",
"      Bodie B, Novick AC, Pontes JE, et al. The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol 1989; 141:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/51\">",
"      Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/52\">",
"      Barzon L, Fallo F, Sonino N, et al. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997; 54:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/53\">",
"      Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994; 69:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/54\">",
"      Barzon L, Fallo F, Sonino N, et al. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1999; 84:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/55\">",
"      Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/56\">",
"      Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology 2009; 55:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/57\">",
"      Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 2010; 28:e401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/58\">",
"      Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf) 2010; 73:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/59\">",
"      Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/60\">",
"      Giordano TJ. The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma. Am J Surg Pathol 2011; 35:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/61\">",
"      Fassnacht M, Lib&eacute; R, Kroiss M, et al. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7:323.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trials information available online at file://clinicaltrials.gov/ct2/show/NCT00777244?term=adrenocortical+cancer&amp;rank=20 (Accessed on June 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/63\">",
"      de Reyni&egrave;s A, Assi&eacute; G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009; 27:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/64\">",
"      Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/65\">",
"      van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/66\">",
"      Hermsen IG, Fassnacht M, Terzolo M, et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/67\">",
"      Kasperlik-Zaluska AA, Cichocki A. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol 2005; 5:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/68\">",
"      Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/69\">",
"      Maucl&egrave;re-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 2012; 166:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/70\">",
"      Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/71\">",
"      Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/72\">",
"      Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011; 2:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/73\">",
"      van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 1991; 124:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/74\">",
"      Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 2011; 96:3775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/75\">",
"      Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 1987; 27:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/76\">",
"      Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5&alpha;-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2013; 98:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/77\">",
"      De Le&oacute;n DD, Lange BJ, Walterhouse D, Moshang T. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2002; 87:4452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/78\">",
"      Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011; 75:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/79\">",
"      van Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/80\">",
"      Hovi L, Wikstr&ouml;m S, Vettenranta K, et al. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report. Med Pediatr Oncol 2003; 40:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/81\">",
"      Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 2000; 11:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/82\">",
"      Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer 2009; 115:2816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/83\">",
"      Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:4501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/84\">",
"      Sabolch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 2011; 80:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/85\">",
"      Markoe AM, Serber W, Micaily B, Brady LW. Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 1991; 14:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/86\">",
"      Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/87\">",
"      Fujii Y, Kageyama Y, Kawakami S, et al. Successful long-term disease-free survival following multimodal treatments in a patient with a repeatedly recurrent refractory adrenal cortical carcinoma. Int J Urol 2003; 10:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/88\">",
"      Sperone P, Berruti A, Gorzegno G, et al. Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane. J Endocrinol Invest 2006; 29:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/89\">",
"      Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999; 6:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/90\">",
"      Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery 1997; 122:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/91\">",
"      Meyer A, Niemann U, Behrend M. Experience with the surgical treatment of adrenal cortical carcinoma. Eur J Surg Oncol 2004; 30:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/92\">",
"      Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg 2011; 92:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/93\">",
"      Gaujoux S, Al-Ahmadie H, Allen PJ, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol 2012; 19:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/94\">",
"      Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/95\">",
"      Datrice NM, Langan RC, Ripley RT, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012; 105:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/96\">",
"      Magee BJ, Gattamaneni HR, Pearson D. Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol 1987; 38:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/97\">",
"      Percarpio B, Knowlton AH. Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 1976; 15:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/98\">",
"      Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/99\">",
"      Mayo-Smith WW, Dupuy DE. Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results. Radiology 2004; 231:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/100\">",
"      Bauditz J, Quinkler M, Wermke W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature. Exp Clin Endocrinol Diabetes 2009; 117:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/101\">",
"      Flynn SD, Murren JR, Kirby WM, et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992; 112:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/102\">",
"      Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993; 29A:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/103\">",
"      Ilias I, Alevizaki M, Philippou G, et al. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 2001; 24:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/104\">",
"      Becker D, Schumacher OP. o,p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 1975; 82:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/105\">",
"      Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA 1973; 223:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/106\">",
"      Jensen JC, Pass HI, Sindelar WF, Norton JA. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. Arch Surg 1991; 126:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/107\">",
"      Hoffman DL, Mattox VR. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am 1972; 56:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/108\">",
"      Assi&eacute; G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007; 92:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/109\">",
"      Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/110\">",
"      Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/111\">",
"      Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/112\">",
"      Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998; 78:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/113\">",
"      Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 2010; 17:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/114\">",
"      Tattersall MH, Lander H, Bain B, et al. Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1980; 1:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/115\">",
"      Chun HG, Yagoda A, Kemeny N, Watson RC. Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 1983; 67:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/116\">",
"      Haq MM, Legha SS, Samaan NA, et al. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 1980; 64:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/117\">",
"      van Slooten H, van Oosterom AT. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983; 67:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/118\">",
"      Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000; 88:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/119\">",
"      Khan TS, Sundin A, Juhlin C, et al. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer. Med Oncol 2004; 21:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/120\">",
"      Johnson DH, Greco FA. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986; 58:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/121\">",
"      Schlumberger M, Brugieres L, Gicquel C, et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991; 67:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/122\">",
"      Chac&oacute;n R, Tossen G, Loria FS, Chac&oacute;n M. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol 2005; 23:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/123\">",
"      Boudou-Rouquette P, Alexandre J, Soubrane O, et al. Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient. Ann Oncol 2009; 20:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/124\">",
"      Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010; 162:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/125\">",
"      Butler C, Butler WM, Rizvi AA. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract 2010; 16:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/126\">",
"      Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol 2009; 39:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/127\">",
"      Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012; 97:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/128\">",
"      Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012; 166:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/129\">",
"      Edgren M, Eriksson B, Wilander E, et al. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997; 17:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/130\">",
"      Kamio T, Shigematsu K, Sou H, et al. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990; 21:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/131\">",
"      Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; 93:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/132\">",
"      Barlaskar FM, Spalding AC, Heaton JH, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009; 94:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/133\">",
"      Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65:765.",
"     </a>",
"    </li>",
"    <li>",
"     Carden CP, Frentzas S, Langham M, et al. Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors (abstract 3544). J Clin Oncol 2009; 27:15s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=65&amp;abstractID=31413 (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     HRA Pharma www.hra-pharma.com (Accessed on August 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/136\">",
"      Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009; 160:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/137\">",
"      Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 2008; 113:3130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/138\">",
"      Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/139\">",
"      Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006; 140:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/140\">",
"      Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004; 22:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/141\">",
"      Lucon AM, Pereira MA, Mendon&ccedil;a BB, et al. Adrenocortical tumors: results of treatment and study of Weiss's score as a prognostic factor. Rev Hosp Clin Fac Med Sao Paulo 2002; 57:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/142\">",
"      Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 2003; 27:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/143\">",
"      Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008; 55:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/144\">",
"      Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009; 15:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/145\">",
"      Fragoso MC, Almeida MQ, Mazzuco TL, et al. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol 2012; 166:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/146\">",
"      Mendonca BB, Lucon AM, Menezes CA, et al. Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J Urol 1995; 154:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/147\">",
"      Ribeiro RC, Pinto EM, Zambetti GP, Rodriguez-Galindo C. The International Pediatric Adrenocortical Tumor Registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Mol Cell Endocrinol 2012; 351:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/148\">",
"      Lack EE, Mulvihill JJ, Travis WD, Kozakewich HP. Adrenal cortical neoplasms in the pediatric and adolescent age group. Clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors. Pathol Annu 1992; 27 Pt 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/149\">",
"      Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors? Pediatr Dev Pathol 2009; 12:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/150\">",
"      Ribeiro RC, Pinto EM, Zambetti GP. Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract Res Clin Endocrinol Metab 2010; 24:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/151\">",
"      Faria AM, Almeida MQ. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol Cell Endocrinol 2012; 351:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/152\">",
"      Lib&egrave; R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007; 13:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/153\">",
"      Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994; 78:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/154\">",
"      Sidhu S, Martin E, Gicquel C, et al. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 2005; 31:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/155\">",
"      Raymond VM, Else T, Everett JN, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98:E119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/156\">",
"      Ronchi CL, Sbiera S, Leich E, et al. Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis. J Clin Endocrinol Metab 2012; 97:E2251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/157\">",
"      Gaujoux S, Grabar S, Fassnacht M, et al. &beta;-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res 2011; 17:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/158\">",
"      Ragazzon B, Lib&eacute; R, Gaujoux S, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 2010; 70:8276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/159\">",
"      Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003; 162:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/160\">",
"      Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab 2010; 95:E161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/161\">",
"      Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and &beta;-catenin. Am J Pathol 2012; 181:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/51/40762/abstract/162\">",
"      Lib&egrave; R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 14:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 165 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40762=[""].join("\n");
var outline_f39_51_40762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H956994\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4164554\">",
"      - Laparoscopic versus open resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adjuvant mitotane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6353019\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6353026\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H957045\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dosing regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192296005\">",
"      - Monitoring response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68910287\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H68910294\">",
"      Biochemical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Toxicities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1762852265\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H718899\">",
"      Hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H192296424\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1762852280\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1762852034\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15861690\">",
"      Adjuvant chemotherapy with or without mitotane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adjuvant radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RECURRENT OR ADVANCED ADRENOCORTICAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Local therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Mitotane monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Chemotherapy plus mitotane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9003599\">",
"      - Chemotherapy without mitotane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4164879\">",
"      - Newer and investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Medical treatment of hypercortisolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS AND PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6355163\">",
"      Modern trends",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6355348\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6355355\">",
"      - Stage and margin status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6355056\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6355636\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Initial treatment, potentially resectable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Unresectable, recurrent, or advanced disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/165|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/7/41084\" title=\"table 1\">",
"      TNM staging adrenal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/54/2924\" title=\"table 2\">",
"      WHO and ENSAT classification of ACC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/6/24683\" title=\"table 3\">",
"      Ann Arbor modification ENSAT staging ACC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/33/5661\" title=\"table 4\">",
"      Recommended monitoring during mitotane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/38/20073?source=related_link\">",
"      Adrenalectomy: Minimally invasive surgery (MIS) and traditional open procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/0/3081?source=related_link\">",
"      Medical therapy of hypercortisolism (Cushing&rsquo;s syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/53/851?source=related_link\">",
"      Patient information: Adrenal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/43/26295?source=related_link\">",
"      Pharmacology and toxicity of adrenal enzyme inhibitors and adrenolytic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/5/32855?source=related_link\">",
"      Stereotactic cranial radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34390?source=related_link\">",
"      Treatment of adrenocortical adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_51_40763="Direct elicitation screens";
var content_f39_51_40763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected developmental screens relying on direct elicitation of skills",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test/age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purchasing information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time frame*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Bayley Infant Neurodevelopmental Screen (BINS) (1995)",
"         </strong>",
"        </p>",
"        <p>",
"         3 to 24 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         The Psychological Corporation",
"        </p>",
"        <p>",
"         555 Academic Court",
"        </p>",
"        <p>",
"         San Antonio, TX 78204",
"        </p>",
"        <p>",
"         Phone: 800.228.0752",
"        </p>",
"        <p>",
"         <a href=\"file://www.pearsonassessments.com\" target=\"_blank\">",
"          www.pearsonassessments.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $265 (includes manual, 25 record forms, stimulus card, and all necessary manipulatives).",
"        </p>",
"       </td>",
"       <td>",
"        10 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Brigance Screens-II (2005)",
"         </strong>",
"        </p>",
"        <p>",
"         0-90 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Curriculum Associates, Inc.",
"        </p>",
"        <p>",
"         153 Rangeway Road",
"        </p>",
"        <p>",
"         N. Billerica, MA 01802",
"        </p>",
"        <p>",
"         Phone: 800.225.0248",
"        </p>",
"        <p>",
"         <a href=\"file://www.curriculumassociates.com\" target=\"_blank\">",
"          www.curriculumassociates.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $822",
"        </p>",
"       </td>",
"       <td>",
"        10 to 15 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes administration and scoring time.",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40763=[""].join("\n");
var outline_f39_51_40763=null;
var title_f39_51_40764="Differential dx ITP";
var content_f39_51_40764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of idiopathic (immune) thrombocytopenia purpura (ITP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Falsely low platelet counts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         In vitro",
"        </em>",
"        platelet clumping caused by EDTA-dependent agglutinins (no clinical importance), giant platelets (not recognized by platelet counting instrument)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common causes of thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Drug-induced thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Common drugs associated with thrombocytopenia:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Heparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Quinine (including quinine in beverages [eg, tonic water, Schweppes bitter lemon] and over-the-counter preparations for leg cramps)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sulfonamides (eg, trimethoprim-sulfamethoxazole [Bactrim])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Acetaminophen (Tylenol, Panadol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cimetidine (Tagamet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ibuprofen (Advil, Motrin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Naproxen (Aleve, Midol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ampicillin (Omnipen, Apo-Ampi)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Piperacillin (Pipracil, Zosyn)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vancomycin (Vancocin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         H. pylori",
"        </em>",
"        (suspected in patients with symptoms of dyspepsia or peptic ulcer disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hypersplenism due to chronic liver disease",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other causes of thrombocytopenia that may mimic ITP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Myelodysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suspected in older patients, in whom a bone marrow biopsy may be appropriate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Thrombotic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients with TTP commonly present with only thrombocytopenia and anemia, without neurologic or other systemic symptoms; anemia may be mistakenly attributed to blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Congenital thrombocytopenias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        An important consideration, especially in young patients who do not respond to treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Von Willebrand disease type 2B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Wiskott-Aldrich syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        MYH9 mutations (eg, May-Hegglin anomaly and others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fanconi syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bernard-Soulier syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40764=[""].join("\n");
var outline_f39_51_40764=null;
var title_f39_51_40765="NI AB values";
var content_f39_51_40765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal arterial and venous values for pH, H+ concentration, PCO2, and HCO3- concentration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 119px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40765=[""].join("\n");
var outline_f39_51_40765=null;
var title_f39_51_40766="Diagnosis neurosyphilis no HIV";
var content_f39_51_40766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for diagnosis of neurosyphilis in a patient without HIV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 610px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF: cerebrospinal fluid; EIA: syphilis enzyme immunoassay; FTA-ABS: fluorescent treponemal antibody-absorbed test; HIV: human immunodeficiency virus; LP: lumbar puncture; NS: neurosyphilis; RPR: rapid plasma reagin test; TPPA: Treponema pallidum particle agglutination test; VDRL: Venereal Disease Research Laboratory test; WBC: white blood cell count.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christina M. Marra, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_51_40766=[""].join("\n");
var outline_f39_51_40766=null;
var title_f39_51_40767="Contents: Lung disease";
var content_f39_51_40767=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lung disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lung disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adult respiratory distress syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/14/4322\">",
"           Patient information: Adult respiratory distress syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asbestos exposure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/17/3347\">",
"           Patient information: Asbestos exposure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/15/33010\">",
"           Patient information: Pleural mesothelioma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Aspergillosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/6/31842\">",
"           Patient information: Chronic pulmonary aspergillosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12658\">",
"           Patient information: Invasive aspergillosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/20/14660\">",
"           Patient information: Asthma and pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/21/18770\">",
"           Patient information: Asthma and pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/11/4275\">",
"           Patient information: Asthma in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/58/17315\">",
"           Patient information: Asthma in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/25/29075\">",
"           Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/3/44083\">",
"           Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/0/37892\">",
"           Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/63/39925\">",
"           Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/60/18374\">",
"           Patient information: Asthma treatment in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16419\">",
"           Patient information: Avoiding asthma triggers (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/26/1442\">",
"           Patient information: Exercise-induced asthma (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/6/31841\">",
"           Patient information: How to use a peak flow meter (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/52/13122\">",
"           Patient information: How to use your child���������s dry powder inhaler (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/4/33858\">",
"           Patient information: How to use your child���������s metered dose inhaler (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/47/9970\">",
"           Patient information: How to use your dry powder inhaler (adults) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/34/41506\">",
"           Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/43/30386\">",
"           Patient information: Inhalers (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/22/30052\">",
"           Patient information: Medicines for asthma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/25/31124\">",
"           Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Atelectasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/1/32785\">",
"           Patient information: Atelectasis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bronchiectasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/25/39314\">",
"           Patient information: Bronchiectasis in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic obstructive pulmonary disease (COPD)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/48/15107\">",
"           Patient information: Chronic bronchitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/52/14148\">",
"           Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/13/1236\">",
"           Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/59/5043\">",
"           Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/9/19603\">",
"           Patient information: Lung transplant (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/11/24755\">",
"           Patient information: Medicines for chronic obstructive pulmonary disease (COPD) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/22/33122\">",
"           Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cough",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/34/28195\">",
"           Patient information: Chronic cough in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/0/43011\">",
"           Patient information: Cough in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13427\">",
"           Patient information: Cough in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/55/18291\">",
"           Patient information: Cough, runny nose, and the common cold (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/43/22195\">",
"           Patient information: Coughing up blood (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/63/32754\">",
"           Patient information: Croup (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/12/35013\">",
"           Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystic fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/57/40850\">",
"           Patient information: Bronchiectasis in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Idiopathic pulmonary fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/31/7666\">",
"           Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Interstitial lung disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/9/14483\">",
"           Patient information: Interstitial lung disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lung cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/12/19650\">",
"           Patient information: Brain metastases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/34/35363\">",
"           Patient information: Lung cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/28/5570\">",
"           Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1076\">",
"           Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/13/11475\">",
"           Patient information: Lung cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/44/3779\">",
"           Patient information: Non-small cell lung cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/22/41314\">",
"           Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/63/17396\">",
"           Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/15/33010\">",
"           Patient information: Pleural mesothelioma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/38/24162\">",
"           Patient information: Small cell lung cancer (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22659\">",
"           Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lung transplant",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/9/19603\">",
"           Patient information: Lung transplant (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pleural disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/50/10018\">",
"           Patient information: Pleural effusion (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/45/4819\">",
"           Patient information: Pleuritic chest pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/30/40418\">",
"           Patient information: Pneumothorax (collapsed lung) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary embolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/3/1075\">",
"           Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/29/2517\">",
"           Patient information: Pulmonary embolism (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/32/24067\">",
"           Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary nodules",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/23/24946\">",
"           Patient information: Multiple pulmonary nodules (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/1/23570\">",
"           Patient information: Single pulmonary nodule (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Quitting smoking",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/13/19670\">",
"           Patient information: Quitting smoking (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/46/18146\">",
"           Patient information: Quitting smoking (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/28/24002\">",
"           Patient information: Acute bronchitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/57/9106\">",
"           Patient information: Acute bronchitis in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/34/13858\">",
"           Patient information: Aspiration pneumonia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39074\">",
"           Patient information: Bronchiolitis (and RSV) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/19/27958\">",
"           Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/29/12754\">",
"           Patient information: Community-acquired pneumonia in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/0/43011\">",
"           Patient information: Cough in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13427\">",
"           Patient information: Cough in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/55/18291\">",
"           Patient information: Cough, runny nose, and the common cold (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/43/22195\">",
"           Patient information: Coughing up blood (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/5/13393\">",
"           Patient information: Histoplasmosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/1/19474\">",
"           Patient information: Hospital-acquired pneumonia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/44/14019\">",
"           Patient information: Mycoplasma pneumonia in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/24/7554\">",
"           Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/38/30308\">",
"           Patient information: Pneumonia in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/18/36130\">",
"           Patient information: Pneumonia in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/17/14611\">",
"           Patient information: Pneumonia in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/57/14225\">",
"           Patient information: Pneumonia prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/42/4770\">",
"           Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/11/44210\">",
"           Patient information: The common cold in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/44/40643\">",
"           Patient information: The common cold in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/19/13617\">",
"           Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/38/36450\">",
"           Patient information: Whooping cough (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sarcoidosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/35/5683\">",
"           Patient information: Sarcoidosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/14/20705\">",
"           Patient information: Sarcoidosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tests and procedures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/11/43186\">",
"           Patient information: Breathing tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/14/32993\">",
"           Patient information: Flexible bronchoscopy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/3/24624\">",
"           Patient information: Thoracentesis (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trouble breathing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/50/28450\">",
"           Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/46/6883\">",
"           Patient information: Shortness of breath (dyspnea) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuberculosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39475\">",
"           Patient information: Tuberculosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/57/25489\">",
"           Patient information: Tuberculosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-FC47B46EB1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f39_51_40767=[""].join("\n");
var outline_f39_51_40767=null;
